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Abstract 
Cardiovascular disease (CVD) has become the most common cause of mortality 
worldwide, accounting for approximately 30% of all deaths. The primary pathological 
process that underlies it is atherosclerosis. Atherosclerosis leads to the development of 
flow-limiting lesions that accumulate over years to decades under the stimulus of genetic 
and environmental factors. These contribute to both impaired tissue oxygen delivery with 
resultant clinical symptoms and acute coronary syndromes carrying a significant burden of 
morbidity and mortality. Within the UK population, 28% of premature deaths in men and 
20% in women are attributable to CVD carrying an estimated £30bn annual economic cost. 
Myocardial revascularisation in the form of coronary artery bypass grafting (CABG) and 
percutaneous coronary intervention (PCI) are established therapies for both acute coronary 
syndromes and symptomatic chronic disease refractory to pharmacological therapy. CABG 
remains the standard for patients with complex multi-vessel disease however in patients 
with less complex disease PCI is a reasonable alternative, and remains the gold-standard 
for patients with simple, focal CAD. The long-term results of CABG are limited by the 
failure of conduit grafts leading to recurrent symptoms, MI and/or repeat revascularization 
that carries with it a significant excess risk. Despite advancements in surgical technique 
and adjunctive medical therapy, the commonly used saphenous vein grafts are constrained 
by a cumulative graft failure rate of 50% at 10 years. Intracoronary stents, used for PCI are 
limited by the restenosis or thrombosis of stented vessel segments, phenomena that also 
confer significant morbidity and mortality. Vein graft disease (VGD) and in-stent 
restenosis (ISR)/thrombosis share similar pathological features related to the response to 
vessel injury, principally thrombosis, the development of neointimal hyperplasia, impaired 
endothelialisation and accelerated atherosclerosis. 
Gene-therapy remains a potential alternative to the use of pharmacotherapy for the 
prevention and treatment of these important clinical entities. Preclinical studies have 
provided a greater understanding of the underlying mechanistic pathways in both VGD and 
ISR and have provided insight into potential pathophysiological targets for manipulation 
with gene therapy. However, as yet, translation to the clinical setting has been less 
successful.  
Although stent technology and associated clinical outcomes continue to improve, 
preclinical studies suggest that gene therapy with a safe and stable vector expressing 
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endogenous proteins that restore normal vessel physiology can be an intuitive alternative to 
cytotoxic drugs for the prevention of stent complications.  
The principal aim of this PhD was to investigate alternative approaches to the prevention 
of coronary in-stent restenosis. It was initially planned to do this using a gene therapy 
approach with development and delivery of therapeutic viral vectors to a large animal 
model of ISR. Subsequently an interest was taken in the role of microRNAs in the 
development of neointimal hyperplasia and the potential for their therapeutic modulation in 
the prevention of ISR and use as cardiovascular biomarkers. 
Initial experiments focused on the assessment of adenoviral and lentiviral vectors for the 
transduction of human coronary artery smooth muscle cells (HCASMC). The 
dedifferentiation of vascular smooth muscle cells (VSMC) to a proliferative and migratory 
phenotype from their differentiated contractile state is a key process in the development of 
neointimal hyperplasia. Unmodified adenoviral (Ad5) and second-generation lentiviral 
vectors were used to transduce HCASMC in vitro. Successful gene expression was 
achieved with both vectors, however, in keeping with previous studies significant 
transduction with Ad5 could only be obtained at higher viral concentrations. Lentivirus 
was much more efficient, showing significant cell transduction at low viral doses. It was 
initially planned to take this vector forward to an in vivo model but it unfortunately proved 
time consuming and prohibitively expensive to produce in large enough titres. Adenoviral 
vectors were therefore used for in vivo delivery. A local delivery catheter approach, for the 
delivery of an adenoviral vector was tested ex vivo and successful viral transduction of 
explanted porcine coronary arteries was obtained.  
The Clearway RXTM (Atrium Medical) perfusion balloon catheter was designed to deliver 
a therapeutic agent directly to intra-coronary lesions. It was therefore hypothesized that it 
may be able to effectively deliver a gene-delivery vector. A porcine model of coronary 
stent delivery and overexpansion has been shown to develop consistent vessel injury and 
the development of neointima. This was therefore used to assess the ability of the 
Clearway RX to deliver an adenovirus expressing β-galactosidase. Measurable viral 
transduction of the arterial wall was not obtained most likely due to the Clearway being 
unable to maintain viral contact with the vessel for long enough to achieve significant 
transduction. Similar issues affected the only other commercially available local delivery 
catheter, the GENIETM which forms a therapeutic drug reservoir between two occlusive 
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balloons. Again, long enough incubation times to mediate unmodified Ad5 arterial 
transduction could not be obtained and the pigs tolerated the procedures poorly.  
To overcome these issues a virus-coated stent was developed using the spray-coatable 
YukonTM stent system and a Poloxamer 407 gel with thermoreversible properties. 
Poloxamer 407 has previously been used to successfully augment adenoviral transduction 
in small animal models. This system was therefore tested in the porcine model. No viral 
transduction of the vessel wall was obtained and analysis of distal organ sites confirmed 
off-target viral sequestration.  
Interest turned to the investigation of the role of microRNAs (miRs) in the development of 
in-stent restenosis. miRs are short, non-coding ribonucleic acids that act to control gene 
expression at a posttranscriptional level. Several miRs have been shown to play key roles 
in establishing smooth muscle and endothelial cell fate, tissue homeostasis and are now 
implicated in the complex regulation of the phenotype of cell types involved in vascular 
remodelling and the development of ISR. Using in vitro models of VSMC proliferation and 
migration, the dynamic expression of regulatory miRs implicated in the control of VSMC 
phenotype was assessed. These experiments suggested that miR-21, miR-146a, miR-221 
and miR-365 overexpression may contribute to the promotion of a dedifferentiated VSMC 
phenotype in the development of human neointimal lesions. The results for miR-143 and 
miR-145 were less clear however.  
It was hypothesised that expression patterns of these regulatory miRs in the vasculature 
would alter in response to stent-induced injury. All previously reported studies in this area 
have used in-vitro or in-vivo rodent models of vascular injury. A more clinically relevant 
large animal (porcine) model of in-stent restenosis was therefore utilised to assess the 
expression levels of miRs previously reported to play a role in VSMC regulation as well as 
novel targets. RNA was extracted from vessels snap frozen at the time of sacrifice and 
changes in miR expression within the vessel wall were determined using quantitative real 
time PCR (qRT-PCR). Using an electrolysis method to achieve stent dissolution it was 
possible to use in-situ hybridization to co-localise dysregulated miRs within neointimal 
lesions. Both miR-21 and the miR-143/miR-145 cluster appear to play a key role in the 
regulation of VSMC phenotypic switch and are shown to be both dynamic and 
significantly upregulated in developing neointima following stent implantation. This 
localised upregulation in the miR-143/miR-145 cluster, despite a consistent overall 
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“whole-vessel” downregulation, is particularly novel and differs from previously published 
findings. This has important implications towards future therapeutic manipulation.  
Additionally, and consistent with suggestions that microRNAs operate in regulatory 
networks, a panel of novel miRs, including miR-142, have been identified that may play an 
important role in the development of ISR and merit future investigation.  
Finally, experiments were performed to investigate the potential role of circulating miRs as 
biomarkers in patients undergoing CABG surgery. RNA was extracted from serum pre- 
and post-surgery and the dynamic and temporal expression of a panel of miRs associated 
with both acute and stable chronic coronary artery disease determined using qRT-PCR. 
Correlation analysis was performed with classical biomarkers and peri-operative factors. 
Dynamic changes were seen in circulating levels of miR-133a (which was seen to correlate 
with the biomarker troponin T), miR-122, miR-92a and miR-126. Although patient 
numbers were small, and this data is therefore observational, it is the first to investigate a 
temporal serum profile of dynamic miRs in the setting of uncomplicated CABG and show 
early potential for their use as biomarkers. It also adds to the growing evidence for the 
presence of a circulating microRNA network for cardiovascular disease that may hold 
significant future potential for therapeutic manipulation in specific pathological settings. 
Although the initial aims of developing a therapeutic gene therapy vector for the 
prevention of in-stent restenosis and its delivery to and testing in a large animal in vivo 
model were not achieved, this thesis adds to the understanding of the developing and 
increasingly complex role played by microRNAs in the setting of vascular remodelling 
following coronary stent implantation. It is hoped that the therapeutic modulation of miR 
levels could become an effective approach for the prevention of ISR and optimisation of 
patient outcomes in the clinical setting.  
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1.1 Cardiovascular Disease 
Cardiovascular disease (CVD) has become the most common cause of mortality 
worldwide, accounting for approximately 30% of all deaths (Libby and Braunwald, 2008). 
This all-encompassing label refers to a spectrum of pathologies affecting the heart and 
circulatory system, including, coronary artery disease, congestive cardiac failure, disorders 
of cardiac rhythm, structural disorders of the cardiac muscle or valves, pericardial disease, 
congenital disease, peripheral arterial disease and stroke. The primary pathology that 
underlies a significant majority of these distinct disorders is atherosclerosis.  
 Atherosclerosis leads to the development of flow-limiting lesions that develop from early 
adolescence and accumulate over years to decades under the stimulus of a variety of 
genetic and environmental factors (Libby, 2013). These atherosclerotic lesions ultimately 
can lead to impaired tissue oxygen delivery and resultant clinical symptoms such as angina 
pectoris or intermittent claudication. Acutely, additional factors such as plaque rupture, 
inflammation and thrombosis result in unstable lesions leading to occlusive myocardial 
infarction (MI) or acute coronary syndromes (ACS) that carry a significant burden of 
morbidity and mortality. Within the UK population, 28% of premature deaths in men and 
20% in women are attributable to CVD carrying an estimated £30bn annual economic cost 
(BHF, 2012). Almost half of these deaths are directly attributable to atherosclerotic 
coronary artery disease.  
The rise in evident atherosclerosis among populations is driven by industrialization, 
urbanization and the associated changes in lifestyle they bring (Libby and Braunwald, 
2008). Conventional risk factors for the development and progression of atherosclerosis 
include hypertension, hypercholesterolaemia, diabetes, sedentary lifestyle, obesity, 
smoking and family history (Bayturan et al., 2010, Frey et al., 2011, Kronmal et al., 2007, 
Nicholls et al., 2010, Otaki et al., 2013, Pekkanen et al., 1990, Perk et al., 2012). Although 
CVD mortality is changing, with declining age-standardized rates in Europe and the USA, 
they remain high and are even increasing in low- and middle-income countries due to this 
spread of risk factors and increased longevity through improved nutrition and public health 
measures. These reductions in mortality seen in high-income countries can be 
predominately explained by the combination of preventive methods leading to attenuation 
of the above risk factors (>50%) and advancing pharmacotherapeutics (~40%) (Perk et al., 
2012).  
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1.2 Revascularization for Coronary Artery Disease 
Advancements in medical therapy have proven to be effective in both controlling 
symptoms and reducing the morbidity and mortality associated with CVD. Optimal 
medical therapy (OMT), comprises the combination of intensive lifestyle and risk factor 
modification with pharmacological therapy including, primarily, anti-platelet agents, 
HMG-CoA reductase inhibitors (statins), β-blockers and angiotensin-converting enzyme 
(ACE) inhibitors (Boden et al., 2007, Wijns et al., 2010). Despite these improvements in 
non-invasive therapies there are key situations when an invasive revascularization strategy 
is required (Levine et al., 2011, Wijns et al., 2010).  
Myocardial revascularisation in the form of PCI or CABG has undergone many 
technological advances and extensive study and validation. In patients presenting with 
acute coronary syndromes (ACS) restoration of coronary flow immediately (STEMI) or at 
an early time-point (NSTEMI) by revascularisation (principally PCI) has been shown to 
confer significant benefits in terms of symptom control and improved prognosis (Hamm et 
al., 2011, Steg et al., 2012). However, in patients with more stable CAD the presence of 
ischaemia, resulting in symptoms that cannot be adequately controlled by OMT or carrying 
an additional prognostic significance, is required for there to be any benefit in outcome 
following revascularisation (Wijns et al., 2010). The ESC recommendations for 
revascularisation in stable CAD are summarised in Table 1.1.  
Arterial bypass surgery has been a mainstay in the treatment of occlusive coronary artery 
disease since its introduction in 1968 (Favaloro, 1968). When PCI was first introduced in 
1977 (Gruntzig, 1978, Gruntzig et al., 1979), it was thought to only be appropriate for 
patients with focal single vessel disease however, with the expansion and advancement of 
operator ability and device technologies, the use of PCI has expanded to treat patients with 
increasingly complex disease involving multiple vessels and/or the left main (LMS) 
coronary artery (Mohr et al., 2013).  
In the UK, numbers of CABG procedures performed have fallen to ~18,000 per annum 
while the growth in PCI has been exponential rising from less than 10,000 in 1991 to 
>85,000 in 2010 (BHF, 2012). PCI is therefore now one of the most frequently performed 
invasive medical procedures in current clinical practice (Garg and Serruys, 2010b).  
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Table 1-1 Indications for revascularization in stable angina or silent ischaemia 
Adapted from European Society of Cardiology Guidelines on Myocardial Revascularization (Wijns 
et al, European Heart Journal (2010) 31, 2501–2555) 
 
 Indications for revascularization 
Left main stem>50% stenosis and 
documented ischaemia or measurable 
impaired coronary blood flow (if <90%) 
Proximal LAD stenosis >50% and 
documented ischaemia or measurable 
impaired coronary blood flow (if <90%) 
2-vessel or 3-vessel disease with 
impaired left ventricular function  
Proven large area of ischaemia (>10% 
LV)  
Prognosis 
Single remaining patent vessel 
>50% stenosis and documented 
ischaemia or measurable impaired 
coronary blood flow (if <90%) 
Any stenosis >50% with limiting 
angina or angina equivalent, 
unresponsive to OMT 
Symptoms 
Dyspnoea/CHF and >10% LV 
ischaemia/viability supplied by 
>50% stenotic artery 
  
Transluminal angioplasty; the widening of a vessel lumen to improve downstream blood 
flow using a percutaneously delivered catheter, was the first described method of 
“minimally-invasive” (i.e. non-surgical) revascularisation. It was first performed in 
peripheral arteries in 1964 (Dotter and Judkins, 1964) and in coronary arteries in 1977 
(Gruntzig, 1978). Balloon dilatation of obstructive or occlusive coronary lesions, or “plain 
old balloon angioplasty” (POBA) as it became known became an important treatment for 
significant angina. It was however limited by significant complications, principally acute 
vessel closure due to coronary dissection or restenosis (luminal re-narrowing) caused by 
elastic recoil of the ballooned vessel segment and negative vessel re-modelling (de Feyter 
et al., 1994).  
This led to the development of coronary stents, the first of which was implanted in 1986 
(Sigwart et al., 1987). An in-situ stent provides a scaffold that prevents acute vessel closure 
and late constrictive recoil and their introduction reduced rates of emergency CABG 
(Roubin et al., 1992, Sigwart et al., 1988). These early stents carried a significant risk of 
occlusive stent thrombosis and subsequently increased bleeding secondary to the 
anticoagulants prescribed to prevent it. Advancements in stent technology (Fischman et al., 
1994, Serruys et al., 1994), use of dual antiplatelet therapy (Barragan et al., 1994, Schomig 
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et al., 1996) and improved technique leading to adequate stent deployment (Colombo et al., 
1995, Cutlip et al., 1999) led to stents becoming widely accepted and the default option 
when performing PCI (Serruys et al., 2006).  
Bare metal stents (BMS) although hugely effective and now widely used, remained limited 
by a small risk of subacute stent thrombosis (~0.5%) and primarily by in-stent neointimal 
hyperplasia resulting in restenosis rates of between 15% to 30% (Moliterno, 2005). To 
combat this, many techniques were tried such as laser atherectomy, brachytherapy and 
systemic and local drug delivery however most were disappointing (Sharma et al., 2011). 
The next step in the evolution of PCI was the development of a stent that would not 
restenose to the same degree and therefore reduce the need for repeat revascularisation 
procedures. Drug-eluting stents (DES) were introduced in 2002 and promised a significant 
reduction in rates of restenosis compared to BMS (Morice et al., 2002). These impressive 
results led to huge uptake and by 2005 80-90% of all PCI cases in the USA involved a 
DES (Jeremias and Kirtane, 2008).  
Safety concerns relating to these first-generation DES, eluting the antiproliferative agents 
sirolimus or paclitaxel, emerged in 2006. Published and presented results from meta-
analyses of SES and PES compared to BMS (Camenzind et al., 2007, Nordmann et al., 
2006), a clinical trial (Pfisterer et al., 2006) and a large Swedish registry (Lagerqvist et al., 
2007) suggested higher rates of late clinical events (such as death and myocardial 
infarction) due to stent thrombosis (ST) in those receiving DES. This resulted in a rapid 
decline in DES use and provided a major stimulus for ongoing research into improving 
outcomes following PCI.  
After careful thought and input from large regulatory bodies such as the FDA and ESC, 
concerns were raised about the methods used in these assessments of DES safety. Multiple 
independent patient-level meta-analyses of the initial DES trials were performed using 
standardised clinical outcomes and these concluded that overall rates of death and MI did 
not significantly differ between DES and BMS (Stettler et al., 2007, Kastrati et al., 2007, 
Spaulding et al., 2007, Mauri et al., 2007, Stone et al., 2007b). However, analysis of large 
patient registries revealed that the risk of very-late ST (>1 year post stent implantation) 
persisted and was estimated at between 0.4-0.6% per annum for at least 5-years post-
implantation (James et al., 2009, Pinto Slottow et al., 2008, Wenaweser et al., 2008). 
Multiple causative factors for stent thrombosis have been identified with acute events 
being more likely due to procedural considerations such as stent underdeployment or 
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undersizing or insufficient platelet inhibition (Holmes et al., 2010, van Werkum et al., 
2009). Very late events are more-likely due to pathological delayed vessel healing, 
impaired endothelialisation, hypersensitivity reactions, inflammation, neoatherosclerosis 
and vascular dysfunction within the stented segements and potentially all secondary to the 
eluted cytotoxic and cytostatic drugs and the stent polymer (Hara et al., 2010, Joner et al., 
2006, Nakazawa et al., 2011). The clinical importance of ST should not be underestimated 
as 70-80% of patients with ST present with MI and of those with definite ST up to one-
third will die (Mauri et al., 2007).  
Although the introduction of DES has led to a significant reduction in rates of ISR it has 
not been eliminated. Late lumen loss has been shown to continue out to at least 5 years in 
some patients having received first-generation DES which is felt to indicate incomplete 
vascular healing, possibly driven by the stent polymer (Raber et al., 2011). It did not 
appear, however, that this late luminal loss contributed to adverse clinical outcomes.  
The above ongoing safety concerns alongside the desire to improve vascular healing have 
led to the development of a multitude of newer generation DES incorporating new stent 
design and materials, more biocompatible polymers, improved drug kinetics and even 
biodegradable polymers and bioresorbable platforms (Garg and Serruys, 2010c).  
The choice of antiproliferative drug has become an important consideration for improving 
outcomes post-PCI. Sirolimus (rapamycin) is a macrocyclic lactone that induces cell cycle 
arrest in VSMC through the inhibition of mTOR, thus reducing neointimal formation 
(Poon et al., 1996). Paclitaxel inhibits VSMC proliferation by inducing cytostasis through 
the stabilisation of microtubules which in turn impairs cell division (Axel et al., 1997). 
Overall, SES are superior to PES with regards to late lumen loss and repeat 
revascularisation when compared in clinical trials (Schomig et al., 2007). Newer-
generation DES have therefore manly used macrolytic lactones, similar to sirolimus, but 
offering differences in degrees of immunosuppression and rate of drug absorption.  
Other pharmacotherapeutic regimens to prevent NIH, delivered both systemically and 
locally have been investigated, however in general results have been disappointing and 
overshadowed by the use of DES. Antiplatelet and anticoagulant agents, although effective 
in reducing abrupt vessel closure due to acute ST do not prevent ISR (Kastrati et al., 1997). 
Many other agents including lipid-lowering drugs, ACE inhibitors, steroids, anti-
inflammatory agents, calcium antagonists and growth factor antagonists have proven 
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disappointing in clinical trials despite some promise in pre-clinical studies (Faxon, 2002). 
This is likely in the main due to the difficulty in achieving adequate drug levels at the site 
of PCI without significant systemic toxicity (Sharma et al., 2011). Local drug delivery, 
intuitively, should allow a greater local drug concentration (and maximal tissue effect) for 
a lower overall dose (and minimised toxicity) than could be achieved if the agent was 
delivered systemically. Again, this approach has been shown to be effective in preclinical 
PCI studies using a variety of pharmacologic agents and delivery devices (Schwartz et al., 
2004). There have been several obstacles to the development of safe and effective 
intracoronary drug delivery and one of the most important, particularly with regard to 
future use of gene-therapy, is the development of a suitable delivery device (Brieger and 
Topol, 1997). The optimal device will enable delivery of a therapeutic dose of drug with 
minimal disruption to the vessel wall and without limitation of distal blood flow.  
The optimal method of revascularization for patients with complex disease has been 
fiercely debated with many clinical trials having been performed comparing outcomes of 
CABG with contemporary PCI (DES) in various groups, including those with LMS and/or 
multi-vessel disease, diabetes, the elderly and stable or unstable symptoms (Boudriot et al., 
2011, Buszman et al., 2008, Chieffo et al., 2010, Kapur et al., 2010, Moshkovitz et al., 
2012, Park et al., 2010, Park et al., 2011, Rodriguez et al., 2006, Serruys et al., 2010, Wu et 
al., 2010, Yan et al., 2011, Serruys et al., 2009). With such a complex and heterogeneous 
group of patients and also study limitations such as non-randomized patient selection, 
insufficient statistical power and the constant evolution of stent technology it is clear why 
the choice of revascularization strategy can be complex. PCI is a less invasive treatment 
than CABG, with associated shorter duration of required hospital stay and recuperation and 
lesser incurred short-term economic costs (Wijns et al., 2010). Many of the above studies, 
however, have suggested that CABG when compared to PCI results in a significantly 
reduced requirement for repeat revascularization and it has been reported that surgery may 
confer improved relief from angina and a better quality of life (Cohen et al., 2012). A large 
collaborative analysis of these previously described studies, covering 7812 patients with 
multi-vessel CAD, showed a similar all cause mortality with both procedures at a median 
follow-up time of 5.9 years (Hlatky et al., 2009). It also suggested that CABG may confer 
a mortality benefit in some subgroups, principally diabetics and the elderly (Hlatky et al., 
2009).  
The SYNergy between percutaneous coronary intervention with TAXus and cardiac 
surgery (SYNTAX) trial was the first randomized trial to compare CABG and PCI in 
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patients with very complex CAD (Serruys et al., 2009). It enrolled patients with de-novo 
LMS and/or three-vessel disease and randomized them to either PCI with a first-generation 
paclitaxel-eluting DES or CABG (Ong et al., 2006). At 1 year, patients undergoing CABG 
displayed significantly lower rates of the primary end-point (a composite of death, MI, re-
revascularization and stroke) than those who had PCI (Serruys et al., 2009). This was 
completely driven, however, by significantly higher rates of repeat revascularization in the 
PCI group, and no significant differences were seen in the composite of death, stroke and 
MI. The SYNTAX study also allowed creation of a score estimating the baseline severity 
of a patient’s coronary disease. This score split trial patients into three tertiles, low (0-22), 
intermediate (23-32) and high-risk (>33). In patients with a low score, there was no 
significant difference in any clinical outcomes between the two groups at 5 years follow-up 
(Mohr et al., 2013). In the intermediate severity group, CABG conferred a lower risk of MI 
and repeat revascularization but this did not translate to any difference in mortality (Mohr 
et al., 2013). In high risk patients, CABG conferred a lower mortality than PCI at 5 years 
follow-up (Mohr et al., 2013).  
This study suggests a place for both CABG and PCI in the modern management of patients 
with CAD. CABG remains the standard for patients with complex multi-vessel disease 
however in patients with less complex disease PCI is a reasonable alternative, and remains 
the gold-standard for patients with simple, focal CAD or those unsuitable for CABG 
surgery. Ongoing clinical trials comparing CABG with modern stent technology and 
emerging techniques, such as the fractional flow reserve assessment of coronary blood 
flow, hope to refine our understanding of this complex area further.  
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1.3 Mechanisms of Vein Graft Disease and In-stent 
restenosis 
1.3.1 Vein Graft Disease  
When performing CABG surgery, surgeons can use the left or right internal mammary 
artery, radial artery segments or even synthetic grafts, however, autologous saphenous 
veins are the most widely used conduit, particularly for grafting to the circumflex or right 
coronary arteries and their branches. The long-term results of CABG are limited by failure 
of these conduits leading to recurrent symptoms, MI and/or repeat revascularization that 
carries with it a significant excess risk compared to native vessel PCI (Lopes et al., 2012, 
Mehilli et al., 2011, Motwani and Topol, 1998). When saphenous vein grafts (SVG) are 
used, 10% of all grafts will fail early (within 1 month) due to thrombotic occlusion, 
another 15% will fail within 1 year due to intimal thickening and a further 25% will fail 
following this due to accelerated atherosclerosis (Hata et al., 2007) leading to a cumulative 
graft failure rate of 50% at 10 years (Parang and Arora, 2009). Over 90% of all CABG 
procedures in the UK, and over 95% in the USA, comprise a combination of a single left 
internal mammary graft and SVG for all other conduits (Bridgewater et al., 2009, Tabata et 
al., 2009). This is despite an estimate that total arterial revascularization can be performed 
in approximately 80% of all cases and confers a 5-15% improvement in mortality at 10 
years (Tatoulis, 2013).  
The use of a SVG as a conduit results in exposing a thin-walled vein to the high-pressure 
arterial system, resulting in a complex series of biological changes. Within the first few 
days following SVG implantation, a proportion of vein grafts fail due to thrombosis as a 
result of endothelial injury which in turn develops due to a combination of mechanical 
injury during surgical preparation of the vein, arterial shear stress and ischaemia resulting 
from removal of the vaso vasorum (Bryan and Angelini, 1994). During the first 24 hours, 
SVG undergo a period of ischaemia followed by reperfusion which triggers VSMC and EC 
cytotoxicity through the generation of reactive oxygen species such as superoxide (West et 
al., 2001). Subsequently, the graft is then targeted by an acute inflammatory response 
involving the recruitment of inflammatory cells (neutrophils, monocytes) and ongoing 
oxidative stress (Shi et al., 2001). Vessel remodeling, through the migration and increased 
proliferation of medial VSMC into the intima and subsequent deposition of ECM occurs 
during the first week post-implantation. This cascade results in the development of intimal 
  Chapter 1 | Introduction 
10 
hyperplasia (Newby, 1997). This resultant thickened intima is highly susceptible to the 
infiltration of monocytes, that differentiate into macrophages and subsequently foam cells 
through the uptake of lipids. These foam cells contribute to accelerated atherosclerosis 
which results in diffuse, concentric, friable plaques with poorly developed or absent 
fibrous caps, susceptible to plaque rupture, thrombosis and graft occlusion (Schwartz et al., 
1995, Virmani et al., 1988). The molecular mechanisms underlying the development of 
VGD will be discussed in further detail in section 1.4, with respect to molecular targets for 
vascular gene therapy. The development of intimal hyperplasia is summarized in Figure 
1.1. 
A degree of protection against these pathological processes can be obtained through the 
use of pharmacological therapies. Aggressive lipid-lowering with statins affords a 
reduction in atheroma formation and an associated improvement in vein graft survival 
(Shah et al., 2008). Antiplatelet and anticoagulant agents provide a reduction in acute 
thrombosis, but systemic anticoagulation carries a significant risk of bleeding (Yusuf et al., 
2001). Despite advancements in pharmacotherapy SVG failure rate has not significantly 
improved over the last 20 years.  
Some improvement in graft survival has been afforded by advancement in surgical 
technique. Vascular injury, caused by surgical preparation of the vein graft, is the principal 
cause of the endothelial injury and dysfunction that promotes platelet aggregation and 
thrombosis and the development of intimal thickening. Standard practice when harvesting 
saphenous veins is to strip the adventitial layer and distend the segment with normal saline 
to avoid vasospasm. A “no-touch” technique, where the graft is harvested with surrounding 
tissue intact and distention is avoided has been shown to improve patency rates in both 
preclinical (Tsui et al., 2002a) and clinical studies (Souza et al., 2002). The use of “off-
pump” surgery and endoscopic saphenous vein harvesting do not lead to an improvement 
in SVG patency, with the endoscopic technique actually proving to be inferior to open 
harvesting in a clinical trial (Zenati et al., 2011).  
1.3.2 In-stent Restenosis 
As previously discussed, the field of PCI has grown rapidly over the past 36 years. The 
observation that success in expanding a narrowed arterial lumen with a balloon was limited 
by acute vessel closure secondary to coronary dissection in the short term and restenosis 
due to elastic recoil, negative remodelling and neointimal hyperplasia (resulting in 
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recurrent symptoms and a requirement for repeat intervention) in the long term led to the 
development of adjunctive devices.  
Bare metal coronary stents (BMS), first introduced in 1986, became widely used by the 
mid-1990s (Al Suwaidi et al., 2000). Stent insertion allowed treatment of the acute 
complications of PCI such as coronary dissection/occlusion and reduced the requirement 
for emergency CABG. Again limitations quickly became evident such as the requirement 
for dual antiplatelet therapy to prevent early thrombotic occlusion and a reduced, but still 
highly significant (15-30%) rate of ISR due to increased neointimal hyperplasia induced by 
stent injury (Hoffmann et al., 1996, Elezi et al., 1998).  
This neointimal growth is a multifactorial response to mechanical vessel injury at the time 
of PCI. The radial force required to dilate the delivery balloon and deploy a stent results in 
fracturing or tearing of atherosclerotic plaque, endothelium and the intimal and medial 
layers of the artery wall. This stent-induced vascular injury results in endothelial 
dysfunction and local apoptosis of medial VSMC which in turn acts as a trigger for a 
regenerative repair response (Isner et al., 1995). Comprising this repair pathway are a 
number of processes including thrombus deposition and leukocyte trafficking to the stent 
site (Mitra and Agrawal, 2006), release of growth factors (Raines, 2004) and eicosanoids 
(e.g. thromboxane A2) (Jones et al., 1995), local thrombin production (Gallo et al., 1998) 
and release of vasoactive agents (e.g. angiotensin II) (Tanski et al., 2004) all of which are 
known to be mitogenic stimuli for VSMC. It has been shown that dysregulation of this 
repair response is primarily responsible for the excessive VSMC proliferation and 
subsequent formation of a stenotic lesion that encroaches upon the vessel lumen (Komatsu 
et al., 1998). Platelet-derived growth factor beta (PDGF-β) is one of the most potent 
VSMC mitogens and induces proliferation via the activation of biphasic extracellular 
signal-regulated kinase, phosphoinositide-3 kinase and Akt which results in downstream 
progression of the cell cycle through G1/S phase (Millette et al., 2005). For a period of 18 
months following stent implantation, neointimal lesion VSMC content is in the region of 
66% (Farb et al., 2004). This subsequently reduces to ~12% due to an increase in 
extracellular matrix (ECM) deposition within the lesion (Farb et al., 2004). Under the 
stimulation of transforming growth factor-beta (TGF-β), VSMC produce a proteoglycan-
rich ECM that contributes to neointimal lesion thickness in the later stages (Schmidt et al., 
2006). Additionally, an inflammatory component mediated by infiltration of macrophages 
and other mediators plays a key role in neointimal progression (Welt and Rogers, 2002). 
Neointimal development leads to luminal narrowing, reduction in coronary blood flow and 
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resultant recurrent symptoms and requirement for repeat revascularisation (with repeat 
exposure to its associated risks) and in some cases thrombotic occlusion leading to MI. 
These described mechanisms underpinning the development of neointimal hyperplasia and 
its role in ISR have been well characterised in animal models of vessel injury and 
atherosclerosis correlated with human autopsy findings (Schwartz et al., 2004, Geary et al., 
1996). The above molecular pathways are summarised in Figure 1.1. 
Many studies have been performed with the aim of reducing ISR using locally or 
systemically delivered pharmaceutical agents but with limited success (Wilensky et al., 
2000, Holmes et al., 2002). Ultimately significant progress was achieved with the 
development of the first drug-eluting stent (DES) delivering sirolimus via a synthetic non-
erodible polymer [polyethylene-co-vinyl acetate (PEVA) and poly n-butyl methacrylate 
(PBMA)] coating (Moses et al., 2003, Sousa et al., 2001). Although the use of DES has 
produced a marked reduction in rates of ISR they continue to exhibit a risk of stent 
thrombosis which occurs due to a combination of incomplete endothelialisation of stent 
struts, intolerance/resistance to or poor compliance with antiplatelet therapy or an 
inflammatory response to the polymer coating (Virmani et al., 2004). Although reduced, in 
certain situations ISR can still occur with DES (Dangas et al., 2010).   
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Figure 1-1 Development of neointimal hyperplasia  
Vascular injury leads to activation of endothelial cells and thrombotic adhesion of platelets and 
circulating leukocytes. The subsequent development of a cytokine-rich pro-inflammatory 
microenvironment leads to proliferation and migration of medial smooth muscle cells (SMC) into the 
neointima after degradation of the basement membrane, accompanied by increased synthesis and 
deposition of collagen-rich extracellular matrix. Superimposed atherosclerosis further increases 
neointimal size, resulting in significant vascular occlusion and recurrence of clinical symptoms and 
syndromes. Taken from McDonald et al, Cardiovasc Res. 2012 Mar 15;93(4):594-604.  
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1.4 Cardiovascular Gene Therapy  
There are three main factors to consider in the assessment of cardiovascular gene delivery. 
First is the identification of a suitable molecular target and therapeutic gene (or genes) to 
be expressed. Second, is to combine the gene of interest with an efficient and safe delivery 
vector. Third, is to develop a suitable process or device to effectively deliver the vector to 
the target cells/tissue/organ (Zuckerbraun and Tzeng, 2002, Rosenzweig, 2003, Gaffney et 
al., 2007). A summary schematic of a gene therapy approach to VGD and ISR is shown in 
Figure 1.2.  
1.4.1 Identification of Therapeutic Targets 
Preclinical studies have allowed a greater understanding of the underlying mechanistic 
pathways in both VGD and ISR and have provided insight into potential 
pathophysiological targets for manipulation with gene therapy. To achieve this, these 
studies have mainly relied on available in vivo animal models with additional in vitro proof 
of concept experiments.  
1.4.1.1   Vein Graft Disease 
Gene delivery can be achieved ex vivo with exposure of the harvested graft or by intra- or 
peri-vascular delivery devices. Major models in use include a porcine model of SV or 
internal jugular vein (JV) anastomosed to the carotid artery (CA) and also a rabbit model 
of JV to CA. Some groups have chosen to use a hypercholesterolaemic rabbit to look at 
effects on atherosclerosis and late VGD. Rodent models have also been extensively used 
including mouse JV or inferior vena cava to carotid artery and rat epigastric vein to 
common femoral artery. Less commonly, canine, ovine and non-human primate models 
have been employed (Schachner et al., 2006).  
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Figure 1-2 Vascular gene therapy for the prevention of ISR and VGD 
During CABG surgery, saphenous veins are extracted from the patient’s leg prior to being grafted 
proximally to the aorta and distally beyond the area of significant coronary disease producing a 
“bypass” for blood flow. This provides a useful window pre-grafting where the vein can be 
incubated ex vivo with a therapeutic vector targeting mechanisms underlying vein graft disease 
including thrombosis, intimal hyperplasia and accelerated atherosclerosis (left of diagram). 
Following percutaneous coronary intervention, (right of diagram) in-stent restenosis (ISR) can limit 
blood flow and result in clinically significant symptoms and acute coronary syndromes. Gene 
therapy vectors targeting the pathophysiological mechanisms underlying ISR could be utilised by 
local delivery devices post-stent placement or, more favourably, by “gene-eluting” stents which 
have the active agent deliverable from the stent surface. SVG – saphenous vein graft. VSMC – 
vascular smooth muscle cell. EC – endothelial cell.  
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1.4.1.2   In-stent Restenosis 
Compared with VGD models, access to target tissue for in vivo ISR studies is more 
complex. Initial mechanistic studies relied on “balloon injury” models, typically rat carotid 
artery, rabbit iliac artery and aorta or porcine femoral or coronary arteries. Subsequently 
these models were adapted to allow delivery of gene therapy. Initially delivery experiments 
focused on a variety of different balloons and catheters to transfer genes of interest to the 
vessel wall following balloon injury or stent deployment. As clinical utility favors use of a 
stent model over balloon injury, interest has switched to “gene-eluting” platforms (Sharif 
et al., 2004). In vivo stent models tend to utilize larger animals such as rabbits, pigs and 
monkeys however a rat carotid stent (Gaffney et al., 2007) as well as complex mouse 
models (Chamberlain et al., 2010, Ali et al., 2007) are also in use. 
1.4.1.3 Neointimal Hyperplasia 
A large body of work exists targeting the cell cycle to prevent stent restenosis. The first 
studies focused on cytotoxic gene therapy, aiming for inhibition of DNA synthesis in the S 
phase to reduce VSMC proliferation. Adenoviral delivery of herpes simplex virus 
thymidine kinase (HSV-tk) which converts co-administered ganciclovir to a toxic 
metabolite resulted in a significant reduction of NIH in balloon injured porcine iliac (Ohno 
et al., 1994) and rat carotid arteries (Guzman et al., 1994, Chang et al., 1995c). This 
suppression of NIH was also seen in injured atherosclerotic arteries (hypercholesterolaemic 
rabbits) using HSV-tk/ganciclovir (Simari et al., 1996, Steg et al., 1997). Another group 
used adenovirus to deliver cytosine deaminase to balloon-injured rabbit femoral arteries. 
This converts co-administered parenteral 5-fluorocytosine to the cytotoxic 5-fluorouracil. 
Again, a significant reduction in NIH was achieved (Harrell et al., 1997).  
A further approach to prevent proliferation of VSMCs in neointimal lesions is to inhibit 
regulators of the cell cycle. Retinoblastoma protein (Rb) is a regulator of DNA 
transcription. Its phosphorylation releases bound transcription factors such as DNA 
elongation factor (E2F) allowing progression through the cell cycle. Chang et al used 
adenovirus to deliver a mutant form of nonphosphorylatable Rb to injured rat carotid and 
porcine femoral arteries suppressing neointimal formation (Chang et al., 1995b). Other 
groups achieved a similar effect using adenoviral overexpression of human (full length and 
truncated) Rb (Smith et al., 1997b) and a related protein RB2/p130 (Claudio et al., 1999) in 
the rat carotid model.  
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p21, a cyclin-dependent kinase (cdk) inhibitor, is an important regulator of the cell cycle 
and a potent inhibitor of VSMC proliferation that arrests cells in G1 through inhibition of 
cdks and proliferating cell nuclear antigen (PCNA). Adenoviral delivery in vivo to rat and 
pig balloon-injury models reduced NIH effectively (Chang et al., 1995a, Yang et al., 1996, 
Ueno et al., 1997a, Luo et al., 1999). Mitomycin C is an antibiotic known to display 
antiproliferative effects in tumour cells. In vitro experiments showed that lower 
concentrations induced VSMC cell-cycle arrest in phase G2/M with associated increase in 
p21 expression. Perivascular delivery post balloon injury reduced NIH in rats (Granada et 
al., 2005). Overexpression of another cdk inhibitor, p27, using adenovirus in the rat 
reduced neointimal formation by inhibition of cdk2 function and cyclin A gene 
transcription (Chen et al., 1997). Adenoviral delivery of a “fusion gene” combining the 
active regions of p27 and p16 (another cell cycle inhibitor) to injured rabbit carotid and 
porcine coronary vessels significantly reduced intimal thickening (Tsui et al., 2001). Viral 
transfer of the tumor suppressor p53 has been shown to inhibit neointimal formation in 
rabbit and rat restenosis models (Yonemitsu et al., 1998, Scheinman et al., 1999).  
Antisense decoy oligodesoxynucleotide (ODN) therapy targeting cell cycle regulators has 
been extensively studied and shown potential clinical utility. The selected targets all play 
important roles in VSMC progression from phase G0/G1 and resultant proliferation. 
Successful reduction in neointimal formation has been obtained in restenosis models by 
targeting c-myb (Simons et al., 1992), c-myc (Shi et al., 1994), cdc2/PCNA (Morishita et 
al., 1993), cdk2 (Morishita et al., 1994), and bcl-x (Pollman et al., 1998). Both non-viral 
and viral methods of gene delivery were used. Mithramycin, an inhibitor of c-myc, was 
shown to be effective at reducing NIH when administered to rats undergoing carotid artery 
balloon injury (Chen et al., 1994).  
As noted earlier, an important step in the development of neointima is the VSMC response 
to circulating mitogens that through interactions with the cell surface stimulate the nucleus 
to promote proliferation. This is mediated by a system of signal transducers within the cell. 
DNA vectors designed to inhibit ras (an intracellular signaling protein) delivered to 
balloon-injured rat carotid arteries via a pluronic gel resulted in a suppression of IH 
formation (Indolfi et al., 1995). Adenoviral delivery of mutant H-ras (Ueno et al., 1997b) 
and a G-protein inhibitor (Iaccarino et al., 1999) in vivo were also effective in rats. 
Antisense ODNs to A-Raf and C-Raf kinases administered to in vitro rat SMCs resulted in 
reduced serum-induced proliferation suggesting that they may also be involved in 
intracellular signaling and may be useful therapeutic targets (Cioffi et al., 1997).  
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Other groups have chosen to target transcription factors involved in VSMC proliferation 
and migration. Antisense ODN to the p65 subunit of nuclear factor-κB (NF- κB) inhibited 
in vitro VSMC proliferation and in vivo neointimal formation in rats (Autieri et al., 1995). 
A decoy ODN to E2F has been shown to markedly reduce neointimal formation in balloon-
injured rat carotids (Morishita et al., 1995). Overexpression of transcription factor gax 
using adenovirus was shown to induce G0/G1 cell cycle arrest in VSMCs in vitro. This 
appeared to be due to upregulation of p21. Viral delivery to rat carotid (Smith et al., 1997a) 
and rabbit iliac (Maillard et al., 1997) injury models significantly reduced NIH. GATA-6 is 
another transcription factor that, like gax, is downregulated in dedifferentiated compared to 
contractile VSMCs. Adenoviral overexpression in the rat model incurred a similar 
reduction in NIH (Mano et al., 1999). Using a different carotid artery ligation model of 
restenosis in the rat, perivascular antisense ODN targeting early growth response factor 
(Egr-1) was shown to suppress neointimal formation (Lowe et al., 2002). The same group 
also used adenovirus-mediated overexpression of an injury-inducible transcription factor 
Yin Yang 1 to reduce NIH in balloon-injured rat and collar injured rabbit carotids. The 
authors reported that this was mediated by effects on p21 and p53 (Santiago et al., 2007).  
Cytokines and growth factors represent further attractive targets in the restenosis cascade. 
Local delivery of adenovirus expressing β-interferon reduced neointimal formation in 
injured porcine iliofemoral arteries (Stephan et al., 1997). Basic fibroblast growth factor 
(bFGF) and platelet derived growth factor (PDGF) are well recognized as being important 
in neointimal formation. Antisense bFGF delivered via adenovirus (Hanna et al., 1997), 
direct perivascular delivery of antisense ODN to PDGF-BB (Sirois et al., 1997) and 
adenoviral transfer of a PDGF-BB antagonist (Deguchi et al., 1999) all produced reduced 
intimal thickening in rats. Another group used this PDGF antagonist to reduce neointimal 
formation in a different way. They found that perivascular delivery to injured arteries 
reduced the migration of adventitial fibroblasts, another important component of post-
angioplasty remodeling (Mallawaarachchi et al., 2006). Yang et al used polymeric 
nanoparticles as a novel method of gene delivery to target the inflammatory chemokine 
monocyte chemoattractant protein (MCP)-1. This method was effective at reducing NIH in 
both a rabbit restenosis and VGD model (Yang et al., 2008).  
Induction of apoptosis in VSMCs programmed to proliferate following vascular injury is 
another potential therapeutic approach to restenosis. One group used adenovirus to 
overexpress Fas ligand (FasL), an inducer of apoptosis, in injured rat carotids. A 
significant reduction in NIH was obtained. They also looked at the issue of immunity to 
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adenovirus by showing that AdFasL maintained its ability to suppress neointimal 
formation despite immunological priming, whereas Ad delivery of p21 did not (Sata et al., 
1998, Luo et al., 1999).  
Reactive oxygen species such as superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl 
radicals (OH-) have been shown to be potential mediators of VSMC proliferation. They act 
through direct cell damage, induction of proinflammatory gene expression and by forming 
peroxynitrite (ONOO-) wihich catabolises NO (Griendling et al., 2000). Qian et al 
developed a Hantavirus glycoprotein pseudotyped lentivirus and used it to overexpress the 
antioxidant SOD3 in balloon injured rabbit CAs. A significant reduction in NIH resulted 
with no evidence of off-target organ transgene expression or significant toxicity evident 
(Qian et al., 2006). This retargeting approach to a lentiviral vector produced much more 
efficient VSMC and EC transduction than unmodified lentivirus or Ad5 and certainly holds 
potential going forward. 
1.4.1.4 Extracellular Matrix Formation 
Extracellular matrix (ECM) degradation is an important component of neointima formation 
as it allows SMC migration. It is controlled in vivo by matrix metalloproteinases (MMPs) 
and their endogenous inhibitors, tissue inhibitor of metalloproteinases (TIMPs) (Baker, 
2002). MMPs have been found to be elevated in multiple models of vascular injury and 
there has been considerable interest in the potential therapeutic gain in overexpressing 
TIMPs. Inhibition of neointimal formation was first shown in ex vivo human saphenous 
vein grafts following adenoviral delivery of TIMP-1 (George et al., 1998b). In vivo 
experiments were performed by Eefting et al, who used a novel non-viral delivery model in 
mice. They injected the gene of interest into the calf muscles of APOE*3Leiden 
hypercholesterolaemic donor mice and administered electroporation. The following day 
caval veins were harvested and grafted to the carotid artery of another mouse. 
Administration of TIMP-1 combined with the amino terminal fragment (ATF) of urokinase 
(involved in plasminogen activator proteolyis) resulted in reduced vein graft thickening 
and increased lumenal area, with a more marked effect than TIMP-1 alone (Eefting et al., 
2010a). In a further study they added bovine pancreas trypsin inhibitor (BPTI), a potent 
protease inhibitor, to the TIMP-1.ATF complex and demonstrated a further significant 
reduction in thickening (Eefting et al., 2010b).  
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Overexpression of TIMP-2 by Ad5-mediated gene transfer successfully inhibited 
neointimal formation in in vitro and in vivo rodent models (Cheng et al., 1998) and also in 
a human SVG in vitro culture model (George et al., 1998a).  When applied to a porcine 
VGD model however, no effect was demonstrated (George et al., 2000). This is likely due 
to the inability of TIMP-2 to bind to ECM or promote apoptosis of SMC (unlike TIMP-3). 
TIMP-3 has been shown to reduce neointimal formation in pig grafts using ex vivo 
adenoviral gene delivery (George et al., 2000, George et al., 2011) and non-viral 
ultrasound enhanced plasmid delivery (Akowuah et al., 2005) approaches. This reduction 
in vein graft intimal thickening was sustained at 3 months of follow-up suggesting 
potential long-term efficacy despite only a single incubation with the Ad vector (George et 
al., 2011).  
Overexpression of TIMP-3 in human VSMC in vitro, by a lentiviral vector, efficiently 
reduced migration and induced a pro-apoptotic effect (Dishart et al., 2003). This approach 
could have potential for clinical suppression of NIH but requires further assessment in in-
vivo models. TIMP-3 is felt to be effective due to its ability to promote apoptosis in and 
inhibit migration of SMCs in addition to ECM degradation (Baker et al., 1998).  
These pre-clinical results are encouraging and the manipulation of ECM formation merits 
further testing in human controlled trials to see if it is an effective approach for limiting 
ISR or VGD.  
1.4.1.5   Endothelialisation  
An intact endothelium is important for control of VSMC proliferation and prevention of 
thrombus deposition (Van Belle et al., 1997b). Denudation of the endothelium during 
balloon angioplasty or stent deployment is unavoidable and represents an important factor 
in the development of neointima. This has led to studies exploring the potential role of 
vascular endothelial growth factors (VEGFs), a group of endothelium specific mitogens in 
the control of re-endothelialization after vascular injury. Isner’s group were the first to 
report accelerated endothelialization associated with reduced neointimal formation in 
balloon-injured rabbit femoral arteries receiving recombinant VEGF165  (Asahara et al., 
1996). The same group then investigated the ability of rhVEGF165 to promote 
endothelialization of a stent and limit ISR in rabbits. A significant reduction in intimal 
growth within the stented vessels, as well as a reduction in mural thrombus, compared to 
controls was reported (Van Belle et al., 1997a). At a similar time Yla-Herttuala’s group 
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reported suppressed intimal thickening via plasmid-mediated delivery of VEGF to the 
adventia of a rabbit carotid collar model. It should be noted that in this study the 
endothelium is intact as the injury stimulus is extravascular. They were able to abolish the 
protective effect of VEGF using co-administration of L-NG-Nitroarginine methyl ester, a 
nitric oxide (NO) synthase inhibitor. The authors reported that VEGF suppressed VSMC 
proliferation by a mechanism involving endothelial NO production (Laitinen et al., 1997). 
The same group subsequently reported similar reductions in intimal thickening using 
intravascular adenovirus-mediated delivery of VEGF-C and VEGF-D isoforms to balloon-
denuded rabbit aortas (Hiltunen et al., 2000a, Rutanen et al., 2005).  
Conversely, other investigators have suggested that VEGFs may promote the development 
of restenotic lesions. Ruef et al found increased expression of VEGF in the neointima and 
media of balloon-injured baboon aortas with in vitro evidence of VEGF overexpression 
induced by reactive oxygen species, suggesting a potential role in neointimal development 
(Ruef et al., 1997). Consistent with this another group reported increased expression of 
VEGF, fms-like tyrosine kinase (flt)-1 and PDGF in neointimal VSMCs, macrophages and 
peri-stent endothelial cells following stent delivery to porcine coronary arteries. They 
suggested that VEGF promoted ISR through angiogenic and chemotactic properties as well 
as through synergy with PDGF (Shibata et al., 2001). These differing results led the 
Kuopio group to return to the rabbit carotid collar model and use adenovirus to deliver the 
six members of the VEGF family (VEGF-A, -B, -C, -D, -E and PIGF) known at that point.  
These isoforms are grouped according to the VEGF receptor they bind to and each differs 
in both molecular weight and biological properties. Isoforms A and D have strong 
angiogenic effects whilst B is less angiogenic and C primarily produces 
lymphangiogenesis with some angiogenic effects (Bhardwaj et al., 2003, Cao et al., 1998, 
Rissanen et al., 2003). VEGF-A and PIGF however have been shown to influence VSMC 
migration (Ishida et al., 2001). Isoforms A, D and D∆N∆C (a proteolytically processed 
mature form of VEGF-D) all increased NIH (Bhardwaj et al., 2005). A significant increase 
in levels of MMP-2 and MMP-9 was noted in these arteries. The authors concluded that 
factors including endothelial integrity, site and method of gene delivery, dose and even 
model used could all influence the role of VEGFs. Evidence suggests that any positive 
effect in terms of NIH suppression using VEGFs would be produced by re-
endothelialisation. In the rabbit collar model the endothelium is intact, a potential reason 
why a different effect may have been observed to the early rabbit stent models. In 
Bhardwaj’s study, high concentrations of VEGFs were produced in the adventitia and this 
resulted in significant angiogenesis and VSMC proliferation and migration. There is 
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therefore the potential that lower concentrations of VEGF could have a different biological 
effect with implications for the mode of delivery used (e.g. non-viral vs. viral). Lastly, with 
a difference seen between stented rabbit and pig arteries, significant species differences 
may play a role. These are all important considerations for progression to clinical studies 
from pre-clinical studies.  
Lastly, the role of nitric oxide in preventing NIH has been a focus of study. Viral liposome 
delivery of endothelial NOS (eNOS) significantly reduced intimal thickening in the rat 
restenosis model (von der Leyen et al., 1995). Retroviral seeding of SMC expressing eNOS 
into injured rat arteries was another approach that resulted in suppression of NIH (Chen et 
al., 1998). Adenoviral delivery of eNOS to rodent, rabbit and porcine models also 
significantly reduced NIH (Sato et al., 2000, Janssens et al., 1998, Varenne et al., 1998, 
Kullo et al., 1997). The relatively more efficient inducible form of NOS (iNOS) was 
shown to significantly reduce intimal thickening in balloon-injured rat carotid and porcine 
iliac vessels using much lower doses of adenovirus than normally required (Shears et al., 
1998).  
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1.4.2 Development of Gene Therapy Vectors 
The development of optimal gene delivery for the vasculature has been an area of intense 
research, however the optimal vector remains somewhat elusive. The optimal delivery 
vector for vascular tissue should be efficient in transducing target vascular cells with 
minimal transduction of non-target cells, have low toxicity and immunogenicity and allow 
sufficient longevity of transgene expression so that an adequate and sustained clinical 
response can be obtained (Baker, 2002). Several vectors have been used in both preclinical 
and clinical studies, each with pros and cons, and much effort has been expended trying to 
optimize efficiency and safety. 
1.4.2.1   Non-viral Vectors 
Non-viral vectors have been extensively used in early trials of cardiovascular gene therapy 
(Yla-Herttuala and Martin, 2000, Isner, 2002). Many different forms of non-viral gene 
transfer have been tested including “naked” plasmid DNA, cationic liposomes, DNA-
polycation complexes, decoy or antisense oligodeoxynucleotides (ODNs) and small 
interfering RNAs (siRNAs). Although easy to produce, and with minimal biosafety risks, 
non-viral vectors generally offer a low efficiency of cell transduction and transient effect 
due to intracellular degradation (Kratlian and Hajjar, 2012). Some studies have used 
adjunctive methods to improve transduction efficiency such as ultrasound mediation 
(Akowuah et al., 2005) and electroporation (Eefting et al., 2010a). Non-viral gene transfer 
methods are not subjected to the same regulatory issues facing viral vectors, and this 
remains a significant advantage. However, even with adjunctive methods it is unlikely that 
clinically effective transduction can be achieved in the human vasculature using non-viral 
vectors, therefore, their role in VGD and ISR remains limited currently.  
1.4.2.2   Retroviruses 
The first experiments showing effective in-vivo gene transfer to the vascular system were 
published over 20 years ago (Nabel et al., 1989). These demonstrated effective delivery 
and seeding of endothelial cells expressing a retrovirally transduced reporter gene into 
porcine iliofemoral vessels and were the catalyst for the field of vascular gene therapy. 
Retroviruses are RNA viruses whose viral genome inserts into the host chromosome. This 
provides stable transgene expression but raises safety concerns regarding insertional 
mutagenesis. Several patients who received retroviral gene therapy in a clinical trial to treat 
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X-linked severe combined immunodeficiency syndrome developed evidence of 
malignancy (Hacein-Bey-Abina et al., 2003). Furthermore, retroviral vectors produce poor 
transduction of non-dividing cells limiting efficacy in the vasculature. In one small clinical 
trial a retroviral vector was used to express the low-density lipoprotein receptor in ex-vivo 
hepatocytes which were then autologously transplanted into patients with familial 
hypercholesterolaemia (Grossman et al., 1994). Some reductions in circulating low-density 
lipoprotein levels were observed, however, these were short lived due to unstable transgene 
expression. Retroviral vectors are therefore generally not utilised for CVD gene therapies 
and research interest has shifted to different vector systems. 
1.4.2.3   Adenoviruses 
Adenoviruses (Ad) are the most frequently used vector in gene therapy clinical trials 
(23.5% of all trials, http://www.abedia.com/wiley/vectors.php). Ads are non-enveloped 
double-stranded DNA viruses. There are 57 known human serotypes divided into seven 
species (A-G). They can, in general, be relatively easily engineered to be replication-
deficient, produced in high viral titres at clinical grade and do not integrate into the host 
genome meaning insertional mutagenesis is not a concern. They efficiently transduce 
dividing and quiescent cells although their broad cell tropism means they carry a risk of off 
target effects. They are also highly immunogenic with transduced cells being eliminated 
reasonably rapidly through cytotoxic T-cell mediated clearance (Yang et al., 1994). This 
results in a transient in-vivo gene expression which peaks at 7-14 days and is generally lost 
by 28 days (Guzman et al., 1993, Kass-Eisler et al., 1993). Although this may be too short 
a duration for some therapeutic applications it may be suitable in certain scenarios, 
possibly including vein graft failure and the acute complications following PCI. The 
serotype Ad species C serotype 5 (Ad5) is the most commonly used in experimental and 
clinical studies. This virus is reliant on the coxsackie and adenovirus receptor (CAR), a 46 
kDa transmembrane receptor, for cell transduction (Bergelson et al., 1997, Kirby et al., 
2000). Further interaction of the Ad5 with cellular integrins mediates capsid internalization 
(Wickham et al., 1993). While CAR is abundantly expressed on hepatocytes, expression on 
endothelial cells (ECs) is low and is absent on vascular smooth muscle cells (VSMCs), 
reducing Ad5 transduction efficiency unless high doses of vectors are used. Moreover, 
clinical efficacy of Ad5-based vectors is hampered by pre-existing immunity (neutralizing 
antibodies) and high affinity interactions with cellular and non-cellular blood factors 
(Coughlan et al., 2010).  These interactions result in rapid clearance of the virus from the 
circulation and sequestration in the liver, limiting in-vivo targeting efficiency and resulting 
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in dose-limiting hepatotoxicity, thus suppressing clinical potential to-date. Ad5 cellular 
uptake mechanisms are summarized in Figure 1.3.  
In vitro experiments indicate that primary cell tethering involves the Ad5 fiber knob 
domain engaging CAR for all species besides B-species viruses, which use alternate 
receptors, predominately CD46 (Bergelson et al., 1997, Gaggar et al., 2003, Wang et al., 
2010b). Subsequent studies by Roelvink et al defined a number of amino acids located on 
the fiber knob domain that can prevent CAR binding in vitro (Roelvink et al., 1998). 
However, the introduction of mutations within the fiber knob domain that abrogate CAR 
binding and infectivity in vitro has no discernible effect on Ad5 biodistribution and 
transduction profiles in vivo following intravenous delivery (Alemany and Curiel, 2001, 
Nicol et al., 2004). These results were somewhat surprising, since it had been widely 
assumed that a large component of the hepatic sequestration of Ad vectors was mediated 
by the high level of CAR-expression on hepatocytes.  Subsequent findings by a number of 
independent groups have shown that direct interactions between the viral capsid of several 
adenoviral serotypes and various blood factors including complement-4 binding protein, 
Factor IX, VII, protein C, but predominantly Factor X, can mediate hepatocyte 
transduction via heparan sulphate proteoglycans (HSPGs) (Kalyuzhniy et al., 2008, Parker 
et al., 2006, Shashkova et al., 2008, Shayakhmetov et al., 2005a, Shayakhmetov et al., 
2005b, Vigant et al., 2008, Waddington et al., 2008).  
These interactions with circulating blood factors have proven to be important in explaining 
why adenoviral vectors have not yet reached their full potential as in-vivo gene delivery 
vectors. Aside from Factor X-mediated liver gene transfer, when delivered intravascularly 
Ad5 has been shown to bind directly to platelets. These resultant platelet-virus aggregates 
are then degraded by the reticuloendothelial system, further impairing transduction 
efficiency (Stone et al., 2007a). This, along with activation of the complement system 
contributes to the development of thrombocytopenia, commonly seen following in-vivo 
Ad5 administration (Kiang et al., 2006). Interactions with neutrophils and monocytes and 
hemagglutination following vector binding with erythrocytes (shown to express CAR in 
humans, but not mice) have all also been implicated in limiting the efficacy of in-vivo 
adenoviral gene delivery (Lyons et al., 2006, Seiradake et al., 2009).  
To avoid these interactions and improve the clinical potential of Ad-based therapeutics, 
particularly with regard to vascular gene therapy, research effort has focused on vector 
“retargeting and detargeting” strategies. Detargeting involves modification or shielding of 
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the main viral capsid proteins (hexon, penton base and fiber) that mediate interactions with 
native cell receptors (CAR/integrins/HSPGs) and circulating coagulation factors. 
Modification of the fiber knob domain, to abrogate CAR binding, could also reduce the 
potential toxicity caused by hemagglutination following binding of erythrocytes (Carlisle 
et al., 2009). Alongside genetic modification, chemical alteration of the viral capsid is 
another approach to allow vector detargeting. This typically involves the use of polymers 
to “shield” the capsid from undesirable in-vivo interactions with native receptors, 
coagulation factors or neutralizing antibodies. By removing these interactions and thus 
preventing or significantly reducing unwanted viral sequestration and removal, a much 
improved bioavailability can be obtained and toxicity reduced. An Ad5 vector, coated with 
the multivalent polymer poly[N-(2-hydroxypropyl)methacrylamide], showed a 100-fold 
reduction in liver transduction following iv injection in mice (Green et al., 2004). This 
vector showed a 42% increase in circulating plasma levels, compared to an unmodified 
vector, at 30 minutes post injection confirming increased blood persistence. There was also 
evidence of reduced hepatotoxicity with circulating liver enzyme levels being comparable 
to untreated controls. A downside to the detargeting approach is that transduction 
efficiency can be reduced as the capsid may be shielded from the target tissue of interest 
also, a problem retargeting looks to address.  
These previously described physiological barriers and counter strategies are particularly 
important in relation to the systemic delivery of adenoviral vectors. They merit 
consideration however, as virus “escape” into the circulation following catheter-mediated 
local delivery to the vasculature can be substantial (Hiltunen et al., 2000b). Of potentially 
greater importance, with regard to the local delivery approaches relevant to the prevention 
of VGD or ISR, are strategies focused on optimising the uptake of viral particles by target 
vascular cells. Retargeting focuses on genetic or chemical modification of the vector (e.g. 
through alteration of the fiber or use of monoclonal antibodies) to improve transduction of 
a specific tissue, such as VSMC or EC (Coughlan et al., 2010). This targeting of a specific 
tissue type would allow improved efficacy for a given dose of vector, reducing off-target 
effects and dose-related toxicity. Modification of an Ad5 vector to target vascular ECs 
using the fms-like tyrosine kinase receptor-1 promoter was shown to increase transduction 
levels 7-fold in ex-vivo rat aortas (Work et al., 2004b). This was associated with a 
significant reduction in liver transduction. Similarly, Reynolds et al used a bispecific 
antibody retargeting approach to create an Ad5 vector directed to angiotensin-converting 
enzyme (ACE) (Reynolds et al., 2000). ACE is preferentially expressed on pulmonary 
capillary EC, and this approach resulted in a 20-fold increase in lung vasculature 
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transduction with an 80% reduction in off-target liver transgene expression in-vivo in rats. 
By combining the insertion of the vascular-targeted peptide SIGYPLP with fiber mutations 
blocking CAR binding, Nicklin et al developed an Ad5 vector displaying efficient and 
selective tropism for vascular EC in vitro (Nicklin et al., 2001b). Particularly relevant to 
VGD and ISR, targeting peptides such as RGD4C, EYHHYNK and GETRAPL, when 
incorporated into the fiber HI loop, have been shown to enhance Ad5 uptake into VSMC in 
vitro and intact vein graft tissue ex vivo 10-100 fold (Work et al., 2004a, Nicklin et al., 
2000). A further potential approach involves combining traditional retargeting strategies 
with rare serotype pseudotyping (Bradshaw and Baker, 2012). Rare and non-human 
serotype vectors, with low seroprevalence, often display increased transduction efficiency 
of cells that do not display CAR through their use of alternate receptors (Teigler et al., 
2012). Ad5 vectors can be pseudotyped with fibres from these rare serotypes, thus 
conferring high-affinity binding to alternate receptors such as CD46 which is highly 
expressed on the surface of vascular cells (Larochelle et al., 2008). For example, 
significantly improved targeting of the cardiac vasculature in vivo in rats was obtained by 
insertion of a vascular-targeted peptide (DDTRHWG) into the HI loop of an Ad5 vector 
pseudotyped with a fiber protein from a rare serotype (Ad19p) virus (Nicol et al., 2009). In 
clinical cancer studies, “oncolytic” vectors modified to enhance tumour transduction have 
shown potential clinical effectiveness with up to 61% of patients exhibiting evidence of 
anti-tumour activity (Nokisalmi et al., 2010, Pesonen et al., 2010).  
Optimal design of viral vectors must also include strategies to evade the host immune 
system. Activation of the innate immune response by either the vector or transgene, leads 
to an acute inflammatory response, resulting in a rapid release of various pro-inflammatory 
cytokines and chemokines (1-6 h post injection) which leads to a rapid clearance of the 
virus from the circulation. The clinical importance of the innate immune response to 
adenoviral vectors was reinforced by the unfortunate death of a young patient in a non-
vascular clinical trial (Raper et al., 2003). These initial events prime the adaptive immune 
response, which mediates a more selective (specific) response (Liu and Muruve, 2003, 
Worgall et al., 1997). It is estimated that up to 97% of the population have neutralizing 
antibodies against type C Ads, including the commonly studied Ad5, contributing to a lack 
of efficacy thus far in clinical trials (Nayak and Herzog, 2010). Specifically, high dose 
intravascular administration of Ad vectors has been found to induce high levels of 
cytokines, tumour necrosis factor α, interleukin-6, interleukin-12, interferon γ, interleukin-
1 and the chemokines, regulated on activation, normal T cell expressed and secreted 
(RANTES) and monocyte chemoattractant protein-1 (Di Paolo et al., 2009, Hartman et al., 
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2008, Alba et al., 2010). The precise origins of these pro-inflammatory mediators in vivo in 
humans is not known, however numerous studies have implicated macrophages 
(particularly liver Kupffer cells) and endothelial cells (Thaci et al., 2011). Certainly in 
rodent models, Kupffer cells have been shown to rapidly scavenge and remove Ad5 
vectors from the circulation (Lieber et al., 1997) and contribute to the inflammatory 
response through release of cytokines and chemokines (Shayakhmetov et al., 2005b). This 
inflammatory response results in increased vector related toxicity and contributes to the 
extensive liver pathology that has been observed with the administration of Ad5 in-vivo 
(Lieber et al., 1997). Again, retargeting and detargeting approaches are being employed to 
circumvent these issues with immune responses (Nayak and Herzog, 2010, Ahi et al., 
2011, Thaci et al., 2011).  
A further approach to the issue of vector-induced immunogenicity has been the 
development of third-generation or “helper-dependent” Ad vectors. These Ads have had all 
viral genes removed from the genome resulting in minimal immunogenicity and prolonged 
transgene expression (Jozkowicz and Dulak, 2005). This removal of viral coding 
sequences prevents the production of viral proteins in infected cells. Therefore significant 
cytotoxic T-cell reactions do not occur and an adaptive immune response is not promoted 
(Vetrini and Ng, 2010). Helper-dependent Ad have been shown to be effective in gene 
transfer to the liver (Oka et al., 2001) and the vasculature (Wen et al., 2004, Flynn et al., 
2010, Jiang et al., 2011) but remain untested in human clinical trials.  
Taken together, the above interactions highlight the difficulty of using first generation 
adenoviruses in the setting of in-stent restenosis, where the virus is exposed to blood cells 
and serum proteins even if attached to a stent or delivered locally to the site of stent 
deployment.  However, first generation Ad vectors do have proven efficacy in the setting 
of pre-clinical vein graft disease (George et al., 2011) where the virus is incubated with the 
target tissue (saphenous vein segment) for a period of 30 minutes ex vivo before flushing 
and engraftment. This opportunity to treat the target tissue ex vivo and wash out any 
unbound virus reduces the potential of adverse events and off-target effects.  
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Figure 1-3 Cellular uptake mechanisms of Adenovirus serotype 5 viral vectors  
Following local delivery, the cellular uptake of the Ad5 vector is mediated by a primary interaction 
of the fiber knob with cell surface coxsackie and adenovirus receptors (CAR). Ensuing engagement 
of membrane αv integrins by the Ad5 penton base protein leads to endocytosis of the viral particle. 
Following intravascular delivery, liver sequestration and hepatocyte uptake of Ad5 virons results 
from a nanomolar-affinity interaction between circulating coagulation factor X and viral hexon 
proteins. Immune cell-mediated phagocytosis also occurs following both local and systemic 
delivery. Taken from Bradshaw and Baker, Vascular Pharmacology. 2013; 58(3):174-181. 
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1.4.2.4   Adeno-associated Viruses 
Adeno-associated viruses (AAVs) are from the family of parvoviruses and have broad 
ranging potential as gene therapy vectors (Tilemann et al., 2012). They are not associated 
with pathology in humans (Flotte and Carter, 1995). Their main advantages are a lack of 
toxicity in vivo and the ability to infect non-dividing cells (Monahan and Samulski, 2000). 
They display excellent long-term gene expression without excessive insertion into the host 
genome (Heistad, 2006). Disadvantages include limited space for cloning (<5kb) and also 
the potential for humoral immune response related to vector-specific antibodies and pre-
existing immunity in the population (Monahan and Samulski, 2000). Multiple serotypes 
exist (11 identified to-date) with differences in organ biodistribution and expression 
profiles (Karvinen and Yla-Herttuala, 2010). Serotypes 1/6/8 and 9, for example, have 
been shown to mediate high transduction efficiency in cardiomyocytes (Pacak et al., 2006, 
Palomeque et al., 2007, Gregorevic et al., 2004).  
Strong cardiomyocyte transduction in animal models using recombinant AAV vectors led 
to their use in the first human clinical trial of congestive heart failure, the CUPID trial 
(Jessup et al., 2011). Using a single intracoronary injection of an AAV1 vector expressing 
sarcoplasmic reticulum Ca2+-ATPase, the investigators showed that the treatment was safe 
and well-tolerated. This phase IIa trial also suggested treatment efficacy with 
improvements in clinical variables, heart failure biomarkers and imaging parameters in the 
high dose group. These results are encouraging and follow-up trials are awaited with 
interest.  
With respect to vascular gene therapy, focus has been on improving the relatively poor 
gene transfer to ECs and VSMCs by AAV. Modification of AAV-2 serotype with the 
peptide SIGYPLP resulted in enhanced transduction of ECs (Nicklin et al., 2001a). As in 
Ad5, modification of AAV-2 with EYH increases selective transduction of VSMCs (Work 
et al., 2004a). In vivo delivery to rat aortas suggested that serotypes 1 and 5 may be 
superior to AAV2 for gene therapy to ECs and VSMCs (Chen et al., 2005). Insertion of an 
integrin-targeting peptide into the capsid of AAV1 enhanced transduction of human 
umbilical vein ECs and human saphenous vein ECs (Stachler and Bartlett, 2006). Further 
work has shown that serotypes 7 and 8 are very poor at transducing ECs due to sensitivity 
to proteasomal activity (Denby et al., 2005). While modifying capsid proteins is one 
approach to targeting the vasculature, pseudotyping AAV2 transgene cassettes in 
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combination with capsids from other serotypes may allow more efficient vectors to be 
produced (Lebherz et al., 2004). Finally, in vivo biopanning using phage display libraries 
can be used to identify peptides allowing modification of AAV2 and specific targeting to a 
particular vascular bed (Work et al., 2006).  
While AAV vectors now appear to hold the most potential for cardiac gene transfer, it is as 
yet unclear whether retargeted vectors will be able to provide sufficient transduction 
efficiency in vascular cells to make them the vector of choice for clinical trials in ISR or 
VGD. If this, as well as circulating neutralizing antibodies, can be overcome however, 
their improved safety profile compared with Ad vectors certainly would make them 
attractive options.  
1.4.2.5   Lentiviruses  
Lentiviruses are from the retrovirus family and vectors can be derived from human 
immunodeficiency virus-1 (HIV-1). Unlike other retroviruses these vectors can transduce 
quiescent and dividing cells and are efficient at transfecting vascular cells as well as 
offering long-lasting transgene expression and low immunogenicity. Effective transduction 
of both ECs and VSMCs by a third-generation vesicular stomatis virus glycoprotein (VSV-
G) pseudotyped lentiviral system was achieved in vitro (Dishart et al., 2003). Cefai et al 
displayed superior transduction of human coronary ECs and VSMCs in vitro and rat 
carotid arteries in vivo using a similar lentiviral vector, compared with Ad5 (Cefai et al., 
2005). Effective therapeutic vascular gene transfer using lentiviral vectors has been shown 
in pre-clinical models of VGD and ISR hinting at their potential for use in the clinical 
settings and these will be discussed later (Qian et al., 2006, Dishart et al., 2003).  
Disadvantages of the lentivirus include difficulty in producing vectors at titres suitable for 
clinical testing and also the potential for insertional mutagenesis, although clinical data to-
date with HIV-based lentiviruses has not shown vector-induced mutagenesis.  
To combat this theoretical risk of oncogenesis non-integrating lentiviral vectors have been 
developed. These have been shown to provide stable transgene expression in vitro (Vargas 
et al., 2004) and in vivo (Yanez-Munoz et al., 2006, Philippe et al., 2006). The 
incorporation of a mutated integrase gene allows the viral genome to remain episomal 
resulting in transient gene expression in dividing cells and long-term gene expression in 
quiescent cells. The potential of these vectors for vascular gene therapy remains to be 
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explored and depends on their ability to sustain transgene expression for a sufficient length 
of time, a critical factor when considering vasculoproliferative disorders.  
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1.4.3 Delivery of a Therapeutic Vector to the Target Tissue 
1.4.3.1   Stent Models 
With the expanding and widespread clinical use of stents the development of true 
preclinical ISR, rather than vessel injury, models has become of increasing relevance. The 
use of a coated stent to deliver gene therapy is attractive as it is site-specific, potentially 
helping to avoid the distal spread of therapeutic agents and viral vectors, thus minimising 
systemic toxic effects. The first progress in the field of gene therapy to prevent ISR was 
made by Dichek et al, who successfully seeded stainless steel stents with sheep endothelial 
cells that had been modified to express markers using retroviral gene transfer (Dichek et 
al., 1989). Much later the efficiency of this process was improved using endothelial cells 
expressing VEGF (Koren et al., 2006). The first successful use of a “gene-eluting stent” in-
vivo was performed in a pig coronary angioplasty model. The stent polymer eluted plasmid 
DNA for green fluorescent protein (GFP) allowing detection of arterial transfection 
(Klugherz et al., 2000). The same group also reported successful transfection of porcine 
coronary arteries using a collagen coated stent with covalently-bonded monoclonal 
antibodies to adenovirus. This allowed binding of adenoviral particles to the stent allowing 
a degree of controlled site-specific local release (Klugherz et al., 2002). Another group 
used a different approach, seeding SMC harvested from porcine jugular veins onto 
fibronectin-coated stents, transducing them to express GFP and inserting them into porcine 
coronary arteries (Panetta et al., 2002).  
Adding to the controversy surrounding the role of VEGF, Walter et al inserted human 
VEGF-2 plasmid coated polymer stents into the iliac arteries of normocholesterolemic and 
hypercholesterolemic rabbits. In their study VEGF accelerated endothelialisation compared 
to control stents (98% vs. 79% endothelial cover at 10 days) and also inhibited NIH as 
assessed by intravascular ultrasound with an 87% increase in lumenal cross-sectional area 
and a 54% reduction in cross-sectional narrowing (Walter et al., 2004). In a similar study 
however, it had been reported that VEGF-eluting stents tested in a rabbit model 
significantly reduced thrombosis but did not promote endothelialization or reduce NIH 
(Swanson et al., 2003). It is possible that differences in stent types used (polymer coated 
with plasmid DNA vs. radiolabelled absorption of VEGF) could explain the differences 
seen in these rabbit iliac studies.  
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Unsurprisingly, with such noted similarities in their pathologies, many targets thought to 
have potential in vein graft failure have also been tested in stent models. Johnson et al 
coated stents with an adenovirus expressing TIMP-3 and applied them to porcine coronary 
arteries (Johnson et al., 2005). A 40% reduction in neointimal area compared to bare metal 
stents at 28 days was conferred. Stents coated with a biocompatible polymer expressing 
7ND-MCP-1 reduced neointimal area in rabbits (~60% reduction at 28 days post-stenting) 
and monkeys (25-30% reduction out to 6 months) (Egashira et al., 2007). This provides 
evidence that long-term clinical benefit may be achievable with the use of a gene-eluting 
stent.  
The above studies have all used polymer coated stents to elute the genes of therapeutic 
interest, much in the same way that DES deliver their active compound. This polymer 
component however has been shown to cause a local inflammatory response which 
contributes to delayed healing and late complications such as thrombosis (van der Giessen 
et al., 1996, Garg and Serruys, 2010a). Levy’s group in Philadelphia has therefore 
investigated alternatives to polymer coatings. The first method tested was gene delivery via 
bisphosphonate binding to the metallic stent surface. Following in vitro optimization they 
delivered Ad expressing iNOS to a rat carotid stenting model achieving a significant 
reduction in NIH (Fishbein et al., 2006). Furthermore, to enable better control of vector 
stability and delivery kinetics they developed a synthetic complex allowing adenoviral 
particles to reversibly bind to the stent through a hydrolysable ester bond. Again this 
method achieved a reduction in NIH using AdiNOS in the rat (Fishbein et al., 2008).   
Not all attempts to manipulate growth factors have been successful. Adenoviral delivery of 
an antagonist to TGF-β, shown to be effective in reducing ECM formation in the VGD 
models, did not reduce stent-induced NIH in porcine coronaries despite a small decrease in 
ECM deposition. It did appear to increase vascular inflammation leading the authors to 
conclude that it may have a detrimental effect on lesion progression (Chung et al., 2010). 
These encouraging results in some pre-clinical models of restenosis have been 
demonstrated despite overall low percentages (typically <10%) of transduced VSMC at the 
site of treatment (Sharif et al., 2006).  
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1.4.3.2   Thrombosis 
Although rare, stent thrombosis remains an important complication of PCI. Best 
assessments of risk with DES suggest an ongoing incidence of 0.3-0.6% per annum with a 
mortality rate of 10-30% (Garg and Serruys, 2010b). A significant reduction in risk has 
been obtained by improvement in stent technology and methods of assessing adequate 
deployment as well as the use of prolonged dual anti-platelet therapy. Incomplete stent 
strut endothelialisation and polymer-induced inflammation have been heavily implicated in 
the aetiology of stent thrombosis.  The potential of a gene-eluting stent to accelerate 
endothelialisation, thereby reducing the potential for thrombosis as well as inhibiting NIH 
makes it an intuitive competitor for the DES. To maximise effect however, delivery would 
have to be as biocompatible as possible, both from the perspective of any polymer used to 
bind the vector to the stent, as well as the delivery vector/transgene of choice. As 
previously discussed in the vectors section, local inflammation is a recognised issue. 
Although new-generation vectors may markedly reduce this in terms of systemic effects 
once delivered to the patient, even low-grade local inflammation may be enough to 
contribute to stent thrombosis. This approach requires testing in suitable preclinical models 
to identify safety and efficacy before moving on to randomized, controlled clinical trials 
with long term follow-up.  
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1.5 Human Perspectives and Clinical Trials 
1.5.1 In-stent Restenosis 
Other research began to investigate the safety and feasibility of intracoronary gene transfer 
in humans. A small initial study involved 15 patients undergoing percutaneous 
transluminal coronary angioplasty (PTCA) plus/minus stent delivery for stable 
symptomatic coronary artery disease. VEGF plasmid/liposome was delivered using a 
perfusion-infusion catheter post balloon angioplasty but prior to stent insertion. Of the 10 
patients randomised to receive VEGF, 9 received stents. The procedure was well tolerated 
with no significant adverse effects. However, no difference in restenosis rates were seen at 
follow-up angiography 6-months later. (Laitinen et al., 2000).  
This was followed by a Phase II study called the Kuopio Angiogenesis Trial (KAT) 
(Hedman et al., 2003). This was a randomized, placebo-controlled, double-blind study 
involving 103 patients with symptomatic coronary disease. Gene-delivery was performed 
using a perfusion-infusion catheter post-balloon angioplasty but pre-stenting. This time, 
however, patients were randomised to VEGF-expressing adenovirus (2x1010 plaque 
forming units, n=37), double the dose of VEGF plasmid/liposome used in the previous 
study (n=28) or Ringer’s lactate as control (n=38). Other than transient pyrexia in those 
receiving VEGF, and an elevation in serum C-reactive protein (CRP, a marker of 
inflammation) in those receiving Ad, no significant adverse effects attributable to gene 
therapy were identified. However, at 6-months follow-up using quantitative angiography 
there was no difference in minimal lumen diameter or percent of diameter stenosis 
(markers of ISR) between the groups. The authors did note an improvement in myocardial 
perfusion in the Ad-VEGF treated group and hypothesized that this may be due to VEGF-
induced angiogenesis.  
At a similar time to the KAT, the ITALICS trial was performed at the Thoraxcenter in 
Rotterdam (Kutryk et al., 2002). In this randomized, placebo-controlled, double-blind 
study 85 patients with symptomatic single-vessel coronary disease were assigned to 
placebo (physiologic saline) or antisense-ODN to the cell-cycle regulator c-myc. The gene 
therapy was delivered using a local-delivery catheter post-stent insertion. The dose of 
antisense ODN delivered was based on results from pre-clinical studies and pre-existing 
safety/efficacy data. Follow-up was again at 6 months but in this trial intravascular 
ultrasound (IVUS) as well as quantitative angiography was used. When results were 
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analysed no differences were seen in the rates of restenosis, degree of lumenal loss or 
clinical outcomes.  
A few other small clinical ISR studies exist including AVAIL (antisense oligomer to c-
myc post-PCI, n=44) (Kipshidze et al., 2007) and REGENT I Extension (iNOS lipoplex 
post-PCI, n=30) (von der Leyen et al., 2011). Both these studies suggested safety and 
feasibility of their compounds but were not powered for efficacy. ISR clinical trials are 
summarised in Table 1.2.  
The KAT trial aside, all studies to-date looking at gene therapy in ISR have used non-viral 
transduction methods. As histological analysis cannot be performed in these live patients, 
we are only able to hypothesise about the degree of cell transduction obtained. Based on 
what is known from pre-clinical studies, and with the perfusion catheters used, it is highly 
unlikely that these non-viral methods were able to provide sufficient cell transduction 
during delivery and following restoration of coronary blood flow, to provide a measureable 
clinical reduction in ISR. The study numbers were also low as these were Phase I studies, 
not designed to adequately assess efficacy. They did, however, show safety and feasibility 
of their approach. The KAT, the only Phase II trial, used an Adenoviral vector expressing 
VEGF in the hope of promoting re-endothelialisation. Again, through rigorous assessment 
this study showed that the process was safe, and well tolerated. Reasons for lack of 
efficacy likely include, poor transduction efficiency in VSMCs with first-generation Ad 
vectors (due to lack of CAR expression), presence of neutralising antibodies to the vector 
and interaction with circulating blood components (e.g. Factor X) as previously discussed.  
Ongoing developments in viral vector design and biocompatible polymers that can stably 
and measurable express a vector/gene of interest provide an avenue of continued hope for 
the role of gene therapy in preventing ISR. Although stent technology and associated 
clinical outcomes continue to improve (Bangalore et al., 2012), preclinical studies suggest 
that gene therapy with a safe and stable vector expressing endogenous proteins that restore 
normal vessel physiology can be an intuitive alternative to cytotoxic drugs for the 
prevention of stent complications.  
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Table 1-2 Clinical trials of gene therapy for the prevention of in-stent restenosis  
Trial N Gene 
Effect on ISR 
markers  
Adverse 
Effects 
Ref 
(Unnamed ) 15 VEGF P/L 
Nil  
 
Transient 
rise in CRP 
Laitinen et 
al, 2000 
Kuopio 
Angiogenesis 
Trial (KAT) 
103 
VEGF-
AdV 
VEGF P/L 
No effect on ISR 
Increase in 
myocardial 
perfusion in VEGF-
AdV group  
Pyrexia 
CRP rise 
Hedman et 
al, 2003  
ITALICS 85 
c-myc 
antisense-
ODN 
Nil Nil 
Kutryk et al, 
2002 
AVAIL 44 
c-myc 
antisense 
oligomer 
Nil Nil 
Kipshidze et 
al, 2007 
REGENT I 
Extension  
30 
iNOS 
lipoplex 
Nil Nil 
von der 
Leyen et al, 
2011 
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1.6 MicroRNA  
As previously discussed, vascular injury following stent delivery results in endothelial 
dysfunction, activation of inflammatory pathways, the proliferation and migration of 
smooth muscle cells, accumulation of neointima and the development of in-stent restenosis 
(Clowes et al., 1986, Gordon et al., 1993, Karas et al., 1992, Mitra and Agrawal, 2006, 
Jukema et al., 2012). The role of microRNAs (miRs) in the maintenance of EC and VSMC 
homeostasis and also the negative remodelling following vascular injury is an area of 
intense research. Increasingly, there is significant interest in the potential therapeutic role 
that modulation of these novel regulatory molecules may play. 
1.6.1 MicroRNA Processing and Function 
MiRs are a group of highly conserved, short (20-25 nucleotides), non-coding ribonucleic 
acids that act to control gene expression at a posttranscriptional level (Lee et al., 1993, 
Bartel, 2004). This is accomplished through translational repression or mRNA decay (Zhao 
and Srivastava, 2007) and has lead to them being described as an “efficient molecular 
switch” (Abdellatif, 2012). They have been shown to be increasingly important in the 
modulation of various biological functions in animals, plants and unicellular eukaryotes, 
are tissue specific and developmentally regulated. Their abnormal expression is known to 
cause developemental abnormalities and be important in the process of human disease, 
importantly cancer and disorders of the cardiovascular system (Thum et al., 2007, Calin 
and Croce, 2006, Kloosterman and Plasterk, 2006).  
1.6.1.1   MicroRNA Biogenesis 
The mechanism for the formation of miRs is evolutionarily conserved. MiRs are encoded 
in the genome and initial transcription by the enzyme RNA Polymerase II creates long 
precursor molecules called primary microRNAs (pri-miRs) that are hundreds to thousands 
of nucleotides long and 5′-capped and 3′-polyadenylated in a similar way to messenger 
RNA (mRNA) (Lee et al., 2004). Within the nucleus, endonucleolytic cleavage of these 
pri-miRs occurs, mediated by the RNase III enzyme Drosha, producing  ~60-100 
nucleotide hairpin-shaped precursor microRNAs (pre-miRs) (Lee et al., 2003, Gregory et 
al., 2004, Denli et al., 2004). Under the control of the nuclear export factor exportin 5 these 
pre-miRs are exported out of the nucleus and into the cytoplasm (Bohnsack et al., 2004). 
Within the cytoplasm a second cleavage occurs, this time mediate by the RNase III enzyme 
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Dicer, forming a mature miRNA/miRNA* double-stranded duplex ~22 nucleotides in 
length (Lee et al., 2002). This duplex miRNA undergoes incorporation into the RNA-
induced silencing complex (RISC) with the mature strand remaining part of the RISC 
while the passenger miRNA* strand is thought to be degraded, although this is increasingly 
less clear (Flynt and Lai, 2008).  The combination of RISC with mature miRNA then 
allows association predominately with the 3′-untranslated (3′UTR) region of target genes 
(Flynt and Lai, 2008). It acts as a negative regulator of gene expression by promoting 
mRNA degradation and/or translational inhibition depending on the degree of 
complementarity involved (Valencia-Sanchez et al., 2006). The imperfect nature of the 
miR:mRNA base pairing means that a single miR can target tens to hundreds of distinct 
mRNAs (Baek et al., 2008, Friedman et al., 2009, Selbach et al., 2008). The biogenesis 
pathway is summarised in Figure 1.4.  
Although typically it is through association with the 3′UTR that a miR regulates gene 
expression, it has been shown that base pairing can occur with the 5′UTR, exons or 
regulatory DNA sequences (Valencia-Sanchez et al., 2006). Complementarity between 
nucleotides 2 through 8 of the miRNA (“seed” region) appears to be essential for 3′UTR 
binding. This is why miRs with high sequence homology and identical seed regions are 
grouped into “families” likely to target similar sets of mRNAs (Lewis et al., 2005). To-date 
over a thousand miRs have been identified within the human genome, each of which could 
potentially target hundreds of mRNAs showing the depth of gene regulation involved (van 
Rooij, 2011, van Rooij, 2012). The majority of 3′UTRs contain binding sites for many 
individual miRs giving potential for cooperative interactions. Additional complexity is 
introduced with the potential for positive or negative feedback loops as the targets of many 
miRs can in turn modulate the expression of additional miRs. Furthermore, genetically 
clustered and cotranscribed miRs can often be expressed at different levels due to 
sequence-specific posttranscriptional maturation (Davis et al., 2008).  
Thus miRs elicit critical changes in expression of genes important in many biological 
functions including developmental timing, cell differentiation, proliferation and death and 
also metabolism (Bushati and Cohen, 2007, Grosshans and Filipowicz, 2008, Kloosterman 
and Plasterk, 2006).  
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Figure 1-4 The microRNA biogenesis pathway  
MicroRNAs (miRs) are encoded in the genome and transcribed by RNA Pol II to form long pri-
miRNAs that are 5′-capped and 3′-polyadenylated. In the nucleus, pri-miRNAs undergo initial 
cropping by Drosha to form ~60–100 nt pre-miRNAs. These pre-miRNAs are exported to the 
cytoplasm by exportin V and undergo second cropping by Dicer to form the mature miRNA/miRNA* 
duplex. The miRNA/miRNA* duplex is subsequently separated and only the ~22 nt miRNA strand 
stably associates with the RISC complex. The RISC complex, loaded with miRNA, then directs 
translational inhibition or promotes degradation of mRNAs containing partially complementary 
miRNA recognition sequences often located in the 3′UTR. Taken from Davis-Dusenbery and Hata, 
J Biochem. 2010;148:381–392. 
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1.6.2   MicroRNAs in the vasculature  
Several miRs have been shown to play key roles in establishing smooth muscle and 
endothelial cell fate and tissue homeostasis (Small and Olson, 2011, McDonald et al., 
2011b). For example, a number of groups have shown in mice that SMC-specific 
deficiency in Dicer results in embryonic lethality due to defective blood vessel formation 
(Albinsson et al., 2011, Albinsson et al., 2010, Pan et al., 2011).  Multiple miRs are now 
implicated in the complex regulation of the phenotype of cell types involved in vascular 
remodelling and the development of ISR (Figure 1.5). A list of miRs currently implicated 
in ISR and their proposed biological effects is given in Table 1.3.  
Table 1-3 MicroRNAs implicated in the vessel response to injury and development of 
neointimal hyperplasia  
MicroRNA Regulation after 
vascular injury Target Cell  Biological effect 
Molecular 
Targets Key References 
miR-21 Upregulation VSMC  Pro-synthetic or pro-contractile PTEN, PDCD4 Ji et al, 2007; 
miR-133a Downregulation VSMC Pro-contractile  SP-1, Moesin Torella et al, 2011; 
miR-143 Downregulation VSMC Pro-contractile ELK1, FRA1 
Fujita et al, 2008; 
Horita et al, 2011; 
Cordes et al, 
2009; 
Hergenreider, et 
al 2012; 
miR-145 Downregulation VSMC Pro-contractile ACE, KLF4/5, CALMK, MRTF 
Cheng et al, 2009; 
Boettger et al, 
2009; Xin et al, 
2009; Davis-
Dusenbery et al, 
2011; 
miR-146a Upregulation VSMC Pro-synthetic KLF4 Sun et al, 2011; 
miR-221 Upregulation VSMC  Pro-synthetic  C-KIT, p27, p57 Davis et al, 2009; Liu et al, 2011; 
 
     
miR-92a Unclear EC Cell adhesion and interactions  ITG-α 
Bonauer et al, 
2009; Iaconetti et 
al, 2012; 
miR-126 Unclear EC 
Cell adhesion, 
interactions, 
proliferation, 
migration, 
apoptosis and EPC 
recruitment 
VCAM-1, 
KLF2/VEGFR-2, 
CXCL12 
Kuhnert et al, 
2008; Wang et al, 
2008; 
 
     
miR-155 Upregulated Macrophages ?VSMC 
Inflammatory 
response, unclear 
role in ISR 
Yet to be 
established 
Nazari-Jahantigh 
et al, 2012; Wei 
et al, 2013; 
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Figure 1-5 MicroRNAs implicated in the vessel injury response, vascular remodelling, 
and angiogenesis  
Purple and green shaded regions indicate microRNAs with “pro-angiogenic” and “anti-angiogenic” 
characteristics, respectively. SMCs – smooth muscle cells; ECs – endothelial cells; ACE - 
angiotensin converting enzyme; SuFu - suppressor of fused (Fus-1); Shh - sonic hedgehog; HGS - 
Hepatocyte growth factor-regulated tyrosine kinase substrate; IGF - insulin-like growth factor; 
ITGA5 - integrin-α5; PIK3R2 - phosphoinositol-3 kinase regulatory subunit 2 (p85β); PTEN - 
phosphatase and tensin homolog; Spred-1 - sprouty-related EVH domain-containing protein-1; 
VCAM-1 - vascular cell adhesion molecule. Taken from Small et al, Circulation. 2010 March 2; 
121(8): 1022–1032 
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1.6.2.1   Complex role of miR-21 in restenosis 
MiR-21 is transcribed from within the coding gene TMEM49 (vacuole membrane protein) 
on chromosome 17 and was first described as an “oncomir” due to its high level of 
expression in various cancers (Bonci, 2010). It has subsequently been shown to play an 
important role in the proliferation of VSMC in response to injury (Ji et al., 2007), 
atherosclerosis (Raitoharju et al., 2011), EC response to shear stress (Kuehbacher et al., 
2007, Voellenkle et al., 2012, Weber et al., 2010b, Zhou et al., 2011) and the development 
of pulmonary hypertension (Parikh et al., 2012, Yang et al., 2012).  
Initial work by Ji et al, showed that following balloon injury expression levels of miR-21 
in rat carotid arteries were increased over 5-fold (Ji et al., 2007). Downregulation of miR-
21 using a locally delivered antisense oligonucleotide significantly reduced neointima 
formation in the same model. This was supported by the observation that the expression 
level of miR-21 was significantly higher in dedifferentiated (serum cultured) rat VSMC 
than freshly isolated differentiated cells. The authors demonstrated that their observed 
effects on neointima formation were mediated, at least in part, by suppression of 
phosphatase and tensin homolog and upregulation of Bcl-2 (Ji et al., 2007). PTEN is a 
tumour suppressor gene with known antiproliferative effects while Bcl-2 is an oncogene 
involved in promoting cell survival and proliferation (Matsumoto and Hwang, 2007). In a 
separate study, Yang et al, validated that miR-21 expression was upregulated in 
dedifferentiated VSMC and in ligated mouse carotid arteries (Yang et al., 2011). In their 
in-vitro model, the authors showed that miR-21 overexpression repressed the transcription 
factor specificity protein-1 leading to the down-regulation of cystathionine gamma-lyase, 
an enzyme responsible for producing hydrogen sulphide. This reduced H2S production 
contributes to stimulation of VSMC proliferation and reduced expression of differentiation 
markers.  
Conversely, however, when pulmonary VSMCs were differentiated using TGF-β and 
BMPs the expression of miR-21 was increased at a post-transcriptional level through the 
promotion of pri-miR-21 processing by SMAD protein binding to Drosha (Davis et al., 
2008). In this model the authors argued that miR-21 downregulates PDCD4 which acts as a 
negative regulator of VSMC contractile genes.   
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1.6.2.2   MiR-143/145 
The VSMC associated miR-143/miR-145 gene cluster has been implicated as being 
important in the regulation of SMC contractility and stress response following vascular 
injury (Small et al., 2010, O'Sullivan et al., 2011, Robinson and Baker, 2012). These 
highly conserved, bicistronic miRs lie close together on chromosome 5 (Boettger et al., 
2009, Cordes et al., 2009, Quintavalle et al., 2010).  Both miRs are highly expressed in 
VSMC, particularly within the walls of the aorta and coronary arteries in mice (Boettger et 
al., 2009, Cheng et al., 2009, Cordes et al., 2009, Elia et al., 2009, Xin et al., 2009).  
Initial in-vitro studies revealed that overexpression of miR-145 increases the expression of 
VSMC differentiation marker genes including smooth muscle alpha-actin (α-SMA), 
calponin and myosin heavy chain (MHC) (Cheng et al., 2009). When treated with miR-145 
the VSMC maintained a differentiated phenotype, while miR-145 inhibitor decreased 
levels of these differentiation marker genes (Cheng et al., 2009). Further work supported 
these findings with evidence of a strong regulatory effect exerted by miR-143/145 on 
VSMC differentiation (Cordes et al., 2009). Studies performed using in-vivo rodent models 
and utilising miR-143/miR-145 knockout animals demonstrated a reduction in miR-143 
and miR-145 expression following acute vascular injury (Xin et al., 2009, Elia et al., 2009, 
Boettger et al., 2009, Quintavalle et al., 2010). Furthermore, inhibition of neointimal 
development and promotion of contractile gene expression was achieved by miR-143 and 
miR-145 abrogation. Although miR-143/145 KO mice were found to be hypotensive, with 
abnormally thin vessel walls due to a reduction in contractile VSMC, and a concurrent 
increase in synthetic VSMCs they were however viable and fertile with no gross 
macroscopic defects (Boettger et al., 2009, Xin et al., 2009, Elia et al., 2009). This 
suggested that although fundamental for VSMC homeostasis in-vivo these miRs were not 
essential for development.  
The effects of the miR-143/miR-145 cluster on VSMC phenotype are mediated by diverse 
and complex signalling pathways. These are summarised in Figure 1.6. Serum response 
factor (SRF) and its cofactors myocardin and myocardin-related transcription factors 
(MRTFs) are key regulators in VSMC differentiation and de-differentiation (Miano et al., 
2007). SRF acts by binding to CArG-box elements within the promoter regions of 
contractile genes thus promoting gene expression (Miano et al., 2007). This results in  
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Figure 1-6 Summary of signalling pathways mediating effects of miR-143/miR-145 
cluster on VSMC phenotype 
KLF2 binds to putative KLF2-binding site in the miR-143/miR-145 promoter activating transcription, 
which leads to enrichment of miR-143/miR-145 in microvesicles that can be transferred to vascular 
smooth muscle cells. TGF-β promotes the binding of SMADs to SBEs in the miR-143/miR-145 and 
myocardin promoters, thereby increasing miR-143/miR-145 transcription both directly and indirectly 
through increasing myocardin–SRF interaction. TGF-β also promotes myocardin expression 
through a p38MAPK-dependent pathway. BMP4 promotes nuclear translocation of MRTF-A 
increasing its interaction with SRF and promotes miR-143/miR-145 transcription through the CArG 
box upstream of miR-143/miR-145 cluster. Jag-1 promotes the nuclear translocation of the 
NotchICD which forms a complex with CBF1 activating a CBF1-binding site in the upstream of miR-
143/miR-145. MiR-143 reduces miR-21 availability by negative regulation of FRA-1 leading to 
increase in PTEN expression. Mature miR-143 and miR-145 promote the expression of SMC 
marker genes and negatively regulate the transcription factors which promote proliferation and 
migration. BMP4 - bone morphogenetic protein 4; KLF2 - Kruppel-like factor 2; NotchICD - Notch 
intracellular domain; SBEs - SMAD-binding elements; SMC - smooth muscle cell; SRF - serum 
response factor. Taken from Robinson and Baker, Curr Opin Lipidol. 2012 Oct;23(5):405-11.  
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activation of miR-143 and miR-145 transcription (Cordes et al., 2009, Xin et al., 2009). 
Further contribution is provided by signalling molecules TGF-β and BMP4 which promote 
miR-143 and miR-145 expression by acting on myocardin (via both p38MAPK and 
SMAD-dependant pathways) and MRTF-A respectively (Davis-Dusenbery et al., 2011, 
Long and Miano, 2011). It is worth noting that these signalling pathways act 
independently. A further, SRF-independent pathway has been suggested to play a part in 
miR-143 and miR-145 regulation. In in-vitro studies the activation and nuclear 
translocation of Notch receptors by Jagged-1 led to an increase in miR-143/miR-145 
expression via formation of a complex with the transcriptional regulator CBF1 and 
subsequent SMAD-mediated CArG activation. (Boucher et al., 2011). This activation of 
Notch receptors promotes expression of VSMC contractile proteins calponin, α-SMA and 
SM22α, which are found to be reduced in cells treated with inhibitors of both miR-143 and 
miR-145 (Boucher et al., 2011).  
As previously discussed, miR-21 has been implicated in the regulation of VSMC 
proliferation through suppression of the anti-proliferative PTEN. SRF promotion of miR-
143 expression has been shown to indirectly decrease transcription of miR-21 via negative 
regulation of FRA-1, the net effect being an increase in PTEN levels (Fujita et al., 2008, 
Horita et al., 2011).  
Mature miR-143 and miR-145 act  by promoting the expression of VSMC marker genes 
and negative regulation of transcription factors involved in VSMC proliferation and 
migration (Rangrez et al., 2011). Krueppel-like factor 4 (KLF4) and Krueppel-like factor 5 
(KLF5) have been shown to be key targets of miR-145 (Cordes et al., 2009, Xin et al., 
2009, Cheng et al., 2009). These factors act as transcriptional repressors, playing a role in 
the regulation of VSMC phenotype by inhibiting proliferation and downregulating VSMC 
differentiation marker genes, notably α-SMA and myocardin (Garvey et al., 2010). 
Adenovirus-mediated restoration of miR-145 levels in rat carotid arteries subjected to 
balloon-injury was shown to reduce neointima formation through the promotion of 
myocardin secondary to KLF5 suppression (Cheng et al., 2009).  
Lastly, both miR-143 and miR-145 have been implicated in the paracrine regulation of 
VSMC phenotype by endothelial cells (Hergenreider et al., 2012). Krueppel-like factor 2 
(KLF2) is a transcription factor induced in endothelial cells following injury. When 
overexpressed in in-vitro ECs it results in enrichment of extracellular microvesicles with 
miR-143 and miR-145. When placed in co-culture with VSMCs these microvesicles 
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induced downregulation of KLF4 and also Ets LiKe gene 1 (ELK1) a transcription factor 
targeted by miR-143 with an inhibitory effect on VSMC differentiation (Hergenreider et 
al., 2012, Cordes et al., 2009). Additionally, injection of microvesicles taken from KLF2-
transduced ECs into fat fed ApoE-/- mice, reduced atherosclerotoic lesion area 
(Hergenreider et al., 2012). Taken together these results support functional miR transfer 
between ECs and VSMCs highlighting the importance of endothelial integrity in 
maintaining a contractile VSMC phenotype and the role miRs may play in this.  
These important in-vitro and in-vivo studies show that miR-143 and miR-145 expression is 
potentially very important in the regulation of VSMC phenotype through manipulation of 
key regulators of contractile gene expression. These models argue that miR-143/miR-145 
mediated downregulation of proproloferative and promigratory targerts is a key “molecular 
switch” in the maintenance of a contractile differentiated VSMC phenotype in-vivo that is 
lost following acute vascular injury and therefore may be a key modifiable factor in the 
development of ISR.  
1.6.2.3   MiR-221 
miR-221, a non-VSMC specific antiangiogenic oncomir, positively regulates SMC 
proliferation through modulation of cell-cycle regulators (McDonald et al., 2011b, Small et 
al., 2010). It is upregulated in VSMCs in response to platelet-derived growth factor beta 
(PDGF-β) and acts to reduce SMC differentiation by down-regulation of cKit and increase 
SMC proliferation by suppressing p27Kip1 and p57Kip2, two important cell cycle 
suppressors (Davis, Hilyard et al. 2009; Liu, Cheng et al. 2009; Liu, Cheng et al. 2011). In 
similarity to miR-21, Ji et al showed a moderate elevation in miR-221 expression 
following carotid artery angioplasty in the rat (Ji et al., 2007).  
1.6.2.4   miR-92a and miR-126 
Although not directly associated with VSMCs these EC-specific miRs have been shown to 
be important in the maintenance of vascular integrity and angiogenesis (McDonald et al., 
2011b, Small et al., 2010). Depletion of miR-126 in mice results in vascular leakage and 
haemorrhage with impaired wound healing and angiogenesis (Kuhnert et al., 2008, Wang 
et al., 2008).  
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miR-92a is also EC-enriched and shown to be upregulated following ischaemia with an 
apparent role as a negative regulator of vessel growth (Bonauer et al., 2009). In murine 
models of limb ischaemia and myocardial infarction, antagomir knockdown resulted in 
improved tissue recovery secondary to accelerated vessel growth (Bonauer et al., 2009). 
Using an in-vivo model of rat carotid artery balloon injury and stent delivery, Iaconetti et 
al, achieved enhanced re-endothelialization and reduced neointimal formation using an 
antagomir to miR-92a (Iaconetti et al., 2012). This lead the authors to hypothesise that 
inhibition of miR-92a held potential as a therapeutic strategy to improve endothelial 
regeneration and reduce restenosis after vascular injury (Iaconetti et al., 2012).  
1.6.2.5   miR-146a  
Following balloon angioplasty to the carotid artery in rats it was shown that levels of miR-
146 were elevated 2-3 fold (Ji et al., 2007). This was not further investigated in this study, 
however. Subsequently, it was shown that miR-146a may have a role in promoting VSMC 
proliferation in-vitro and vascular neointimal hyperplasia in-vivo (Sun et al., 2011). This 
effect appeared to be mediated by a negative feedback loop involving miR-146a and 
KLF4. Interestingly, KLF4 was shown to compete with KLF5 to bind to and regulate the 
miR-146a promoter resulting in opposing effects on miR-146a expression levels 
(decreasing and increasing respectively). By using both gain- and loss-of-function 
approaches, the authors found that miR-146a promoted VSMC proliferation in-vitro. Also, 
transfection of antisense miR-146a oligonucleotide into balloon-injured rat carotid arteries 
markedly decreased neointimal hyperplasia (Sun et al., 2011).  
The miR-146a/b family has also been implicated in the negative regulation of 
inflammation both in human peripheral blood monocytes following exposure to 
atherogenic stimuli (Chen et al., 2009) and also alveolar epithelial cells following exposure 
to cytokines (Perry et al., 2008). Overexpression of miR-146a was shown to reduce 
inflammatory cytokine release from dendritic cells subjected to an acute stimulus while 
antagomirs to miR-146a increased inflammatory cytokine secretion (Chen et al., 2011). In 
a chronic model of pulmonary inflammation miR-146a levels were reduced (Sato et al., 
2010). This potential role in the inflammatory response for a miR also implicated in 
neointimal formation is interesting in view of the previously discussed role for 
inflammation in both ISR and stent thrombosis.  
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1.6.2.6   miR-155 
miR-155 has been shown to be expressed in VSMC, ECs and primarily activated 
macrophages as well as being upregulated in human atherosclerotic lesions (O'Connell et 
al., 2007, Raitoharju et al., 2011). In the setting of ISR the recruitment of monocytes to the 
vessel wall and subsequent differentiation into macrophages is a crucial component of the 
inflammatory response that occurs during vessel remodelling (Wei et al., 2013). During 
this proinflammatory activation of macrophages, miR-155 has been shown to be 
upregulated and seen to exert a variety of pro and anti-inflammatory effects (Nazari-
Jahantigh et al., 2012). Whether it has any role in the development of restenotic lesions or 
regulation of VSMC phenotype awaits clarification.  
1.6.2.7   miR-133a 
miR-133a is abundantly expressed within the heart and plays a key role in both 
development and maintenance of cardiac and skeletal muscle (Care et al., 2007, Liu and 
Olson, 2010). There is also some evidence that it may play a role in VSMC phenotypic 
switch. In an elegant study, Torella et al revealed that miR-133a is negatively regulated by 
PDGF (an established promoter of VSMC proliferation) and that overexpression in-vitro 
inhibits both VSMC proliferation and Sp-1 (a promoter of KLF4) induction by PDGF 
(Torella et al., 2011). Using an in-vivo model of balloon-injured rat carotid arteries the 
authors showed that adenoviral overexpression of miR-133a resulted in reduced cell 
proliferation markers, prevented upregulation of Sp-1 and provided a significant (~60%) 
reduction in neointimal formation (Torella et al., 2011). Lastly they showed that silencing 
of miR-133a using an antagomir approach augmented intimal lesion formation suggesting 
that this pathway merits further investigation with regards to prevention of ISR.  
  Chapter 1 | Introduction 
51 
1.7 HYPOTHESIS  
The principle aim of this thesis was to investigate the potential of vascular gene therapy in 
the prevention of coronary in-stent restenosis, as an alternative to the current 
pharmacological approach of DES. It was hypothesized that a viral vector could be used to 
effectively deliver a therapeutic transgene to a porcine model of coronary in-stent 
restenosis and achieve a measurable reduction in neointimal hyperplasia. This hypothesis 
was tested in vivo using both a local delivery catheter approach and also the coating of a 
metal stent with viral vector using a thermoreversible gel.  
It is becomingly increasing evident that microRNAs play an important regulatory role in 
the maintenance of VSMC and EC homeostasis and that their dysregulation may play an 
important role in the development of neointimal hyperplasia and hold potential for  
therapeutic modulation. This remains to be tested in a large animal model of coronary stent 
delivery. It was hypothesized that miRs implicated in the development and regulation of 
NIH in rodent models of vascular injury would show similar patterns of dynamic 
dysregulation in a porcine model of coronary stent delivery. This hypothesis was tested 
using an in vitro model of VSMC proliferation and migration, and qRT-PCR and in-situ 
hybridization approaches in the in vivo porcine model.   
Lastly, miRs have been shown to be present, stably, in the circulation leading to interest in 
their potential use as cardiovascular biomarkers. This was assessed in the serum of patients 
undergoing CABG surgery. RNA was extracted from serum and dynamic expression of 
miRs determined using qRT-PCR. Correlation analysis was performed with classical 
biomarkers and perioperative factors. It was hypothesized that a panel of cardiovascular 
miRs showing measurable and consistent changes in expression would be identified 
allowing future correlation with clinical outcome in patients undergoing CABG surgery.    
  
2 Materials & Methods 
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2.1 CHEMICALS 
All chemicals, unless otherwise stated, were obtained from Sigma-Aldrich (Poole, UK). 
All cell-culture reagents were obtained from Gibco (Paisley, UK) unless otherwise stated. 
Dulbecco’s calcium and magnesium free phosphate buffered saline (PBS) was obtained 
from Lonza (Basal, Switzerland).  
 
2.2 CELL LINES 
Primary Human Coronary Artery Smooth Muscle Cells (HCASMC) were obtained from 
PromoCell GmbH (Heidelberg, Germany).  
Surplus human saphenous vein tissue was obtained with informed consent from patients 
undergoing CABG at the Golden Jubilee National Hospital. All procedures had local 
ethical approval (Research Ethical Committee number: 06/S0703/110 and 12/NW/0036) 
and experimental procedures conformed to the principles outlined in the Declaration of 
Helsinki.  Primary Human Saphenous Vein Smooth Muscle Cells (HSVSMC) were 
isolated from medial explants. 
For adenovirus production, human embryonic kidney cell line (293) cells were used. The 
transformed human embryonic kidney cell line (293T) was used for lentiviral production.  
 
2.3 TISSUE AND CELL CULTURE  
All experiments involving tissue and cell culture were performed under sterile conditions 
using biological safety class II vertical laminar flow cabinets. Cell lines were grown as a 
monolayer in 150 cm2 tissue culture flasks, maintained in appropriate cell culture media 
and incubated at 37oC in a 5% CO2 atmosphere incubator. Both HCASMC and HSVSMC 
were maintained in Smooth Muscle Cell Growth Medium 2 (PromoCell, Heidelberg, 
Germany) supplemented with 15% foetal bovine serum (PAA laboratories, UK), 2 mM L-
Glutamine (Invitrogen, Paisley, UK), 50 µg/ml penicillin (Invitrogen) and 50 µg/ml 
streptomycin (Invitrogen).  
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For the 293 and 293T cell-lines, cells were maintained in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% foetal bovine serum, 2 mM L-Glutamine, 50 
µg/ml penicillin and 50 µg/ml streptomycin 
Both in-vitro and ex-vivo experiments involving viral vectors were performed in a 
dedicated tissue culture laboratory with separate incubators to avoid cross-contamination.  
2.3.1 Preparation of smooth muscle cells from saphenous vein 
explants  
Saphenous vein explants were transported to the institute in culture medium immediately 
following completion of surgery by courier. Vessel segments were transferred to a large 
glass petridish containing sylgard and culture medium. The vein segment was cut 
longitudinally and pinned out using 25G hypodermic needles. The EC layer was removed 
by gently rubbing the inner vessel wall with the plunger from a 2ml syringe. Using a 
disposable blade the medial layer was scored at 1cm intervals. Using forceps the VSMC 
layer was then removed in squares and transferred to a separate petridish containing culture 
media. Following recovery, all VSMC layers were placed onto the white ceramic disc of a 
chopping table and chopped into approx. 1mm2 segments. These segments were washed 
from the chopping disc into a 50ml falcon tube containing culture medium. After allowing 
the VSMC segments to sink to the bottom of the tube, the culture media was siphoned off 
using a 20ml syringe with quill. The remaining cells were washed twice with 20ml of 
culture medium then transferred to a 25cm2 tissue culture flask with 5ml of fresh culture 
medium. Cells were incubated overnight then managed as per maintenance of established 
cell lines.  
2.3.2 Maintenance of established cell lines 
Cells were grown as a monolayer and the media replaced every 3-4 days. Cells were 
routinely passaged at approximately 80% confluence to prevent overgrowth and loss of 
surface contact in culture flasks. To passage, cells were washed twice in PBS and 
incubated with 5ml of trypsin-ethylenediamine tetra-acetic acid (trypsin-EDTA, Gibco, 
Paisley, UK) for 5 min at 37oC or until the majority of cells had detached from the flask 
surface. The action of trypsin-EDTA was then attenuated by the addition of 5ml culture 
medium. Cells were pelleted by centrifugation at 1500rpm for 5 min. Media/trypsin-EDTA 
were poured off and the pellet re-suspended in culture media for further passaging or 
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plating. Before plating cells were counted using a haemocytometer (Hausser Scientific, 
PA, USA) to allow calculation of the required seeding density.  
2.3.3 Cryopreservation and recovery of cultured cell lines 
For cryopreservation cells were harvested as described in section 2.3.2. The cell pellet 
from an ~80% confluent 150cm2 culture flask was re-suspended in 2ml culture media 
supplemented with 10% dimethyl sulphoxide (DMSO). This cell suspension was then 
aliquoted into a cryopreservation vial and cooled at a constant -1oC/min to -80oC using 
isopropanol. Frozen vials were then transferred to liquid nitrogen tanks and stored at -
196oC indefinitely.  
Cell recovery was achieved by rapid thawing in a water bath at 37oC, followed by drop-
wise addition of 10ml pre-warmed culture media to allow for slow change in the osmotic 
gradient. Cells were pelleted by 1500rpm centrifugation for 5 min and resuspended in 
culture media before addition to a 25cm2 culture flask. Following overnight incubation, the 
medium was changed and cells were managed as per section 2.3.2.  
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2.4 PRODUCTION OF VIRAL VECTORS 
2.4.1 Recombinant Ad5 production 
The AdGFP vector used in Chapter 3 is a recombinant Adenovirus species C serotype 5 
expressing enhanced GFP from the CMV promoter. This RAd-eGFP vector was previously 
generated in-house as described by Dishart et al and Nicklin et al (Nicklin et al., 2001b, 
Dishart et al., 2003).  
High titre stocks were obtained through large-scale expansion of a plaque pure stock of 
AdGFP in 293 cells. Cells were grown to approximately 80% confluence as previously 
described and then infected with virus using a multiplicity of infection of 1 plaque forming 
unit (pfu) per cell. After 3 to 4 days incubation the cytopathic effect of the virus caused the 
cells to detach from the base of the culture flask and the media/cell suspension was 
collected. Cell harvesting was achieved by centrifugation at 2000rpm for 10min. The 
supernatant was removed and the cell pellet re-suspended in 8ml PBS. To remove excess 
non-viral proteins, 8ml Arklone P (trichlorotrifluoroethane) was added and mixed by 
gentle inversion. This mixture was then centrifuged at 3000rpm for 15 min. The top 
aqueous layer containing the virus was removed and stored at -80oC.  
2.4.2  AdGFP purification through caesium chloride gradient 
Sterilised (70% Ethanol/30% sterile dH2O) clear 14ml ultracentrifuge tubes (Beckman 
Coulter, London, UK) were placed in a tube rack. A caesium chloride (CsCl) gradient was 
produced by adding, in order, 2.5ml of CsCl with a concentration of 1.45g/ml, 3ml of CsCl 
with a concentration of 1.32g/ml and 2ml of 40% glycerol. Care was taken not to mix the 
layers. The crude Ad5 stock from section 2.4.1 was then added and the remaining volume 
of the tube filled with PBS. 
Tubes were transferred to a Sorvall Discovery 90 rotor container (Sorvall Centrifuges, 
Connecticut, USA) and ultracentrifuged at 25,000rpm for 1.5h at 4oC with maximum 
acceleration and zero deceleration. This creates a distinct opalescent band of virus situated 
between the two CsCl layers. The virus is removed by carefully piercing the tube below the 
band using a 21G needle and removing the band in the minimal volume possible while 
taking care not to disrupt the other layers. This extracted virus is carefully added to a 
SlideA-Lyzer dialysis cassette with a molecular weight cut-off of 10,000 Da (Perbio 
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Science, Cramlington, UK). The virus was dialysed against 0.01M Tris pH 8.0 and 0.001M 
EDTA (2L volume), first for 2h then overnight in fresh buffer and finally for a further 2h 
in fresh buffer supplemented with 10% (v/v) glycerol. Purified virus was finally extracted 
from the cassette and stored at -80oC in 50µl aliquots.  
2.4.3 Virus titration by end-point dilution assay 
Initially 293 cells were seeded to approximately 60% confluence in a 96-well plate. Ten-
fold serial dilutions of virus stock were made using PBS and then added to the plate with 
ten replicates of each titration (100µl/well). Following overnight incubation the media was 
replaced with 200µl culture medium. Media was replaced every 2-3 days and wells were 
examined for cytopathic effects using a microscope. The development of cytopathic effects 
represented infection and once apparent the well was “marked-off” and the media no 
longer replaced. Following 8 days incubation the number of wells containing plaques were 
counted. From these, the titre of the adenoviral stocks in pfu/ml can be obtained as follows: 
• The proportionate difference = (%positive above 50% - 50%) / (%positive above 
50% - % positive below 50%) 
• Log ID50 (infectivity dose) = log dilution above 50% + (proportionate distance x -1) 
x dilution factor 
• TCID50 (tissue culture infectivity dose) = 1/ID50 
• TCID50/100µl x dilution factor (10) = TCID50/mL 
• 1 TCID50/ml = 0.7pfu  
2.4.4 Quantification of virus particles 
Virus particle titre was determined using the protein content of the virus stock. This was 
established using the Micro bicinchoninic (BCA) Protein Assay Kit (Thermo Fisher 
Scientific, IL, USA). Bovine serum albumin (BSA) standards at concentrations of 200, 40, 
20, 10, 5, 2.5, 1 and 0.5µg/ml were prepared in PBS and 150µl of each pipetted in 
duplicate into a 96-well plate. A blank control of 150µl PBS was used. 1, 3 and 5µl of the 
virus stock was then added in duplicate and made up to 150µl with PBS. A working 
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reagent comprising 25 parts reagent A, 24 parts reagent B and 1 part reagent C from the kit 
was then prepared and 150µl added to each well. The plate was then covered and incubated 
at 37oC for 2h. After cooling to room temperature levels of absorbance at 570nm are 
measured using a plate reader. The values from the blank control (background) are 
subtracted from all samples and standards. A standard curve was then created allowing the 
amount of protein present in each virus to be established. The virus particle number can 
then be calculated using the formula 1µg protein = 1x109 viral particles. 
2.4.5 Recombinant Ad5 expressing LacZ 
All experiments in this thesis involving AdLacZ used a high grade commercial virus RAd 
35 (Baylor College of Medicine Vector Development Lab, TX, USA). This Ad5 vector 
expresses β-galactosidase, a hydrolase enzyme coded by the gene lacZ from its CMV 
promoter. All virus used (in-vitro and in-vivo) came from the same production batch and 
had titres of 4.7x1012 particles/ml and 2.5x1011 pfu/ml.  
2.4.6 Production of Lentivirus expressing eGFP 
The second-generation lentiviral vector expressing enhanced GFP used in Chapter 3 had 
previously been developed in-house (Dishart et al., 2003). It utilises a lentiviral construct 
plasmid encoding the marker gene, enhanced green fluorescent protein (eGFP), (pHR’SIN-
cPPT-SFFV-eGFP-WPRE) under the control of the spleen focus forming virus (SFFV) 
promoter, pseudotyped with the vesicular stomatitis virus glycoprotein (VSV-g) expressed 
by the pMD.G2 plasmid and the lentivirus packaging plasmid containing the wildtype 
integrase gene (pCMV delta R8.74) (Demaison et al., 2002, Yanez-Munoz et al., 2006).  
This vector was produced in low passage 293T cells by standard triple transfection with a 
vector construct, envelope plasmid (pVSV-G) and packaging plasmid (Int 8.74). Low 
passage 293T cells were seeded (12x106/T175 flask) and incubated overnight at 37oC. Into 
5ml of OptiMEM (Life Technologies, CA, USA), 50µg of vector construct, 17.5µg of 
envelope plasmid and 32.5µg of packaging plasmid were added and then sterilized by 
filtration through a 0.22µm filter. In a separate tube, 1µl of 10mM polyethylenimine (PEI) 
was added to 5ml OptiMEM and sterile filtered. Both solutions were then combined and 
incubated at room temperature for 20min. After washing with OptiMEM I reduced serum 
media with Glutamax I to remove any remaining serum, 10ml of the transfection mixture 
was added to each T175 flask and incubated at 37oC for 4 hours in 5% CO2. The 
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transfection mixture was then removed and replaced with 20ml fresh DMEM media and 
returned to the incubator. The virus-containing supernatant was collected 48h later and 
filtered in a 0.22µm filter unit before being stored at 4oC. Fresh DMEM (10ml) was added 
to the flasks and the final supernatant collected, filtered and added to the first batch at 72h.  
2.4.7 Concentration of Lentivirus 
A Beckman Optima L-80 XP Ultracentrifuge (Beckman Coulter Ltd, Buckinghamshire, 
UK) was pre-cooled to 4oC using the vacuum setting. Six 15ml ultra-clear centrifuge tubes 
were sterilised in ethanol and 15ml of the previously collected and sterilised virus-
containing supernatant was added to each. The tubes were loaded into the SW-32.1 Ti rotor 
system (Beckman Coulter) and ultracentrifuged at 23,000rpm for 2h at 4oC (maximum 
acceleration, 9 deceleration). The supernatant was immediately removed, care being taken 
not to disturb the virus pellet and the tubes were refilled with remaining supernatant from 
section 2.4.6 and re-centrifuged until complete. After the final spin and removal of 
supernatant, 100µl of OptiMEM I reduced serum media with Glutamax I, was added to 
each tube followed by 20min incubation on ice. After thorough pipette resuspension the 
tubes were pooled and then aliquoted (5µl aliquots) before freezing at -80oC.  
2.4.8 Calculation of virus titre in 293T cells 
Firstly, a 12-well plate was seeded with a 293T cells at a density of 5x104cells/well and 
incubated for 24h. The media was then removed and replaced with 1ml fresh supplemented 
DMEM (section 2.3). Serial dilutions (10-2-10-6) of the freeze-thawed lentiviral stock 
(section 2.4.7) were prepared and added to each well in duplicate (30µl then 100 µl). 
Following a 72h incubation (37oC, 5%CO2) the media was removed, each well was washed 
with 500µl PBS and then cells were re-suspended in 200µl PBS following detachment with 
a rubber policeman.  
Viral DNA was extracted from each sample using the QIAamp DNA Mini Kit (QIAGEN, 
Limburg, Netherlands) according to manufacturer’s instructions. The detached cells were 
transferred to 1.5ml eppendorfs and then 20µl of the broad-spectrum serine protease 
proteinase K added. This step is required to break down contaminating proteins present 
during DNA extraction. Next, 200µl of lysis buffer AL (SDS, EDTA and guanidine 
hydrochloride) was added before incubation at 56oC for 10 min to achieve optimal lysis. 
SDS acts as a detergent, disrupting the phospholipids present in cell membranes and EDTA 
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chelates divalent metals (mainly magnesium and calcium) resulting in cell membrane 
destabilisation and cell lysis while also inhibiting DNases. Guanidine hydrochloride is a 
chaotropic salt that facilitates the absorption of DNA (but not RNA, polysaccharides, 
proteins etc) onto the silica-gel membrane in the QIAamp spin columns.  
Following the addition of 200µl of 100% ethanol each sample was mixed by pulse-vortex 
and loaded into a QIAamp spin column. Samples were centrifuged at 6000g for 1 min to 
allow DNA absorption onto the silica membrane. Flow-through was discarded. The spin 
column was then washed with 500µl buffer AW1 (guanidine hydrochloride and ethanol) 
and centrifuged at 6000 x g for 1 min. A second wash of buffer AW2 (ethanol) was added 
and the samples centrifuged at 20,000 x g for 3 min to dry the columns. Each spin column 
was then placed in a clean eppendorf and 50µl sterile water added. After leaving to rest for 
5 min to allow DNA elution, a final centrifuge step (6000 x g for 1min) was performed. 
This final elution step was repeated to maximise DNA yield and then DNA levels were 
measured using spectrophotometric quantification.  
The lentivirus  genomic copy number was quantifed in this extracted DNA by TaqmanTM 
quantitative real time PCR (qRT-PCR) according to a published protocol for late reverse 
transcriptase amplicon (Butler et al., 2001). Standard curves for quantification were 
prepared by serial dilution of lentiviral vector construct plasmid DNA of known 
concentrations (determined as above), based upon the following equations:  
• Molecular weight of plasmid DNA = (Base Pairs) x (330 Daltons x 2 nucleotides / 
base pairs) = Daltons (1 Dalton = 1 g/mole) 
• Weight of one copy of plasmid DNA (molecule) = g/mole / Avagadro’s constant 
(molecules/mole) = g/molecule 
• Copy number of plasmid DNA per ml of plasmid stock = Concentration of plasmid 
(g/ml) / g/molecule  
• Initial dilution for top standard = Copy number of plasmid/ml / top standard 
required  
• Convert to microlitres = 1000 / initial dilution factor for top standard = µl of 
plasmid DNA stock required for 1ml 
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For each 12.5µl reaction of the 384-well TaqManTM plate the following was added: 
• 6.25µl of 2 x TaqMan universal mastermix (contains AmpliTaq Gold DNA 
polymerase, dNTPs, passive reference and optimised buffer components).  
• 3.125µl primer/probe mix 
• 250ng DNA or 1µl plasmid DNA standard 
• 2.125µl sterile water 
Each standard and sample was run in triplicate. A non-template control (substitute 1µl 
sterile water for plasmid DNA), again in triplicate, was added to eliminate false positives.  
The plate was run on an Applied Biosystems 7900HT fast real-time PCR system, under the 
following conditions: an initial incubation of 50oC for 2 min then an initial denaturing step 
of 95oC for 10 min, followed by 40 cycles of amplification consisting of denaturing (95oC, 
15s) and annealing/extending (60oC, 1 min). The amount of real RT amplicons during each 
cycle were detected by measuring the increase in FAM fluorescence (quenched by 
TAMARA) with excitation at 540nm and emission at 570nm. Data acquisition was 
performed during the exponential phase.  
The raw cycle number or cycle-threshold (Ct) for both standards and samples were 
exported from SDS v2.3 software (Applied Biosystems, Foster City, CA, USA) and 
exported into a spreadsheet. The standard curve of the measured standards was plotted 
using the formula x = log(x) to form a linear regression and allow calculation of the 
equation of the line. Titre samples were then averaged across the triplicates and corrected 
using the equation of the line. Infectious viral units per ml (iu/ml) of each sample dilutent 
were calculated using the following sequential equations: 
• Total DNA extracted = concentration of DNA (ng/µl) x volume of DNA eluted (µl) 
• %Total DNA added to TaqMan = (250ng/total DNA extracted)x100 
• Cell number used in qRT-PCR reaction = (5x104) x (%Total DNA added/100) 
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• Amplicon copy number/cell = Corrected samples (from spreadsheet) / cell number 
used 
• Infectious viral units / ml (iu/ml) = [(Dilution factor x 1000) / volume of virus 
added to plate (µl)] x copy number/cell 
The mean of all sample diluents from the titre plate was taken to give a final titre and 
reported in iu/ml.  
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2.5 VIRUS TRANSDUCTIONS 
These experiments were performed in Chapter 3 to test the ability of adenoviral and 
lentiviral vectors to transduce human VSMC.  
2.5.1 Virus cell binding 
Cells were seeded in a 12-well plate at a seeding density of 2x105 cells / well and 
incubated overnight at 37oC to achieve 70-80% confluence the following day. The cells 
were subsequently washed twice with PBS before being transferred to serum-free media. 
Viruses were diluted to the desired concentration using serum free media. For Ad5 
transductions, concentrations were calculated in viral particles /cell (vp/cell). Lentiviral 
vectors were diluted to the required MOI using the following equation:  
Amount of viral stock required (µl) = (Number of cells x MOI needed) / iu/µl 
All infection incubations were performed for 4h at 37oC unless otherwise stated. Cells 
were washed twice in PBS to remove unbound virus then placed in fresh complete media 
and incubated for 48h before transgene expression was assessed by microscopy and 
transgene quantification.  
For experiments involving RAd 35 transduction, cells were washed in phosphate buffered 
saline (PBS) and infected with 5000vp/cell of virus in the presence or absence of 
physiological concentrations (10µg/ml) of coagulation FX (Haematologic Technologies, 
Vermont, USA) and presence or absence of 15% Poloxamer 407 (BASF, Ludwigshafen, 
Germany) in serum-free media. Incubation times used were 1, 5, 10, 30 and 60mins, after 
which cells were washed twice with PBS, transferred into standard VSMC media and 
incubated for a further 48 hours at 37°C.  Cells were harvested and lysed by freeze-
thawing in 0.2% Triton-X100/PBS. All experiments were performed 3 separate times in 
triplicate. 
2.5.2 Determination of Protein Concentration in Cell and Tissue 
Lysates 
The amount of protein in cell lysates was determined using the micro bicinchoninic acid 
(BCA) assay kit (Pierce, Rockford, USA) as per manufacturer’s instructions. Briefly, a 
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standard curve was generated using dilutions of BSA ranging from 25µl/ml to 2000µg/ml. 
200µl of BCA working reagent (Reagent A:B, 49 parts:1 part dilution) was added to 25µl 
of cell or tissue lysate or standard in duplicate in a 96-well plate. The plate was covered to 
protect from light then incubated at 37oC for 30 min. The absorbance was measured at 
570nm on the Wallac VICTOR2 plate reader (Wallac, Turku, Finland).  
2.5.3 GFP transgene quantification 
After PBS washing, 50µl of 1 x Reporter Lysis Buffer was added. Cells were placed on ice 
and mechanically dislodged from the plate surface using a rubber policeman. A standard 
curve of recombinant GFP, ranging from 0.01 to 1µg/ml was produced and 100µl of each 
dilution was added in duplicate to a 96-well plate. 100µl of PBS was added in duplicate as 
a blank control. 20µl of each sample from section 2.5.1 was then added to a fresh well in 
duplicate 80µl 1 x Reporter Lysis Buffer was added. The plate was incubated at room 
temperature for 10 min before luminescence was measured using a Wallac VICTOR2 plate 
reader (Wallac). GFP activity was then normalised to the total protein content of the 
samples, measured by bicinchoninic acid assay (section 2.5.2) producing relative light 
units per milligram protein (RLU/mg protein).  
2.5.4 Β-galactosidase transgene quantification 
Expression of β-galactosidase was quantifed using the Tropix Galacto-Light Assay Kit 
(Applied Biosystems, Foster City, CA, USA) as per the manufacturer’s instructions. After 
removal of media, cells were rinsed with PBS. 1ml of lysis buffer (500ml PBS/1ml Triton-
X) was added to each well of the 12-well plate and cells scraped with a rubber policeman. 
The plate was freeze/thawed and cell lysis was confirmed using microscopy. 10µl of each 
sample was transferred to a black 96-well plate and 70µl of Tropix Galacton Plus:Galacto-
Light Diluent mix (1:100 dilution of Tropix Galacton Plus in 100mM NaH2PO4 and 1mM 
MgCl2, pH 8) was added. Cells were covered in tinfoil to protect from light and incubated 
at room temperature for 1 hour. 100µl of Tropix Accelerator II was added to each well and 
incubated for 2 min. Luminescence was measured using a Wallac VICTOR2 plate reader 
(Wallac) as in section 2.5.2. β-galactosidase activity was normalised to total protein 
content of the samples, measured by bicinchoninic acid assay as before (section 2.5.2) 
giving results in relative light units per milligram protein (RLU/mg protein).  
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2.5.5 LacZ staining  
Cells that had been transduced by RAd 35 were fixed for 10 minutes in 4% 
paraformaldehyde (PFA) at 4oC. After 3xPBS washes (5 min) cells were then stained with 
sterile-filtered X-gal working solution- [(20ml): 1.54 ml 1M Na2HPO4, 0.46 ml 1M 
NaH2PO4, 26µl 1M MgCl2, 1.2ml 50mM K3Fe(CN6), 1.2ml 50mM K4Fe(CN6), 1ml of 
20mg/ml x-gal (dissolved in dimethyl formamide) and 14.574ml dH2O].  Cells were 
incubated at 37°C for 24 hours in the dark and were then washed twice in PBS (5 min) 
prior to imaging by microscopy (section 2.9).  
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2.6 HAEMAGGLUTINATION ASSAY 
With regard to the use of a porcine model of ISR to test viral gene delivery it was 
important to establish any potential interaction between Ad5 and porcine erythrocytes. This 
was assessed using a haemagglutination assay performed according to previously 
published methods (Cichon et al., 2003, Nicol et al., 2004).  
2.6.1 Preparation of erythrocytes 
Blood was taken from pigs, by puncture of the pulmonary arteries at time of euthanasia 
using an 18G needle and 20ml syringe, and added to a 15ml falcon tube containing 140ul 
citrate phosphate dextrose (CPD) (Sigma) per ml of blood. Human blood was taken from 
healthy volunteers and treated the same. 8ml of Percoll (Sigma) solutions of 81%, 70%, 
and 55% (v/v) were prepared using HBSS pH7.2 (Gibco, Paisley, UK). For example, for 
55% (v/v): 4.4ml Percoll was added to 3.6ml HBSS. Percoll gradients were then prepared 
in a 15ml Falcon tube with 2ml of 81% Percoll solution at the bottom and 2ml of 70% 
Percoll solution carefully added on top followed by 2ml 55% Percoll solution.  2ml of 
blood was then carefully pipetted on top of the gradient. The tubes were transferred to a 
centrifuge and spun at 3000rpm for 4 min and then at 2500rpm for 6 min. This forms a 
series of bands with the erythrocytes contained in the dense red band in the middle. The 
solution above the erythrocyte band was carefully removed before the erythrocyte band 
was then siphoned off using a P200 pipette and the volume recorded. To the erythrocytes, 
an equal volume of filtered 4% dextran (v/v) was added and the solution was mixed well 
and incubated for 6 min at room temperature. An equal amount of 2 % dextran (volume of 
erythrocytes + same added volume of 4% dextran) was then added and the suspension 
incubated for 30 min at 37oC. The upper layer of dextran sedimentation was removed (the 
erythrocytes are now the lowest layer in the dextran sedimentation) and 5mls of PBS was 
added to re-suspend the erythrocytes. After further centrifugation at 865rpm for 8 min the 
cells were washed then re-suspended in 2mls of 55% Percoll. This suspension was applied 
to a fresh Percoll gradient and centrifuged as before. Finally, the erythrocyte band was 
removed and diluted to the required concentration (v/v) in PBS.  
2.6.2 Haemagglutation Analysis 
Virus solutions were diluted by 1/25, 1/50, 1/100, 1/200 in PBS. 50µl of the chosen 
erythrocyte solution was pipetted into each well of a concave bottomed 96-well plate.  
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Carefully, 50µl of a virus dilution was added doing each virus dilution in duplicate where 
possible. PBS was used instead of virus for uninfected control wells and a positive control 
for agglutination was added (1% Triton X-100 to lyse the RBCs). Plates were gently 
swirled to mix erythrocyte and virus solutions together and incubated at 37oC for 2hrs to 
allow sedimentation. Plates were then graded as according to published criteria (Cichon et 
al., 2003). A red button shaped spot in centre of well = no haemagglutination, and a cloudy 
well with no spot = complete haemagglutination.  
 
2.7 GENERAL MOLECULAR BIOLOGY TECHNIQUES 
2.7.1 Vascular Smooth Muscle Cell Stimulation  
This section, and 2.7.2 describe the methods used in Chapter 4 human in vitro experiments. 
HCASMC were seeded at a density of 5x104 cells per well in a 12-well plate using normal 
SMC media (see section 2.3) and incubated overnight at 37oC to achieve ~80% 
confluency. The media was removed and cells washed once with PBS. To each well, 1ml 
of serum-free (0.1%) high-glucose DMEM was added and the plates incubated for a further 
48h (quiescence) to induce a differentiated contractile state.  
The cells were then stimulated to a dedifferentiated proliferative phenotype by replacing 
media with the following mitogens (in duplicate): 
• No serum (serum-free DMEM) as an undifferentiated control 
• 15% serum (in normal SMC media) 
• PDGF-BB at 20ng/ml (stocks at 10µg/ml so 2µl added to 1ml media) 
• IL-1α at 10ng/ml (stocks at 1µg/ml [made up in 0.1% BSA/PBS as per 
manufacturers instructions] so 10µl stock added to 1ml media)  
• Combined PDGF_BB and IL-1α (at same concentrations as above)  
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• bFGF at 20ng/ml (stocks at 10µg/ml so 2µl added to 1ml media) 
Each plate was then incubated at 37oC for a variable duration of time dependant on the 
time-point being studied (1h, 5h, 18h or 24h).  At the appropriate time point, cells were 
washed again with PBS and 700µl QIAzol (QIAGEN) added to allow cell harvesting and 
extraction of RNA.  
2.7.2 Cell migration 
HCASMC were seeded in 12-well plates and quiesced in 0.1% media for 48 hours as 
described in section 2.7.1. A previously described scratch assay was then used as this has 
been shown to effectively and simply mimic cell migration in-vivo (Liang et al., 2007). 
This method is based on the observation that, upon creation of a new artificial gap (a 
scratch or wound) on a confluent cell monolayer, the cells on the edges of the newly 
created gap will move together to close the scratch until new cell–cell contacts are 
established again. In this thesis, the purpose of this assay was not to directly measure the 
degree of migration obtained, but to promote a migratory cell phenotype and measure 
associated changes in microRNA expression. Direct quantification of the degree of 
migration was therefore not obtained and microscopy was only used to confirm the 
presence of cell migration at each time-point. A 200µl pipette tip was used to produce three 
evenly sized vertical scratches per well. Cells were then washed with PBS, placed in fresh 
media and returned to the incubator. Images were captured at 0, 6 and 16 hours post-
scratch. At the appropriate time point, cells were washed again in PBS and harvested by 
the addition of 700µl QIAzol (QIAGEN) as in section 2.7.1.  
2.7.3 RNA extraction 
The following sections describe methods used in Chapter 4 for the quantification of miR  
both in vitro and in vivo. 
2.7.3.1  Total RNA extraction from cells  
RNaseZap (Ambion, TX, USA), a surface decontamination solution that destroys RNases 
on contact, was used to clean all apparatus and work surfaces. RNase-free filter tips were 
used in all experiments using RNA. Total RNA (including miRNA and small RNA 
fractions) was extracted from cells using the miRNeasy Mini Kit (QIAGEN) as per 
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manufacturer’s instructions. Briefly, cells were harvested in QIAzol, transferred to RNase-
free 1.5ml eppendorfs and 140µl of cholorform was added. The samples were mixed by 
15s of vigorous shaking. Following a 2-3 min incubation at room temperature, the 
homogenate was centrifuged at 12,000 x g for 15 min at 4oC. The upper aqueous phase was 
added to a new collection tube (care taken to avoid transfer of any interphase) and 1.5 
volumes (usually ~525µl) of 100% ethanol added to ensure ideal binding conditions. The 
samples were then mixed thoroughly by pipetting and up to 700µl transferred into a 
RNeasy Mini filter column in a 2ml collection tube. After centrifugation at > 8000 x g for 
15 secs at room temperature the flow-through is discarded. This centrifugation allows the 
RNA to bind to the silica-gel membrane of the spin column. This spin is repeated until all 
of the sample (in aliquots of up to 700µl) has passed through the membrane. At this point, 
on-column DNAse treatment was performed using the RNase-Free DNase Set (QIAGEN) 
as per the manufacturer’s instruction. Briefly, 350µL of buffer RWT was added to the 
column and centrifuged for 15 secs at 8000 x g to wash. The flow-through was again 
discarded. 10µL of DNAse I stock solution was added to 70µL of buffer RDD in a clean 
eppendorf and mixed by gentle inversion. This DNase I incubation mix was then pipetted 
directly onto the RNeasy Mini spin column membrane and incubated on ice for 15 min. A 
further wash step, adding 350µL of buffer RWT into the column and centrifuging for 15s 
at 8000 x g was then performed and the flow-through discarded. Returning to the protocol, 
two further wash steps using 500µL of buffer RPE with spins of 8000 x g for 15s and 2 
min respectively are followed by elution of the RNA into 30µl of RNase-free water in a 
fresh collection tube (1.5ml eppendorf). The eluted RNA was passed through the spin 
column again to increase the RNA yield. The quantity of total RNA in each sample was 
quantified by NanoDropTM (ND-1000 spectrophotometer [Labtech International, Ringmer, 
UK).  
2.7.3.2   Total RNA extraction from tissue  
RNA extraction from porcine tissue was perfomed using the above method with some 
modifications. Frozen vessels were disrupted under liquid nitrogen in a pestle and mortar. 
Any stent present was removed at this point using careful dissection. The arterial fragments 
were homogenized (Polytron, Switzerland) in a bijou containing 1400µl of QIAzol 
(Qiagen) with intermittent cooling of the sample on ice. The homogeniser blade had been 
cleaned with 3% H2O2 for 30 mins before and after use and then washed with Nuclease 
free water prior to use. Once completely homogenized, the sample was left to incubate for 
5 min at room temperature before the addition of 280µl of cholorform and thorough 
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mixing. From this point on the method followed was as documented above for extraction 
from cells.  
2.7.4 cDNA synthesis  
For miRNA expression analysis, cDNA was synthesized from total RNA using stem-loop 
reverse transcription primers and RT kit (Applied Biosystems, Foster City, CA, USA). 
Each reaction utilises an RT primer specific to an individual miR. The RT product 
therefore contains single-stranded cDNA complimentary to the miR of interest only. Total 
RNA was diluted into aliquots at 2ng/µl concentration using RNase-free water. RT was 
performed in a 96-well PCR plate (Thermo Scientific) and is prepared on ice. Each well 
contains 2.5µl of total RNA (5ng) in addition to the following: 0.075µl of 100mM dNTP 
mix (with dTTP), 0.5µl MultiScribeTM Reverse Transcriptase (50U/µl), 0.75µl 10x RT 
buffer, 0.1µl RNase Inhibitor (20U/µl), 2.08µl Nuclease-free water and 1.5µl of specific 
miR (or endogenous control) primer. The plate was then mixed by gentle centrifugation 
and run on a PCR block. Thermal cycling conditions were 16oC for 30 min (to allow for 
primer annealing), 42oC for 30 min (to allow for cDNA synthesis) then finally 85oC for 5 
min to stop the cDNA synthesis reaction and to destroy any DNase activity. Plates were 
then stored at -20oC until required for qRT-PCR.  
2.7.5 Quantitative Real Time Polymerase Chain Reaction 
TaqManTM qRT-PCR (Applied Biosystems, ABI Prism, 7900HT Sequence Detection 
System) was used to quantify the relative concentration of miRNA present in all 
experiments (cells and tissues) in this thesis. This quantitative process is based on the 
detection of a fluorescent signal produced proportionately during amplification of a PCR 
product. During the target amplification step, the AmpliTaq Gold DNA polymerase 
amplifies target cDNA synthesized from the RNA sample (section 2.7.4) using sequence-
specific primers. The subsequent cleavage of TaqMan probes releases fluorescent signals. 
The amount of fluorescence released during the amplification cycle is proportional to the 
amount of product generated in each cycle and can be measured directly. When PCR 
amplification is in the exponential phase then data is acquired. qRT-PCR was performed 
using TaqMan Universal Master Mix II with TaqMan miR/endogenous control expression 
probes (Applied Biosystems) according to the manufacurer’s instructions. Reactions were 
performed using 384-well PCR plates and optical lids. Each well contained 5µl TaqMan 
Master Mix, 0.5µl miR-specific probe, 3.835µl nuclease-free water and 0.67µl of RT 
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product (section 2.7.4). Reactions were performed in triplicate and plates were set up on 
ice. 3 extra wells for each probe were added to the plate (with 0.67µl nuclease-free water 
instead of cDNA) as negative template control. Expression was normalized to miR-199a-
3p or RNU-48 for pig and human samples respectively.  The plates were run using the 
TaqMan detection system under the following cycle conditions: 40 cycles of 95oC for 15s 
(amplification) then 60oC for 1 min (annealing). Delta(d)-Ct values were determined by 
subtracting the Ct of the appropriate endogenous control from the Ct of the miR in 
question. A reference sample is determined and the ddCt calculated by subtracting the 
reference value from each sample. The RQ is then determined by raising ddCT to power of 
-2 and raising negative ddCT to power of 2 (Schmittgen and Livak, 2008).  
 
2.8 HISTOLOGY 
2.8.1 Stent Electrolysis 
For morphometric and in-situ hybridisation analysis of stented segments of porcine arterial 
tissue, removal of the stent with preservation of vessel architecture was a key 
consideration. As discussed in Chapter 3, the common method of resin embedding and 
rotary saw sectioning is time consuming, expensive and allows only limited analysis 
(Rippstein et al., 2006). The experiments in this thesis utilised a method of stent 
dissolution previously published by Bradshaw et al to circumvent these issues (Bradshaw 
et al., 2009, Samra et al., 2010). This process utilises the reverse of methods routinely used 
in industrial electroplating where a differential voltage is applied to two metallic objects 
placed in a mildly acidic salt solution.  The result is that metal ions dissolve from the 
object with the more positive voltage and either from complexes in solution or diffuse 
through the solution to deposit onto the object with the more negative voltage. The 
assembled apparatus for stent dissolution is shown in Figure 2.1 (Panels A-B). Two holes 
were made through the lid of a 5ml bijou using a 14G needle. A 22G needle was blunted 
and passed through one hole to allow passage of a stilette (taken from an angioplasty 
balloon). An electrical wire was used to attach the stilette to the positive terminal of a 10V 
power supply. A copper wire was attached to a metallic washer placed at the bottom of the 
bijou, passed up through the second hole in the bijou lid and attached to the negative 
terminal of the power supply by electrical wire.  
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One end of the fixed stented segment was dissected to expose stent struts. These were 
attached to the stilette by moulding the end to interweave through them. The bijou was 
then filled with 5% citric acid containing 5% (w/v) NaCl. The volume of solution was 
adjusted so that the lower end of the stent was submerged but the stilette/stent connection 
lay above the fluid level. The voltage source was then turned on to 5V (Current 1-2mA). 
The flow of ions from the positive to the negative terminal signifying stent dissolution is 
shown in Figure 2.1 Panel B. Completion was signalled by the corrosion of the stent to 
stilette connection. After completion the tissue was carefully sectioned using a scalpel. An 
arterial segment free of stent is shown in Figure 2.1 Panel C. Typically, small fragments of 
un-dissolved stent were left and these were carefully removed using a dissecting 
microscope and forceps (Figure 2.1 Panel D). The arterial segments could then undergo 
conventional histological techniques as described in section 2.8.3 onwards. 
 
 
Figure 2-1  Stent dissolution using electrolysis method 
Assembled apparatus for stent electrolysis (A) with close-up of a dissolving stent (B). Movement of 
ions in solution can be seen as linear yellow discolouration emerging from the lower aspect of the 
tissue. En-face sectioned arterial segment following stent removal by electrolysis showing absence 
of stent struts in the vessel wall (C). Residual stent fragments carefully removed with forceps (D). 
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2.8.2 En-face β-galactosidase staining 
Excised vessel segments that had been treated with RAd 35 (expressing LacZ) were fixed 
in 2% paraformaldehyde at 4oC for 5 hours. Each vessel was carefully opened en-face 
using a scalpel, with care taken to minimise any disruption to tissue architecture, and 
pinned onto a glass petridish containing sylgard. Samples were then immersed in X-gal 
working solution (section 2.5.5) for 24 hours at 37oC. Arteries were then washed 3 times 
with PBS and analysed for β-galactosidase expression using microscopy.  
2.8.3 Paraffin processing 
Following tissue fixation in 4% paraformaldehyde for 5 hours at 4oC, arterial samples were 
washed in PBS, transversely sectioned as required using a scalpel and placed into 
individual labelled cassettes. Tissues were then processed routinely in an enclosed tissue 
processor (Shandon Excelsior, Thermo Scientific) and dehydrated through a serial alcohol 
gradient and xylene before embedding in paraffin wax ready for subsequent histological 
analysis: 
1. 70% (v/v) Ethanol    30 min  10oC 
2. 95% (v/v) Ethanol     1h   30oC 
3. 100% (v/v) Ethanol (1)   1h  30oC 
4. 100% (v/v) Ethanol (2)   1h  30oC 
5. 100% (v/v) Ethanol (3)   1h  30oC 
6. 100% (v/v) Ethanol (4)   1h  30oC 
7. 100% (v/v) Ethanol (5)   1h 30min 30oC 
8. 50% (v/v) Ethanol/50% Xylene (v/v)  1h 30min 30oC 
9. Xylene (1)     1h  30oC 
10. Xylene (2)     1h 30min 30oC 
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11. Paraffin wax (1)    30min  62oC 
12. Paraffin wax (2)    1h 30min 62oC 
13. Paraffin wax (3)    2h  62oC 
14. Paraffin wax (4)    2h  62oC 
The arterial segments were then embedded in a block of paraffin wax. These were allowed 
to set by placing on a cooling block once the segment had been placed end-on to allow 
transverse sections to be cut.  
2.8.4 Tissue Sectioning 
Prior to sectioning, the paraffin wax blocks containing arterial segments were pre-cooled 
on a cooling block for a minimum of 30 min to aid acquisition of sections. Blocks were 
pared until one full face of tissue could be cut then serial 3µm (for IHC or H&E staining) 
or 6µm (for ISH) sections of paraffin embedded tissue were obtained through the whole 
segment using a rotary microtome (RM2235, Leica). Sections were placed onto the surface 
of a water bath containing nuclease-free water at 50oC and separated with forceps to allow 
collection onto poly-L-lysine coated slides (Starfrost® Adhesive Microscope Slides). All 
slides were placed in an oven at 60oC overnight to fix the section to the slide surface and 
melt surrounding paraffin wax.  
2.8.5 Haematoxylin and Eosin Staining  
Haematoxylin and Eosin (H&E) histological staining is routinely performed to assess 
morphological detail. The basic dye haematoxylin stains acidic structures, such as nuclei 
and rough endoplasmic reticulum (due to high content of DNA and RNA respectively), a 
dark purplish blue. Eosin is an acidic dye that stains basic structures (mainly cell 
cytoplasm) pink or pinkish red.  
To remove wax from slides they were immersed twice in Histoclear (National Diagnostics) 
for 5 min. Rehydration was performed in graded alcohols (100%, 95% and 70% Ethanol 
for 5 min each) then running water for 5 min.   
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Slides were then added to Haematoxylin in a staining jar for 2 minutes before being 
washed in running water. They were subsequently added to Eosin in a separate staing jar 
for 2 minutes before being dehydrated in a second set of graded alcohols (70%, 95% and 
100% for 5 min each) and cleared in Histoclear (2 x 5min) before mounting with 
coverslips using Histomount mounting medium (National Diagnostics).  
2.8.6 Immunohistochemistry (IHC) 
2.8.6.1  Antigen retrival 
Formalin tissue fixation forms protein cross links that can mask antigenic sites within 
tissue specimens. Antigen retrieval methods break these cross-links therefore unmasking 
antigens to allow binding processes to be performed. A sodium citrate buffer (10mM 
Sodium Citrate, 0.05% Tween 20, pH 6.0) was prepared and heated in a microwave to a 
temperature of 95-100oC. Deparaffinized and rehydrated slides (section 2.8.4) were 
immersed in the buffer, covered in cling-film, and returned to the microwave for 5 min at 
high power. The antigen retrieval solution was then topped up and microwaved for a 
further 5 min at high power. The solution was left to cool for 10 min to allow antigens to 
fold correctly and then returned to running tap water prior to the next step.  
2.8.6.2  Quenching 
Quenching is performed by inhibiting endogenous peroxidase using hydrogen peroxide. 
Slides were incubated for 10 min in 3% (v/v) H2O2 before being washed with PBS (3x 5 
min).  
2.8.6.3   Antibody binding  
IHC was performed using fluorescent secondary antibodies. Sections were first placed in a 
blocking solution (20% v/v goat serum in PBS) for 30 min at room temperature in a 
humidified chamber to prevent sections drying out. The serum used is from the species in 
which the secondary biotinylated antibody has been raised and blocks the sites where non-
specific binding would occur between the primary antibody and the tissue section. Excess 
serum was carefully removed before washing in PBS. Sections were then incubated 
overnight at 4˚C in a humidified chamber with the appropriate primary antibody and 
equivalent strength isotype matched IgG negative control diluted in blocking solution. For 
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detection of eGFP, a mouse monoclonal antibody to GFP (Abcam, Cambridge, UK) was 
used at a final concentration of 25µg/ml in blocking solution. A mouse anti-human mAb 
against α-smooth muscle actin (Sigma) at 82µg/ml in 1% (wt/vol) BSA in PBS and a 
mouse anti-rat mAb against PCNA (Abcam) at 0.5µg/ml in PBS were also used in 
experiments in this thesis. Slides were then washed 3 times for 5 min in PBS before 
addition of the biotinylated goat anti-mouse secondary antibody (Dako, Cambridge, UK) 
diluted 1:300 in 3% (v/v) goat serum in PBS and incubation for 1h at room temperature. 
Optimal visualisation of staining was achieved using 3’,3’-diaminobenzidine 
tetrahydrochloride dihydrate and hydrogen peroxide. Sections were counter-stained with 
haematoxylin. 
2.8.7 In-situ hybridisation 
In-situ hybridization (ISH) is a well-developed method for visualising gene expression and 
localisation in specific tissues and cell types. It uses a labelled complementary DNA or 
RNA strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or 
section of tissue. The protocol used in this thesis is optimised to detect individual miRs 
using specific double-DIG-labelled LNATM probes (Exiquon, Vedbaek, Denmark) as per 
the manufacturer’s description, with some modification (Jorgensen et al., 2010, Tesch et 
al., 2006). Probe chemistry is summarized in Figure 2.2.  
 
 
Figure 2-2  In-situ hybridization for microRNA 
Following microRNA demasking using Proteinase-K, double-DIG-labeled LNA™ probes hybridize 
to the microRNA sequence. The digoxigenins can then be recognized by a specific anti-DIG 
antibody that is directly conjugated with the enzyme Alkaline Phosphatase (AP). AP converts the 
soluble substrates 4-nitro-blue tetrazolium (NBT) and 5-bromo-4-chloro-3’-indolylphosphate (BCIP) 
into a water and alcohol insoluble dark-blue NBT-BCIP precipitate. [Taken from Exiquon miRCURY 
LNATM microRNA ISH Optimisation Kit (FFPE) Instruction manual v1.3 (Nov 2010)]. 
 
2.8.7.1   Preparation 
All solutions, where possible, were treated with diethyl pyrocarbonate (DEPC) to prevent 
RNase contamination. As with all RNA work, surfaces and equipment were treated with 
RNaseZap (Ambion). Formalin-fixed paraffin embedded sections (6µm) were incubated at 
60oC in an oven overnight. Samples were cleared and hydrated through histoclear and 
graded ethanol as follows: 
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• 2 x 10 min Histoclear 
• 2 x 10 min 100% Ethanol 
• 1 x 5 min 90% Ethanol 
• 1 x 5 min 90% Ethanol 
• 1 x 1 min DEPC-treated water  
2.8.7.2   Unmasking and Deproteinating Sections 
All solutions were made with, and all washes performed with, DEPC-treated PBS unless 
otherwise stated. Slides were placed in freshly prepared 0.1% DEPC (200ul DEPC in 
200mL of distilled water) for 1hr with stirrer then unmasked with 10mM sodium citrate 
(pH6) in a microwave for 10-12 min at 800W. After cooling on ice for 10 mins, slides 
were immersed in 0.2M HCL for 20mins then washed twice for 5 min each. Slides were 
immersed in 0.3% Triton-X for 10 mins followed by 3 x 5 min washes. Proteinase K 
treatment was performed with prewarmed (37oC) 10µg/ml proteinase K (Sigma-Aldrich) 
added to the sections and incubation in a humidified chamber for maximum 20 minutes at 
37oC. This step was reduced to 15 min for miR-21. Slides were then rinsed in DEPC-
treated PBS before being immersed in 0.2% glycine, washed (5 min) and then fixed with 
4% paraformaldehyde for 10 min on ice. Finally, slides were washed 3 times (5 min each).  
2.8.7.3   Hybridisation  
Hybridisation with 40 nM double digoxigenin-labelled miR-21, miR-143, miR-145 or 
scrambled control probes (Exiqon, Vedbaek, Denmark) was carried out with hybridisation 
temperatures of 55˚C for miR-21, 60˚C for miR-143 and miR-145 and 57˚C for the 
scramble control probe.  50-100µl of hybridisation buffer [25ml: 12.5ml deionised 
formamide, 5ml 20x SSC buffer, 1.25ml 50x Denhart’s solution, 5ml (2.5mg/ml) salmon 
sperm, 1.5ml (10mg/ml) yeast, 250µl of 2.5% SDS, 500µl of 10% DIG blocking reagent 
and 4.5ml DEPC-treated water] was added to each section. Slides were placed in a 
humidified RNase-free box and incubated at the appropriate hybridisation temperature for 
1 hour. The probe was diluted to a final concentration of 40mM in hybridisation buffer and 
sparingly added to sections before covering with DEPC-treated coverslips. Slides were 
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hybridised overnight at the appropriate hybridisation temperature in humidified RNase-free 
boxes.  
2.8.7.4   Stringency washing  
The following day, coverslips were gently removed in a container of 5xSSC at room 
temperature before the slides were transferred to a staining rack. Slides were washed in 
1xSSC at hybridisation temperature for 20 min, 0.2xSSC at hybridisation temp for 20 min, 
0.2xSSC at room temperature for 5 min with gentle agitation on a shaking plate and finally 
in PBS at room temperature for 5 min with gentle agitation.  
2.8.7.5   Immunological detection 
After completion of wash steps, sections were covered with blocking buffer (0.5% 
blocking reagent [Roche, 10% (w/v) in 100mM maleic acid:150mM NaCl buffer], 10% 
heat-inactivated goat serum [70oC for 30 min prior to use], 0.1% Tween, 1x DEPC-treated 
PBS) and incubated for 1 hour at room temperature. Anti-DIG-AP Fab fragments (Roche, 
Basel, Switzerland) and BM purple AP substrate (Roche) were used for detection (Figure 
2.2).  Anti-DIG-AP Fab fragments were diluted 1:500 in blocking reagent and added to 
sections which were then incubated overnight at 4oC in a humidified chamber. Slides were 
then washed for 3x5min in PBS with 0.05% Tween 20 (a detergent) before a final 5 min 
wash in AP buffer (100mM Tris HCL pH9.5, 100mM NaCl, 0.1% Tween 20).  
2.8.7.6   Colour solution  
NBT/BCIP solution (Roche) was prepared in DEPC-treated water as per the 
manufacturer’s instructions with addition of tetramisole hydrochloride (2mM final 
concentration) and applied to cover each section. Slides were placed into humidified trays, 
covered with tinfoil to protect from light and left to incubate at room temperature for 
between 1-3 days. Colour solution was topped up every couple of days as required. Slides 
were observed using microscopy regularly for staining. Once colour staining had appeared 
slides were washed 3x5 min in PBS with 0.05% Tween 20 then mounted with aqueous 
mounting solution and edges fixed with clear nail varnish. Imaging was performed as 
described in section 2.9.  
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2.9 MICROSCOPE IMAGING 
All images were captured using a BX41 optical microscope (Olympus Optical Co Ltd) 
with Cool Snap MP3 camera (Media Cybernetics, Wokingham, UK) and Q Capture Pro 
software (Qimaging, Surrey, BC Canada).  Measurements were taken using Image Pro-
Plus® Analyzer 7.0 (Media Cybernetics). 
2.9.1 Morphometric analysis  
Morphometric analysis was performed on formalin-fixed arterial segments subjected to 
stent dissolution through electrolysis and H&E staining. Borders were manually traced for 
lumen area and area circumscribed by the internal elastic lamina. The neointimal area was 
calculated from the internal elastic laminal area minus the lumen area. Results are 
expressed as the mean value for each treatment group.  
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2.10 EX-VIVO METHODS 
2.10.1 Delivery of adenovirus to ex-vivo porcine coronary 
arteries using the ClearwayTM RX Therapeutic Perfusion 
Catheter 
The ClearwayTM RX (Atrium Medical, New Hampshire, USA) is a semi-compliant 
microporous polytetrafluoroethylene (PTFE) balloon perfusion catheter. It is delivered on a 
monorail platform over a standard 0.014” coronary wire and fully inflates at low pressure 
(1-4 atm). The balloon material has a microporous structure of tortuous channels allowing 
an infused agent to weep out in a controlled manner along the whole length of the balloon 
coating its entire surface (Fig 2.3). This prevents the vessel trauma seen to be caused by 
jets of drug being eluted at high pressure with early porous balloon devices. The low 
pressure inflation of the device allows the balloon to occlude the vessel preventing the 
therapeutic agent from being lost in the circulation and allowing direct contact with the 
vessel intima without trauma from stretching of the vessel (Saraf et al., 2008). 
 
 
Figure 2-3 ClearwayTM RX Therapeutic Perfusion Catheter (Atrium Medical) 
 
To assess the potential of the ClearwayTM RX for viral gene delivery it was tested in ex-
vivo porcine coronary arteries (n=3). Previously untreated animals were sacrificed and the 
heart removed as described in section 2.11.3.8. Intact 40mm segments of proximal to mid 
LAD (for viral delivery) and RCA (untreated control) were carefully dissected from the 
myocardium and transferred to sterile PBS on ice. Viral delivery was performed under 
sterile conditions in a biological safety class II vertical laminar flow cabinet. Arterial 
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segments were transferred to a large glass petridish containing sylgard and fixed using 21G 
needles. A longitudinal incision of 3-4mm was made in the proximal portion of the vessel 
using a scalpel to allow direct access to the lumen. The Clearway RX catheter was prepped 
using PBS as per manufacturer’s instructions. The balloon was then introduced to the 
lumen through the incision and positioned at an appropriate distal site. A total of 300µl of 
AdGFP (1.157x1012 particles/ml, 1.51x1010 pfu/ml) diluted to 1ml in PBS (Final 
concentration 4.53x109 pfu/ml) was infused at low pressure (4atm) over approximately 5 
minutes using a  10ml MicroMate pressure-control syringe (Sigma-Aldrich). Apposition of 
the inflated balloon with the vessel wall was confirmed visually. The vessel was then 
flushed with PBS to mimic return of circulatory flow. The treated segment (20mm) of 
vessel was placed in 10% DMEM culture medium and incubated for 24 hours at 37oC 
before fixation, histological processing and antibody staining (section 2.8). 
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2.11 IN-VIVO METHODS 
2.11.1 Ethics and Legislation  
All animal procedures were performed in accordance with Home Office Guidance and the 
Animals (Scientific Procedures) Act 1986. All experimental procedures were performed 
under the project licence PPL 60/3410, held by Dr Simon Kennedy and the personal 
licence 60/11896, held by Dr Keith E. Robertson. All animals received humane care 
according to the European Convention on Animal Care. Procedures involving the use of 
ionising radiation were performed in accordance with the Department of Health Ionising 
Radiation (Medical Exposure) Regulations 2000 (IRMER).  
2.11.2 Animals and Environment 
Male large-white/Landrace pigs (20-24kg, 10 weeks old) were bred and supplied by a 
single producer (SAC Commercial Ltd, Edinburgh, UK) and used in all experiments. All 
animals were maintained and procedures performed in the Biological Procedures Unit of 
the University of Strathclyde, Glasgow. In accordance with local guidelines, animals 
received a minimum of 7 days acclimatisation in the unit before any procedures were 
performed. All animals were housed under controlled environmental conditions on a 12-
hour light/dark cycle, with free access to water and twice-daily feeding.  
2.11.3 Coronary Angiography Procedural Technique 
2.11.3.1 General Considerations 
All procedures were performed in a dedicated operating theatre under sterile conditions. A 
mobile image intensifier with a C-arm provided fluoroscopy (Siremobil 4N, Siemens, 
Germany). Continuous single-lead ECG, invasive blood-pressure, oxygen saturation, 
temperature and expired CO2 monitoring was utilised. A monophasic direct-current 
external defibrillator was present in theatre at all times. Standard theatre set-up and 
monitoring is shown in Figure 2.4.  
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Figure 2-4 Theatre set-up for coronary angiography 
Intubated pig in dorsal recumbancy on theatre table (A). C-arm can be seen in the top-left corner 
with trolley containing Boyle’s machine and ventilator at the head of the table. Invasive BP and 
single-lead ECG monitoring (B) and oxygen saturations (C) were used in all animals.  
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2.11.3.2 Periprocedural pharmacotherapy 
Pigs receiving coronary stents were premedicated with aspirin (150mg PO, Teva, Leeeds, 
UK) and clopidogrel (150mg PO, Sanofi-Aventis, Guildford, UK) the day prior to surgery. 
On the day of surgery, all animals received a further 75mg of each agent and this was 
continued every second day until sacrifice. The tablets were crushed and mixed in with the 
animals chow. Following anaesthesia (section 2.11.3.3), all animals received analgesia 
(0.15mg IM buprenorphine, Alstoe Ltd, York, UK) and antibiotics (300mg IM ampicillin, 
IntervetUK Ltd, Walton, UK) to cover the perioprocedural period. As discussed in Chapter 
3, following initial procedural difficulties, an anti-arrhythmic cocktail of amiodarone 
(75mg IV, Sanofi-Aventis) and lidocaine hydrocholoride (50mg IV, Taro Pharmaceuticals, 
Ireland) was administered following the onset of stable anaesthesia. A standard dose of 
anticoagulation (3000Units IV heparin) was administered to all animals following insertion 
of the arterial sheath.  
2.11.3.3 Anaesthesia  
All procedures were performed under general anaesthesia. Animals were sedated by an 
injection of tiletamine/zolazepam (100mg Zoletil IM, Virbac, Suffolk, UK) prior to 
transfer to the theatre. Gas induction of anaesthesia utilising 4% isoflurane (Abbott 
Laboratories Ltd, Maidenhead, UK) in oxygen (7 l/min) and nitrous oxide (2 l/min) via a 
snout mask was used to allow placement of subcutaneous ECG monitoring probes, 
administration of premedication and IV access using a 20G cannula in a large ear vein. To 
facilitate endotracheal intubation, propofol (30mg Rapinovet IV, Schering-Plough, 
Welwyn Garden City, UK) was administered. Pigs were intubated in a supine position 
using a long straight-bladed Magill laryngoscope and a lubricated 6F endotracheal tube 
introduced through the vocal cords under direct vision. Gas maintenance of anaesthesia 
was routine using 2% isoflurane in oxygen/nitrous as above. Maintenance IV normal saline 
was used and the animals temperature monitored using a rectal probe and heating mat 
(VetTech Solutions Ltd, UK). Following anaesthesia, animals were placed into dorsal 
recumbency.  
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2.11.3.4 Arterial access 
Arterial access was obtained via a cut-down approach to the left femoral artery. The left 
groin was sterilised using povidone-iodine solution and the surgical field prepared with 
sterile drapes. The femoral artery was approached through a 6cm transverse incision in the 
cranio-medial aspect of the groin. The artery was identified and exposed using blunt 
dissection, care taken to identify and separate artery from the vein (usually bellow) and 
small femoral nerve. Once the artery was freed from its surrounding fascia, proximal and 
distal suture ties were applied to the exposed artery and the distal suture tied tightly (Figure 
2.5). A loose single loop was placed in the proximal suture and the ends secured in artery 
forceps, in case quick haemostasis was required. Arterial entry was obtained using a 
modified Seldinger technique. The artery was punctured with the needle from a human 
transradial artery access kit (Arrow® International UK Ltd, Middlesex). The 0.025 inch 
soft tipped guidewire was introduced nto the arterial lumen and the needle was removed 
and the 6F radial sheath inserted over the wire. The wire and dilator were removed and the 
sheath was flushed with heparinised saline. The sheath was then secured to the skin with a 
suture (Figure 2.5). 
2.11.3.5 Coronary catheterization  
A selection of standard, human, 6F coronary guide catheters were available for all 
procedures. Common shapes used included Judkins left (JL3.5) and right (JR4), or 
Amplatz right (AR1) and left (AL1). These were advanced up the descending aorta and 
around the aortic arch before being introduced to the coronary ostia using a standard 
0.035” guidewire under fluoroscopy (in the majority of cases in an AP projection). If 
coronary engagement proved difficult then a little RAO (for the LMS) or LAO (for the 
RCA) tilt was used. Catheter position was confirmed, and coronary angiography 
performed, by selective injection of radiographic contrast (Omnipaque 140, GE 
Healthcare, Bucks, UK). For angiography, the catheter was attached via a Y connector 
with O-ring valve to a 3 port manifold, connected to an electronic pressure transducer, 
heparinised saline flush and a luer-lock 10 ml syringe attached to the distal end for intra-
arterial injection of contrast.  
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Figure 2-5 Arterial Access 
After sterile preparation, an incision is made in the left groin and isolation of the femoral artery 
performed by blunt dissection. Distal ligation is performed using a suture and a loose tie placed 
proximally to allow rapid haemostasis (A). A 6F radial sheath is introduced to the vessel using a 
modified Seldinger technique. At the end of the procedure the artery is ligated to achieve 
haemostasis and the wound closed in three layers (C).  
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2.11.3.6 Closure 
After removal of the guide catheter post-procedure, the proximal suture was tightened 
around the sheath which was then withdrawn. The artery is therefore ligated to achieve 
haemostasis. The wound was then closed in 2 deep layers using absorbable sutures 
(Dexon™ II, Covidien Ltd, Dublin, Ireland) and a subcutaneous continuous buried layer 
(Ethilon®, Ethicon Inc, NJ, USA) (Figure 2.5). 
2.11.3.7 Recovery 
Animals were extubated and recovered from anaesthesia under direct supervision in the 
theatre. Once awake, animals were returned to their enclosure and received a normal diet, 
with supplementation of antiplatelets as described above if coronary stents were implanted.  
2.11.3.8 Animal sacrifice 
Animals were sedated with 200mg IM tiletamine/zolazepam (Zoletil, Virbac). Following 
cannulation of a large ear vein, an IV bolus of pentobarbital (100mg/kg, Merial, Harlow, 
UK) was administered. Access to the thoracic cavity was obtained via midline sternotomy 
using a bone cutter and rib retractors. The visceral and parietal pericardium was stripped 
from the cardiac surface and the heart mobilised. Traction was applied to the heart, 
avoiding pressure on areas with coronary stents if present, and the great vessels cut with 
scissors to allow removal of the whole heart from the thoracic cavity. The coronary arteries 
were carefully and immediately dissected out from the cardiac surface. Vessel processing 
and analysis was performed as described in the relevant sections.  
2.11.4 Coronary Stent Model 
The procedure of balloon delivery and stent deployment is identical to that used in humans 
in the clinical catheterization laboratory (Figure 2.6). Once the appropriate coronary 
ostium was selected using a guide catheter a standard 0.014” coronary guidewire was 
introduced and passed to the distal portion of the vessel to be treated. The stent was passed 
to the appropriate region over the guidewire using the monorail technique and expanded to 
the required pressure using an indeflator (Boston Scientific, MA, USA) filled with 50% 
radiographic contrast/50% normal saline. Following deployment, all equipment was 
removed from the vessel and repeat angiography performed to exclude complications. 
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Coronary artery spasm was seen commonly and in most cases responded to an 
intracoronary bolus of glyceryl trinitrate (100-200µg, Hameln Pharmaceuticals Ltd, 
Gloucester, UK) delivered via the guide catheter.  
 
Figure 2-6 Stent delivery to porcine Left Anterior Descending (LAD) artery  
Following catheter engagement of the left main coronary artery (LMS) a guide-wire is passed to the 
distal LAD (A). The stent is introduced by monorail and inflated in the mid-vessel at a stent:vessel 
ratio of 1.2:1 (B). Final angiogram showing vessel patency and adequate stent overexpansion (C). 
All projections are right anterior oblique.  
 
2.11.5 Development of in-stent restenosis 
The porcine model of ISR is well established and provides reliable neointimal development 
at 28 days following stent implantation to healthy porcine arteries (Schwartz et al., 1992, 
Schwartz et al., 1990). It is achieved by controlled stent overexpansion to a stent:artery 
ratio of 1.2:1 (as assessed visually by angiography) and was used in all experiments in this 
thesis. Balloon inflation was performed for 30 seconds. The proximal to mid portion of a 
given vessel was generally chosen for stent delivery as this was most commonly the area of 
appropriate size to allow stent overexpansion. Once the luminal diameter had been 
assessed visually, the stent was deployed at the appropriate pressure (usually 8-14atm) to 
achieve 1.2:1 over-sizing. Sufficient injury was confirmed by angiography.  
2.11.6 Local delivery of viral vectors  
2.11.6.1 Development of Model and Initial Problems 
The initial planned experiments involved two groups of three animals. Each animal was to 
receive a bare-metal stent (Multi-Link Vision, 3.0x15mm, Abbott Vascular, USA) to 2 of 
the 3 major epicardial coronary arteries, with the third left untreated as a control. The first 
group were then to receive RAd 35 expressing Lac Z and the second AdGFP and pHR SIN 
lentivirus, delievered via a 3.0x15mm ClearwayTM RX catheter.  
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Unfortunately, the first 4 animals suffered intra-procedural death secondary to cardiac 
dysrhythmia. All deaths occurred during initial angiography or following delivery of the 
stents. None had received any virus.  
This led to a review of the model and changes to the experimental protocol which are 
discussed in detail in Chapter 3. Intra-procedural mortality was subsequently much 
improved throughout the rest of the in-vivo work performed.  
2.11.6.2 Viral Gene Delivery using ClearwayTM RX and GENIETM  
The ClearwayTM RX (Atrium Medical) semi-compliant microporous 
polytetrafluoroethylene (PTFE) balloon perfusion catheter is described in section 2.10.1. 
The GENIETM (Acrostak, Winterthur, Switzerland) local drug delivery system is a balloon 
catheter consisting of proximal and distal occlusive balloons with a non-dilatating central 
segment that forms a reservoir. When a suitably sized device is placed over a stented 
segment of artery the reservoir fully covers the stent. The distal balloon has holes that 
directly infuse a therapeutic agent coaxially in a proximal direction. This allows the 
therapeutic agent to be held within the reservoir, while the occlusive segments are inflated, 
without directing any jets towards the vessel wall (Figure 2.7-2.8). This has been used to 
successfully deliver paclitaxel to stented arteries in both pre-clinical in-vivo (Dommke et 
al., 2007) and clinical settings (Herdeg et al., 2009). Like the Clearway, it operates on a 
monorail exchange platform.  
 
 
Figure 2-7 GENIETM local drug delivery system 
Schematic taken from www.acrostak.com. The perfusion balloon is mounted on a monorail 
platform for delivery to the required vessel segment over a standard coronary guidewire (1). A 
therapeutic agent is perfused through a distal port at low pressure, which inflates occlusive 
proximal and distal segments (2). Holes in distal balloon allow therapeutic agent to be delivered 
coaxially (3) and fill a reservoir created between the distal and proximal balloons (4). A fully 
deployed GENIE with reservoir filled with therapeutic agent (5).  
 
All local delivery experiments were performed in animals that had received Multi-Link 
Vision BMS (Abbott Vascular) as described in section 2.11.4. After removal of the stent-
delivery balloon the coronary wire was left in position with the tip in the distal vessel. The 
local delivery device was then exchanged onto the wire using the monorail technique and 
guided to the stented segment under fluoroscopic guidance. Both devices display radio-
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opaque markers to allow accurate positioning. The chosen viral vector was then delivered 
at the appropriate pressure (1-4atm) using a 10ml MicroMate pressure-control syringe 
(Sigma-Aldrich) (Figure 2.9). Following completion of viral delivery the devices were 
deflated and all equipment removed through the guide catheter. Repeat angiography was 
performed using selective injection of radiographic contrast to confirm vessel patency and 
exclude complications. Animals were recovered as previously described and sacrificed at 7 
days post-procedure.  
 
 
Figure 2-8 GENIETM local drug delivery system  
Coaxial delivery of blue ink from holes in distal balloon shown in a water bath (A). Schematic 
showing a deployed GENIE with occlusive inflation of distal and proximal balloons and a previously 
delivered coronary stent positioned within the device reservoir (B). (Taken from Dommke et al, 
Thromb Haemost 2007; 98: 674–680).  
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Distal port of Clearway/GENIE
Flush syringe
3-way tap
Pressure syringe 
containing viral vector
 
 
Figure 2-9 Schematic for delivery of viral vector using a pressure syringe 
Controlled viral vector delivery was obtained by using a MicroMate (Sigma-Aldrich) pressure 
syringe connected to a three way tap. A flush syringe containing normal saline (0.9%) was attached 
to the upper limb of the three-way tap to allow continued controlled inflation following delivery of the 
virus, for the required duration of time.  
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2.11.7 Stent-based delivery of viral vectors 
2.11.7.1 Poloxamer 407 
Poloxamer 407 (Lutrol F127, BASF, Levallois, France) is a biocompatible polyoxyethyl-
polyoxypropyl block co-polymer used in pharmacology to create sustained release gels 
(Figure 2.10). These are used in a variety of clinical settings e.g. in anti-inflammatory 
indomethacin preparations (Kabanov et al., 2005). It is readily water soluble and has the 
capability to form thermo-reversible gels, the rheological properties of which are 
concentration dependant (BASF Data Sheet). In a solution of 15% concentration, 
poloxamer 407 will be a liquid at 4oC and a viscous gel at body temperature (Feldman et 
al., 1997) (Figure 2.11).  
HO -[CH2 -CH2 -O]101-[CH2-CH -O]56-[CH2-CH2 -O]101 -H
CH3
 
Figure 2-10 Chemical structure of Poloxamer 407 (BASF) 
 
Poloxamer 407 gel was prepared using the “cold process” described by the manufacturer 
(BASF Lutrol F-Grades Technical Information, April 2010). A 15% (w/v) solution was 
used in all experiments in this thesis. Briefly, the required amount of sterile water was pre-
cooled to 4oC in a beaker. This was then placed on a magnetic stirring plate in a cold room 
(4oC). 15g of Poloxamer 407 powder was added per 100ml of water. The solution was then 
covered and left to stir overnight until all the powder had dissolved. It was stored at 4oC (in 
a liquid state) until ready to use.  
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Figure 2-11 Poloxamer 407 as a thermo-reversible gel  
Poloxamer 407 (BASF) as a liquid at 4oC (A) and a viscous gel at 37oC (B).  
 
2.11.7.2 Yukon stent system 
The Yukon stent platform (Translumina, Hechingen, Germany) is a pre-mounted, 
sandblasted 316L stainless steel microporous stent designed for on-site stent coating with 
rapamycin or sirolimus without the obligate use of a polymer (Wessely et al., 2005, Watt et 
al., 2013). The microporous surface allows for abluminal application of a therapeutic agent 
and a degree of delayed elution (Figure 2.12).  
2.11.7.3 Stent preparation and delivery 
All stents used in this experiment were Yukon 3.0x16mm BMS (Translumina). All virus 
used was the RAd 35 adenovirus expressing LacZ (2.5x1011 pfu/ml) as previously 
described. Six animals were used for this experiment and each received a single Yukon 
stent (one spray coated, one manually coated and one with air dried virus only) to all 3 
main epicardial coronary arteries. Stent implantation and viral doses are summarised in 
Chapter 3, Table 3.3. For the first 3 animals a viral dose of 5x109 pfu/stent was used. For 
the second 3 animals a dose of 5x1010  pfu/stent was used. As documented in Table 3.3, the 
appropriate dose of virus was thawed on ice then thoroughly mixed with the appropriate 
volume of cold poloxamer 407 (4oC). This solution was kept at 4oC until required.  
The Translumina stent coating process is summarised in Figure 2.12 and was performed as 
per manufacturer’s instructions with some modifications. The disposable cartridge 
containing the stent was placed into the coating device and a 1ml drug reservoir containing 
the cooled virus/poloxamer solution connected. After input of the appropriate stent length, 
the coating process was initialised by advancement of the reservoir into a mobile positional 
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ring containing 3 jet units. This allows for uniform coating of the stent surface. Coating 
was driven by pressurised air at 1.4bar. Following completion of the spray cycle, the 
cartridge was removed from the coating device and placed in an oven for 30 min at 37oC to 
allow the poloxamer 407 to form a viscous gel. Following incubation the stent was 
removed from the cartridge ready for implantation.  
For manually coated stents the Yukon was removed from its cartridge and the 
virus/poloxamer solution was applied to the abluminal suface as uniformly as possible 
using a sterile (autoclaved), fine paintbrush. Following application the stents were 
incubated at 37oC for 30 min prior to implantation.  
For air dried stents, the Yukon was removed from its cartridge and the appropriate volume 
of virus applied directly to the abluminal surface, as uniformly as possible, using a Gilson 
P20 or P200 pipette (Gilson Scientific Ltd, Luton, UK). No poloxamer 407 was included. 
The stent was then left to dry at room temperature for 10 min prior to implantation.  
All stents were delivered over a 0.014” coronary guidewire as previously described. Stents 
were positioned at appropriate vessel segments for a 1.2:1 overexpansion and deployed 
using an indeflator (9-12atm, nominal pressure for Yukon 9atm). Balloons were inflated 
for 30 seconds. After removal of all equipment from the vessel, angiography was 
performed as previously described to ensure vessel patency and exclude complications. 
Animals were sacrificed at day 7 post-procedure. Stented arterial segments were carefully 
dissected and opened en-face for β-galactosidase staining. Samples of lung, liver, spleen 
and myocardium distal to the site of each stent were removed at the time of euthanasia for 
assessment of distal organ transduction.  
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Figure 2-12 Yukon® stent system (Translumina) 
Scanned electron micrograph image of microporous abluminal surface of the Yukon stent system 
(A) (Taken from www.translumina.de). Theatre set-up for porcine Yukon experiments with spray-
coating machine on the left (connected to pressurised air system) and oven for post-application 
incubation on right (B). Schematic describing stent cartridge and spray coating mechanism (C) 
(Taken from Wessely et al, Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):748-53).  
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2.11.8 MicroRNA expression in neointima 
For this experiment, 3.0x15mm Vision Multi-Link (Abbott Vascular) bare-metal stents 
were delivered randomly to two of the three main coronary arteries (3 groups, n=4/group, 2 
stents/animal). For the 4th group (n=4, 2 stents/animal), Endeavour (Medtronic, 
Minneapolis, MN, USA) drug-eluting stents were used. The stent to artery ratio was 1.2:1 
as before. The pigs receiving BMS were euthanized at 0 (n=4), 7 (n=4) and 28 days (n=4) 
post-procedure. The pigs receiving DES were euthanized at 28 days. After careful 
dissection of the stented segment (and unstented control vessel), the excised vessels were 
divided into 2 parts at the centre of the stent, with half being snap frozen in liquid nitrogen 
for RNA extraction and half fixed in 4% paraformaldehyde (5 hours) for histological 
analysis. After being snap frozen, arteries for RNA extraction were stored in 10x volumes 
of pre-chilled (-80oC) RNAlater-ICE (Ambion Inc) to maintain RNA integrity during the 
RNA tissue extraction process (section 2.7.3.2). The tissue in RNAlater-ICE was 
incubated at -20oC for 16-24h to allow tissue permeation, before being stored at -80oC until 
RNA extraction.  
2.11.8.1 Optical coherence tomography 
Following the realisation that it was not possible to achieve dissolution of the Endeavour 
DES stent using electrolysis, all 28 day samples (BMS and DES, 2 groups, n=4/group, 2 
stents/animal) were analysed ex-vivo using a C7 Dragonfly OCT catheter (St Jude Medical, 
MN, USA). Formalin-fixed arterial segments were placed in a container with PBS. The 
OCT catheter was passed into the arterial lumen using direct vision and a pullback run 
through the whole vessel segment performed. Obtained images were analysed using 
ImageJ software (NIH Imaging, http://rsbweb.nih.gov/ij). Neointimal thickness (defined as 
the minimum distance between each strut and the lumen) was determined at each strut site 
and calculated as a mean for each stented coronary segment.  
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2.12 MICRORNA LEVELS IN CABG PATIENTS 
2.12.1 Study Population 
Twenty-two patients undergoing CABG at a single centre (Prince of Wales Hospital, Hong 
Kong) were prospectively recruited. Written informed consent was obtained in all cases 
and the study was approved by the ethical committee of the Chinese University of Hong 
Kong. Patient baseline characteristics and key features of intra- and post-operative course 
were recorded. One patient (Patient 13) was excluded from all analysis due to a 
complicated peri-operative course. Serum samples for RNA extraction were obtained pre-
op (PO) and at days 1 (POD1) and 5 (POD5) post-op as follows: peripheral whole blood 
was sampled by venepuncture and allowed to clot for 10 minutes at room temperature 
before centrifugation at 4000rpm for 10 minutes. Serum (supernatant) was removed and 
stored in RNase free tubes at -80oC. Serum C-reactive protein (CRP), cardiac isoform of 
troponin T (cTnT), urea, creatinine, albumin, total billirubin, alkaline phosphatase (ALP) 
and alanine transaminase/glutamic pyruvic transaminase (ALT/GPT) levels were also 
measured at all time points as part of normal clinical care. All patients received 
standardised warm (37oC) blood cardioplegia with no cooling during cardiopulmonary 
bypass.  
 
2.12.2 RNA isolation 
Total RNA, including the miRNA component, was isolated from serum using a trizol-
based miR isolation protocol (Fichtlscherer et al., 2010, De Rosa et al., 2011). Prior to 
isolation, serum samples were thawed at 37oC in a water bath. 250µl of serum was added 
to 700µl TRI Reagent BD (Sigma-Aldrich, Poole, U.K.), a blood derivate specific trizol 
compound, and incubated for 5 minutes at room temperature. At this point 5 µl of 5 nM 
Syn-cel-miR-39 miScript miRNA Mimic (QIAGEN) was added to each sample. After the 
addition of 140µl of chloroform, each sample was mixed for 15s using a vortex and 
incubated for a further 2-3 min at room temperature. Total RNA was extracted from the 
homogenate using the miRNeasy Mini Kit (QIAGEN) as previously described (section 
2.7.3.1). On column DNase I digestion is not required when using serum samples (as the 
trizol and RNeasy kits effectively remove most of the trace amounts of DNA in blood 
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components) and this step was therefore replaced with a 700µl buffer RWT wash and 
centrifugation at 8000 x g for 15s.  
 
2.12.3 Quantitative real time polymerase chain reaction (qRT-
PCR) 
Following spectrophotometric quantification (Nano Drop, Thermo Scientific, Inc.), RNA 
was diluted to 2ng/µl before reverse transcription (5ng total RNA) using the Taqman 
microRNA Reverse Transcription kit and miR-specific primers (Applied Biosystems), as 
described in section 2.7.4. MiR levels were determined by qRT-PCR using Taqman assay 
kits for the corresponding miR and the 7900HT Fast Real-Time PCR system (Applied 
Biosystems), as described in section 2.7.5. Threshold cycle (Ct) values were obtained using 
the automatic baseline setting.  
 
2.12.4 Data Analysis and Normalisation 
To-date no established housekeeping miR for serum has been validated, therefore Ct 
values were normalised to a spiked-in nonhuman recombinant miR (Caenorhabditis 
elegans cel-miR-39) as previously described (Mitchell et al., 2008). Cel-miR-39 was 
chosen because of its lack of sequence homology to human miRNAs and previously 
determined absence of empiric hybridization to human miRNA probes on miRNA 
microarrays (Mitchell et al., 2008). The molar concentration of cel-miR-39 to be spiked-in 
has been derived empirically to produce Ct values comparable to those of moderately 
abundant miRNAs (e.g., miR-16) measured in human plasma and serum. For comparison, 
miR expression levels are given as fold-change (RQ – Relative Quantity) from pre-
operative levels, versus cel-miR-39, calculated using the 2-∆∆Ct method (Schmittgen and 
Livak, 2008). To ensure findings were robust, analysis was repeated for all miRs using the 
“standardization to the mean of all measured miRs” approach (Zampetaki et al., 2012a).  
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2.13 STATISTICAL ANALYSIS 
2.13.1 Software 
All data in this thesis were analysed using GraphPad Prism 4 (GraphPad Software Inc., San 
Diego, CA, USA.).  
 
2.13.2 In Vitro 
All in-vitro results are expressed as mean + standard error of the mean (+ SEM). In-vitro 
experiments were performed in triplicate on at least three independent occasions and 
analysis was by unpaired Student’s t test. In the case of multiple comparisons, a one-way 
analysis of variance (ANOVA) with Tukey’s post-hoc correction was used. P-values 
p<0.05 after post-analysis were considered statistically significant.  
2.13.3 In-vivo 
Comparisons between groups were made using a one-way ANOVA with Tukey’s post-hoc 
correction. P-values p<0.05 after post-analysis were considered statistically significant.  
2.13.4 MicroRNAs in CABG patients 
Significance of any temporal change in miR levels was assessed by repeated measures 
analysis of variance (ANOVA) with a Tukey post-test, or a Friedman test with Dunn’s 
multiple comparison if a normality test was failed. Pearson correlation was used to 
compare changes in levels of miRs (∆∆Ct) to rise in serum cTnT and CRP after 
logarithmic transformation. A value of p<0.05 was considered statistically significant.  
  
3 Local Delivery of Viral Vectors in a Porcine 
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3.1 INTRODUCTION 
As discussed in Chapter 1, gene-therapy remains a potential alternative to the use of 
pharmacotherapy for the prevention of coronary in-stent restenosis. The stent-eluted 
antiproliferative agents currently utilised, in addition to inhibiting proliferation of VSMC, 
have also been shown to impair endothelial cell proliferation resulting in delayed recovery 
of the endothelial cell layer and delayed healing (Farb et al., 2001). This impaired 
endothelialisation manifests clinically as late ST (due to exposed stent struts) and increased 
severity of intimal disease (as an intact endothelium is important in maintaining VSMC in 
their differentiated state). A “gene-eluting” stent platform is an intriguing concept, with the 
potential to allow delivery of a site-specific therapy tailored to target specific stages of the 
pathological process (VSMC dedifferentiation) while maintaining or promoting positive 
vessel healing (e.g. re-endothelialisation).  
The initial aim of this chapter was to manufacture then test adenoviral and lentiviral 
vectors in in-vitro and ex-vivo models to assess their suitability for use in intra-coronary 
viral gene delivery.  
Second, was to establish a large animal model of vessel injury and coronary stent 
implantation suitable for use in testing viral-mediated gene delivery.  
The final aim was to deliver therapeutic vectors to this model, using commercially 
available delivery catheters, and assess the potential of this technique in the prevention of 
ISR.  
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3.2 RESULTS 
3.2.1 Manufacture and testing of Viral Vectors 
3.2.1.1  Transduction of Human Saphenous Vein Smooth Muscle Cells Using 
an Adenovirus expressing Green Fluorescent Protein 
As proof of concept before moving to ex-vivo and in-vivo gene delivery, cultured 
HSVSMC were transduced in culture using an Ad5 vector expressing GFP. Significantly 
detectable levels of GFP expression were only obtained following exposure to higher doses 
of Ad (≥5000 vp/cell) (Figure 3.1). Representative images of cells transduced with AdGFP 
are shown in Figure 3.3 Panels A-C.  
 
3.2.1.2  Transduction of Human Saphenous Vein Smooth Muscle Cells Using 
a Lentiviral Vector expressing Green Fluorescent Protein 
The same cultured HSVSMC were also transduced with a second-generation lentiviral 
vector expressing GFP. Significant levels of cell transduction were obtained at ratios as 
low as 5 MOI (Figure 3.2 – 3.3). This is consistent with previously observed work showing 
that lentiviral vectors are more efficient at transducing VSMC than unmodified Ad5-based 
vectors (Dishart et al., 2003).   
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Figure 3-1 Transduction of VSMC with Ad5 expressing eGFP 
Viral transduction of Human Saphenous Vein Smooth Muscle Cells (HSVSMC) in-vitro using 
adenovirus expressing GFP. GFP activity is assessed by luminescence and results expressed as 
relative light units (RLU) normalised to total protein content (mg) (Mean + SEM). * p<0.05 **p<0.01 
NS = non-significant. Bottom panel shows scatter plot of RLU values.  
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Figure 3-2 Transduction of VSMC with SFFV lentivirus expressing eGFP 
Viral transduction of Human Saphenous Vein Smooth Muscle Cells (HSVSMC) in-vitro using 
lentivirus expressing GFP. Confluent HSVSMC were incubated with the appropriate concentration 
of virus for 4h at 37oC. GFP activity is assessed by luminescence and results expressed as relative 
light units (RLU) normalised to total protein content (mg) (Mean + SEM). * p<0.05 **p<0.01 NS = 
non-significant. MOI = multiplicity of infection. Bottom panel shows scatter plot of RLU values. 
Significant levels of cell transduction were obtained at ratios as low as 5 MOI consistent with 
previous findings that lentiviral vectors are more efficient at transducing VSMC than unmodified 
Ad5-based vectors.  
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Figure 3-3 Viral transduction of human smooth muscle cells 
Representative images of HSVSMC transduced with AdGFP at doses of 1000 vp/cell (A), 5000 
vp/cell (B) and 10,000 vp/cell (C) and SFFV lentivirus at MOI 5 (D), MOI 10 (E) and MOI 50 (F). All 
images are at x40 magnification. Scale bars represent 50µm.  
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3.2.2 Haemagglutination 
As discussed in Chapter 1, an important factor limiting the effectiveness of Ad5 as a gene-
therapy vector in-vivo in humans is CAR-mediated interaction with erythrocytes. 
Expression of CAR by erythrocytes has been shown to vary between species with high 
levels in humans and rats and low levels in mice. With regard to the use of a porcine model 
of ISR to test viral gene delivery it was important to establish any potential interaction 
between Ad5 and porcine erythrocytes. This was assessed using a haemagglutination assay 
(Cichon et al., 2003). Multiple plates were run with varying concentrations of porcine 
erythrocyte solution (1%, 3%, 5%, 10% and 15%) to establish the optimal amount for 
analysis. For final analysis concentrations of 8% and 15% pig erythrocytes and 2% human 
erythrocytes were chosen. PBS was used as a negative control and 1% Trition X-100 as a 
positive control (to lyse RBCs). Four dilutions of unmodified Ad5 CMV Lac Z (1/25, 1/50, 
1/100 and 1/200) were applied to the erythrocyte pellets. This was compared to equal 
dilutions of AdKO1, an Ad5 vector with a known CAR-ablating mutation as a further 
control (Nicol et al., 2004). This experiment was repeated on 3 separate occasions. Human 
erythrocytes showed haemagglutination at all concentrations of Ad5 CMV LacZ but none 
when exposed to the KO1 virus (Fig 3.4). Porcine erythrocytes displayed no evidence of 
haemagglutination with either virus. This therefore suggests that CAR-mediated interaction 
with erythrocytes will not occur in-vivo when Ad5 is delivered intravascularly to the pig.  
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Figure 3-4 Haemagglutination Assay 
Rows A-B contain 8% porcine erythrocyte solution, rows C-D 15% porcine erythrocyte solution and 
rows E-H 2% human erythrocyte solution. PBS added as negative control. T = 1% Triton X-100 as 
positive control. Porcine erythrocytes show no evidence of haemagglutination with unmodified Ad5 
or Ad5 with CAR-ablating mutation. Human erythrocytes show evidence of cell lysis with all 
dilutions of unmodified Ad5 consistent with erythrocyte binding (haemagglutination).  
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3.2.3 Delivery of adenoviral vector to ex-vivo porcine coronary 
arteries using the ClearwayTM RX Therapeutic Perfusion 
Catheter  
Prior to progression to the in-vivo model it was important to test the performance of the 
initial local delivery system in an ex-vivo model.  
3.2.3.1  Adenovirus expressing Green Fluorescent Protein 
In arteries incubated with antibody to GFP, immunohistochemical staining was present 
circumferentially throughout the media in the treated segements (Figure 3.5 Panels B,D,F). 
This staining was absent in treated arteries exposed to IgG negative control (Figure 3.5 
Panels A,C,E).  
3.2.3.2  Adenovirus expressing LacZ 
To make the process of histological analysis following vector delivery more 
straightforward it was felt that AdLacZ (RAd 35) could be used instead of AdGFP to allow 
en-face staining with β-galactosidase rather than having to use monoclonal antibodies. The 
above experiment was repeated, this time using 500µl of RAd 35 (4.7x1012 particles/ml, 
2.5x1011 pfu/ml) diluted to 1ml in PBS (Final concentration 1.25x1011 pfu/ml). Following 
24h culture the vessels were opened en-face and stained with β-galactosidase. Again 
results were consistent with successful transduction of the vessel wall (Figure 3.6) 
however, in this experiment the majority of the staining appeared to be adventitial rather 
than medial (Figure 3.6 Panel C).  
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Figure 3-5 AdGFP delivery via Clearway RX to ex-vivo porcine arteries 
All panels are from arteries treated with 4.53x109pfu AdGFP virus. Sections were formalin-fixed 
then sectioned at 3µm. Immunohistochemical staining performed using fluorescent secondary 
antibodies. Panels A,C,E with treated with IgG1 negative control antibody. Panels B,D,F treated 
with antibody against GFP (1/250). Arrows show areas of 3’,3’-diaminobenzidine staining 
consistent with viral transduction within the vessel media. Panels A&B, x10 magnification, Scale 
bar = 300µm. Panels C&D, x20 magnification, Scale bar = 100µm. Panels E&F, x40 magnification, 
Scale bar = 50µm.  
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Figure 3-6 AdLacZ delivery via Clearway RX to ex-vivo porcine arteries 
Each artery received 1.25x1011pfu of RAd 35 adenovirus expressing LacZ. After fixation, arteries 
were opened en face and incubated with X-gal working solution for 24 hours. Panel A shows 
untreated control artery. Panel B shows a segment of treated artery opened en face with the 
lumenal surface visible. Panel C shows the same segment as C turned round to reveal the 
adventitial surface of the vessel. The blue colour represents β-galactosidase staining on adventitial 
surface consistent with successful viral transduction of the vessel wall. 
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3.2.4 Local Delivery of Viral Vectors in a Porcine model of 
Intracoronary Stenting 
3.2.4.1   Viral Gene Delivery using ClearwayTM RX 
As described in Chapter 2, initial problems with high animal mortality (4 of 6 animals) 
were encountered. The remaining 2 animals underwent stent insertion and viral gene 
delivery without complication. Each animal received a Multi-Link Vision 3.0x15mm BMS 
(Abbott Vascular) to both the RCA and LAD with the LCx used as an unstented control. 
The first stented segment received 1x1010 pfu of RAd 35 (40µl) and the second 5x1010 pfu 
(200µl). The diluted viral solution (1ml in PBS) was delivered at low pressure as 
previously described (Chapter 2 Figure 2.9). After viral delivery the animals were 
recovered then euthanized at 7 days post-delivery as previously described. Excised stented 
arterial segments were stained with β-galactosidase. A low level of superficial β-
galactosidase staining was seen in stented segments but not control vessels following 
removal of the X-gal solution (Figure 3.7). Based on prior experience of using β-
galactosidase staining in SVG incubated with Ad expressing LacZ (George et al., 2000) 
this was not felt to represent a clinically relevant level of viral gene transfer.  
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Figure 3-7 Delivery of AdLacZ to stented porcine coronary arteries using Clearway RX 
In-vivo Delivery of AdLacZ (RAd35) via Clearway Rx (n=2 animals). Each animal received 2 Multi-
Link Vision 3.0x15mm BMS with subsequent local viral vector delivery using the Clearway RX 
perfusion catheter. Euthanasia at 7 days post-viral delivery. Following fixation, arteries were 
opened en-face and stained with X-gal working solution. Panel A (Pig 1) from top to bottom RCA 
(1x1010 pfu virus), LAD (5x1010 pfu virus), LCx (unstented control). Panel B (Pig 2) from top to 
bottom RCA (1x1010 pfu virus), LAD (5x1010 pfu virus), LCx (unstented control). Low-grade staining 
only in treated vessels, not consistent with significant viral transduction.  
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3.2.4.2
   Viral Gene Delivery using GENIETM 
It was hypothesized that the GENIETM (Acrostak) could be a more effective device for 
delivery of an adenoviral vector to the pig as its reservoir may have been better suited to 
keeping the virus in contact with the stented segment of arterial wall.  
As gene delivery to two stented vessels per pig had proven to be time consuming with the 
ClearwayTM and to simplify the experiment, we chose to deliver a single 3.5x15mm BMS 
to each animal. Six pigs were used. Again RAd 35 expressing LacZ was the preferred 
vector (2.5x1011 pfu/ml). This was diluted to 5ml in PBS giving a final concentration of 
2.5x1010 pfu/ml. Despite a constant inflation pressure of 2atm the time taken to deliver the 
5ml of viral solution was variable with a mean of 2.75+/-0.89 mins, and range of between 
1 and 6 mins (Figure 3.8, Table 3.2). The total inflation times achieved with heparinised 
saline flush delivered at 2atm were also variable with a mean of 7.08+/-1.88 mins and 
range of between 3 and 15 minutes (Figure 3.8, Table 3.2). The procedure was not well 
tolerated with 50% of the animals suffering complications of varying severity (Table 3.2).  
All pigs were sacrificed at 7 days post-procedure. Stented segments were processed as 
described in Chapter 2. All stented vessels were patent at the time of euthanasia. No β-
galactosidase staining was observed in any of the stented arterial segments (Figure 3.9).  
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Figure 3-8 Time taken to deliver viral vector and total inflation times for GENIETM  
Mean time to infuse 5ml virus at 2atm = 2.75 + 0.89 mins. Mean total GENIE inflation time = 7.08 + 
1.88 mins.   
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Figure 3-9 Delivery of AdLacZ to stented porcine coronary arteries using GENIETM 
In-vivo RAd 35 delivery via GENIETM local delivery catheter (n=6). All animals received a single 
Multi-link Vision 3.5x15mm BMS. 500µl of RAd 35 at 2.5 x 1011 pfu/ml (4.7x1012 particles/ml) was 
diluted in PBS a to final volume of 5ml (Final concentration 2.5x1010 pfu/ml) and delivered via a 
GENIETM perfusion catheter at a constant pressure of 2 atm. Animals were euthanized at 7 days 
post-delivery. Upon harvesting arteries were fixed in 2% PFA for 5 hours before being immersed in 
X-gal stain for 24h at 37oC. Representative images from Pig 1004 (A&B) and Pig 1006 (C&D). 
Panels A&C show stented vessels with viral delivery. Panels B&D unstented control vessels. No β-
galactosidase staining visible in treated arteries or controls.  
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Table 3-1  Viral vector delivery to the porcine model with GENIE catheter 
All stents are Multi-link Vision (Abbott Vascular). 3.5x20mm GENIE used for all animals. Inflation 
pressure 2atm. VDT – viral delivery time.  
 
Pig Stent Vessel 
Virus 
conc 
(5ml total 
vol.) 
VDT 
(mins) 
Total 
Inflation 
Time 
(mins) 
Complications 
1001 3.5x15mm RCA 2.5x10
10
 
pfu/ml 1 15 Nil 
1002 3.5x15mm LCx 2.5x10
10
 
pfu/ml 5 5 
Occlusive stent 
thrombosis →VT → 
VF → Death 
1003 3.5x15mm LCx 2.5x10
10
 
pfu/ml 6 6 VF → resuscitated 
1004 3.5x15mm LAD 2.5x10
10
 
pfu/ml 1 3 Nil 
1005 3.5x15mm LAD 2.5x10
10
 
pfu/ml 1.5 3.5 
Multiple VE’s → 
settled with IV 
Amiodarone 
1006 3.5x15mm RCA 2.5x10
10
 
pfu/ml 2 10 Nil 
  
 
3.2.5   Stent-based delivery of viral vectors 
Results from the above experiments investigating local delivery of adenoviral vectors were 
clearly disappointing. The Clearway RX and GENIE represented the only local delivery 
catheters that could be sourced. Previous devices used in both clinical drug delivery in-vivo 
and pre-clinical gene therapy studies such as the Dispatch catheter (Lincoff et al., 1994) or 
Infiltrator balloon (Barath et al., 1997) are no longer commercially available and could not 
be obtained through parent companies. We therefore returned to the literature to investigate 
the possibility of creating our own gene-eluting stent.  
3.2.5.1   Poloxamer 407 
As previously discussed, clinical utility currently favours use of a stent based platform for 
gene therapy. It was hypothesised that we could combine the coatable properties of the 
Yukon stent system with the improved transduction efficiency provided by poloxamer 407 
and create an Ad5 eluting stent platform for delivery to the porcine model.  
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3.2.5.2   Effect of Poloxamer 407 on transduction of HCASMC in-vitro 
Prior to moving to in-vivo experiments the effect of poloxamer 407 on the transduction 
efficiency of RAd 35 when applied to HCASMC in culture was evaluated (n=3). Based on 
previous work in our laboratory (Bradshaw, Parker et al; unpublished) we used a viral dose 
of 5000 vp/cell as higher doses have been shown to induce cell toxicity during longer 
incubation times. The primary aim was to see if the addition of a 15% poloxamer 407 gel 
reduced the time taken for significant cell transduction. Cells were exposed to virus, virus 
+ 15% poloxamer gel, virus + coagulation FX (10 µg/ml) and virus + poloxamer + FX. 
Incubation times were 1, 5, 10, 30 and 60mins. Previous work in our laboratory has shown 
that the addition of coagulation FX at doses comparable to that in the human circulation 
(10 µg/ml) to unmodified Ad5 vectors can increase transduction efficiency through 
utilisation of the HSPG pathway (Bradshaw, Parker et al; unpublished). This was therefore 
used as a positive control.  
Addition of 15% poloxamer 407 did not increase the transduction efficiency of HCASMC 
compared with RAd 35 virus alone (Figure 3.10-3.13). As expected, addition of FX 
consistently increased transduction efficiency compared with RAd 35 alone. This was not 
significant at 30 mins due to cell toxicity secondary to an experimental error. At 30 mins, 
the combination of RAD35, poloxamer and FX was significantly increased even in 
comparison to RAd 35+FX (Figure 3.10). By 60 minutes these differences were attenuated 
across most conditions due to cell toxicity (Figure 3.11-3.13).  
These results support the potential role of poloxamer gel as a viral delivery reservoir, 
acting to maintain a high pericellular viral concentration.  
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Figure 3-10 Effect of Poloxamer 407 on transduction of HCASMC by AdLacZ 
HCASMC (n=3) transduced in-vitro with RAd 35 (AdLacZ) at 5000vp/cell for varying exposure 
durations and in the presence or absence of Poloxamer 407 (F127) or coagulation factor X (FX) 
(A). Panel B shows same graph as A with RAd35 + F127 + FX excluded. Β-galactosidase activity 
assessed using luminescence and results expressed as mean relative light units/mg total protein 
content + SEM. * = p<0.05 vs. RAd 35, ** = p<0.01 vs. RAd 35, # =p<0.05 vs. RAd 35+FX as 
determined by ANOVA with Tukey post-analysis for multiple comparisons.   
 
 
  
Figure 3-11  Representative images of β-galactosidase expression in HCASMC transduced with AdLacZ +/- Poloxamer 407 
RAd 35 = AdLacZ. F127 = Poloxamer 407. FX = Coagulation factor X. Times indicate duration of cell exposure to virus. x4 
magnification. Scale bars = 300µm.  
 
  
Figure 3-12 Representative images of β-galactosidase expression in HCASMC transduced with AdLacZ +/- Poloxamer 407 
RAd 35 = AdLacZ. F127 = Poloxamer 407. FX = Coagulation factor X. Times indicate duration of cell exposure to virus. x10 
magnification. Scale bars = 100µm. 
  
Figure 3-13 Representative images of β-galactosidase expression in HCASMC transduced with AdLacZ +/- Poloxamer 407 
RAd 35 = AdLacZ. F127 = Poloxamer 407. FX = Coagulation factor X. Times indicate duration of cell exposure to virus. x20 
magnification. Scale bars = 50µm. 
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3.2.5.3   Delivery of RAd 35 stents 
This experiment was performed in 6 animals (Table 3.3). Stents were prepared as 
described in chapter 2. Each pig received 3 stents: 1 spray coated with RAd35 in 15% 
poloxamer 407, 1 with manually applied RAd35 in 15% poloxamer 407 and 1 air dried 
virus without poloxamer. The first three animals received a viral dose of 5x109 pfu/stent, 
consistent with previously published in-vivo work (Table 3.3) (Van Belle et al., 1998). The 
second group of three animals received a higher dose of 5x1010 pfu/stent (Table 3.3). All 
stents were Yukon 3.0x16mm and deployed as described in chapter 2. Representative 
deployment of a Yukon stent into the RCA is shown in Figure 3.14 Panel A).  
The procedure was generally well tolerated. Pig 1009 vomited and clinically aspirated at 
the time of intubation. Oxygen saturations were maintained at 98% throughout the 
procedure. Recovery from anaesthesia was more prolonged than normal but no problems 
were detected with close observation post-procedure and the animal made a full recovery. 
The Pigs were sacrificed at 7 days post-procedure. Figure 3.14 Panel B shows a 
representative oversized Yukon in the LCx coronary artery at time of euthanasia.  
When the stented vessels were harvested all were patent except the Cx from pig 1009 (a 
stent with manually applied virus and poloxamer) which was thrombosed. No gross 
evidence of myocardial infarction was seen on examination of the myocardium supplied by 
this vessel and the pig had displayed no ill effects prior to euthanasia.  
Following incubation with X-gal solution there was no β-galactosidase staining visible in 
any of the stent groups at either viral dose (Figure 3.15). This suggests that there had been 
no effective transfer of LacZ to the arterial wall. Staining of samples of liver, lung and 
spleen however showed marked presence of β-galactosidase consistent with distal organ 
sequestration of virus as seen in previous animal models following in-vivo delivery of 
unmodified Ad5 (Figure 3.16). These findings were consistent across all studied animals. 
No β-galactosidase staining was identified in samples of myocardium taken from the left 
ventricle distal to the deployed stents (Figure 3.16 Panel D).  
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Table 3-2 Delivery of RAd35 using Poloxamer 407-coated stents 
*Air Dried stents did not receive 15% Poloxamer 407 gel. Virus and Poloxamer were pre-mixed at 
4oC and stored on ice. RAd 35 – 2.5x1011 pfu/ml (20µl = 5x109 pfu, 200 µl = 5x1010 pfu). Yukon 
3.0x16mm were used in all animals (9-12atm, nominal pressure 9atm). 30s balloon inflations used.  
 
 Vessel   
Pig Coated Painted Air Dried Virus (µl) Poloxamer 407* 
1007 RCA Cx LAD 20 180 
1008 RCA LAD Cx 20 180 
1009 RCA Cx LAD 20 180 
1010 LAD RCA Cx 200 800 
1011 RCA Cx LAD 200 800 
1012 Cx LAD RCA 200 800 
  
 
 
 
 
Figure 3-14 Deployment of Yukon stent system in the porcine model 
Representative angiogram (PA projection) of Yukon 3.0x16mm stent being deployed in the RCA 
(A). In-situ Yukon stent within the LCx artery of a pig at time of euthanasia (B).  
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Figure 3-15 Delivery of Yukon stents coated with RAd 35  
Representative photographs from Pig 1011. Animal received 3 Yukon stents – Panel A = RCA 
(Sprayed). Panel B = Cx (Manually applied). Panel C = LAD (Air dried, no poloxamer 407). Viral 
dose/stent = 5x1010pfu AdLacZ). No evidence of β-galactosidase staining, following incubation with 
X-gal working solution, with any coating method. This indicates a failure to achieve significant viral 
delivery to the vessel wall.  
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Figure 3-16 Distal organ sequestration of AdLacZ 
Representative images from same animal as in Figure 3.15 (Pig 1011). Viral dose 5x1010pfu 
AdLacZ per stent. Tissues were formalin-fixed and incubated in X-gal working solution for 24h at 
37oC. β-galactosidase staining is present in the liver, spleen and lung consistent with distal organ 
sequestration of virus. No β-galactosidase activity was present in myocardial samples taken distally 
to the deployed Yukon stent (RCA). These results were consistent across all animals.  
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3.3 DISCUSSION 
The experiments in this chapter failed to achieve the initial stated aim of successful viral 
gene delivery to the arterial wall in-vivo using local delivery methods. It was therefore not 
possible to progress to the testing of potential therapeutic vectors with a view to the 
inhibition of ISR. However, the aim of successfully setting up and reproducibly testing a 
large-animal model of both stent deployment and local delivery of a vector suitable for 
future experimental use was achieved.  
The pre-clinical restenosis model chosen for the evaluation of vascular gene therapy in this 
chapter was the porcine model of coronary injury. The undiseased coronary arteries of 
domestic crossbred swine respond similarly to those in humans following injury, with 
reliable development of neointima at 28 days following stent implantation (Schwartz et al., 
1990, Schwartz et al., 1992, Schwartz et al., 2004). Current consensus group guidelines 
recommend juvenile normocholesterolaemic domestic cross-bred farm swine or the adult 
miniature pig as the preclinical models of choice for investigating new stent technologies 
or novel treatments for ISR (Schwartz et al., 2002). Swine with either familial or diet-
induced hypercholesterolaemia are available and do develop advanced atherosclerosis with 
lesions resembling those in humans, replete with a necrotic core and thin fibrous cap 
(Granada et al., 2009, Thim et al., 2010). They are, however, impractical for the majority 
of preclinical studies as the atherosclerotic lesions can take several years to fully develop, 
resulting in animals that weigh in excess of 200kg (Granada et al., 2009). As well as being 
time consuming this results in the addition of considerable cost due to animal upkeep and 
welfare. Furthermore, considerable inter-animal biological variability exists within these 
models and it remains unclear how closely they truly mimic the human chronic 
atherosclerotic process (Williams et al., 2012).  
In the weight range 30-50kg the heart and coronary arteries of the undiseased domestic pig 
approximate in both size and anatomical structure to the adult human (Crick et al., 1998). 
Coronary artery distribution is essentially analogous to that in humans with the LMS 
arising from the left coronary cusp and bifurcating into the LAD, which runs anteriorly in 
the interventricular groove, and LCx, running posterolaterally in the atrioventricular 
groove (Weaver et al., 1986). Similarly the RCA arises from the right coronary cusp and 
when dominant (~80% of animals) supplies the posterior descending artery which runs in 
the posterior interventricular groove (Weaver et al., 1986). Differences do arise in cardiac 
orientation with the more midline position of the porcine heart and its retrosternal apex 
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resulting from the anteroposterior oval shape of the thorax (as opposed to the lateral ovoid 
shape in humans) (Crick et al., 1998). This does result in some practical considerations as 
angiographic views differ slightly when compared to standard human projections 
(Williams et al., 2012).  
When reviewed in 2007, it was noted that adenoviral vectors were the most commonly 
used gene delivery vector in clinical trials (24.7% of all trials) up to that point (Edelstein et 
al., 2007). The majority of these trials used vectors based on Ad species C serotype 5 
(Bradshaw and Baker, 2012). It was therefore appropriate to manufacture and assess the 
transduction efficiency of an Ad5 vector in-vitro in human VSMC, the ultimate target cell 
for the prevention of ISR. In keeping with previously published results (and as discussed in 
Chapter 1) significant transduction could only be obtained at higher viral concentrations. It 
was the initial plan for the experiments in this chapter to use a second-generation lentiviral 
vector expressing GFP in the in-vivo porcine model. As predicted our manufactured vector 
was able to efficiently transduce human VSMC in-vivo at low viral doses. Concurrent work 
in our institution had evaluated and identified efficient gene transfer to human VSMC 
using both integrase-competent and integrase-deficient lentiviral vectors and resultant 
inhibition of cell proliferation and migration through the delivery of the regulatory protein 
Nogo-B (Chick et al., 2012). Unfortunately production of suitable titres of lentiviral vector 
in the laboratory at the required amount proved to be extremely time consuming (3 weeks 
for a viral preparation to produce enough vector for use in 2-3 animals) and prohibitively 
expensive. A decision was therefore made to revert to use of Ad5 vectors initially, which 
can be manufactured at appropriate titres and volumes much more easily, while developing 
the porcine model and testing local delivery catheters.  
Having made the decision to initially test Ad5 vectors it was important to establish the 
extent of CAR-mediated interaction that could occur with circulating erythrocytes when 
introduced to the in-vivo porcine model. Similarly to in murine models, no 
haemagglutination with porcine erythrocytes was noted following incubation with the Ad5 
vector. This would however, have had to be taken into account should any future 
therapeutic benefit have been obtained in the porcine model.  
Several local delivery catheters had previously been developed and used for the purpose of 
initially local drug delivery, then ultimately, delivery of viral gene therapy vectors (Lincoff 
et al., 1994, Barath et al., 1997). However, not only had they generally failed to achieve 
efficient, reliable or reproducible gene delivery, none remain commercially available 
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(Sharif et al., 2004). It was important to source suitable alternatives as when the project 
was first designed it had been planned to use the Dispatch catheter system (Tahlil et al., 
1997). The Clearway RX system was at the time a novel and recently available perfusion 
catheter designed to deliver intracoronary antiplatelet therapy directly to culprit lesions 
without resultant vessel trauma (Saraf et al., 2008). Its ability to slowly elute a therapeutic 
solution, and provide occlusive direct contact with the vessel wall at low inflation pressure 
suggested potential utility as a delivery catheter for a gene therapy vector. 
To test its utility it was first used to deliver both Ad5 expressing GFP then Ad5 expressing 
LacZ to ex-vivo segements of porcine coronary artery. Experimental conditions were set to 
as closely mimic in-vivo conditions as possible. Initial results were encouraging with 
evidence of successful viral transduction of the vessel wall obtained using both vectors.  
Translation to the in-vivo porcine model was to prove initially problematic as 4 of the 
initial 6 animals suffered from intra-procedural dysrhythmic death. The fifth also suffered 
from a dysrhythmia but was successfully resuscitated. There appeared to be no clear 
procedural reason for this. Appropriate antiplatelet therapy with aspirin and clopidogrel 
had been administered with animals receiving a 150mg loading dose of each on the 
preprocedural day and 75mg of each on the day of the procedure. They were also 
adequately anticoagulated with 3000iU of heparin administered intravenously at the start 
of the procedure. It has been noted that peri-procedural mortality is higher in the porcine 
model than for human procedures with published guidelines stating acceptable rates of 
<15% early mortality and <25% overall mortality for a complete study (Schwartz et al., 
2002). It is noted, however, that these rates are somewhat high and that this level of animal 
loss suggests a problem with either the device/agent being tested or general method and 
technique (Schwartz et al., 2002). More recent procedural guidance has suggested that 
while some deaths will be related to the experimental nature of testing new technologies, it 
is likely that a significant proportion are due to poor technique or inexperienced operators, 
and therefore potentially avoidable (Williams et al., 2012). These experienced investigators 
report a mortality of <1% at their institution.  
All of the deaths in this initial group occurred before the introduction of virus and therefore 
could not be explained by this. At this point the experiment was paused and advice sought 
from our institutional vet, veterinary anaesthetists from the University of Glasgow Vet 
School and also from investigators at another institution with considerable experience in 
the use of this experimental model. It was noted that all of the animals came from the same 
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litter. Two potential explanations were put forward. It has been noted that pigs can be 
genetically susceptible to malignant hyperthermia (known as Porcine Stress Syndrome) 
and that this can be induced by inhalational anaesthetics or nitrous oxide. This is known to 
be common in pigs due to inbreeding and is invariably fatal (Williams et al., 2012). All of 
our animals were receiving a combination of isoflurane and nitrous oxide as maintenance 
anaesthesia. At this point temperature monitoring was not in place. The second possible 
explanation is that, again due to inbreeding, pigs can be susceptible to dysrhythmia 
secondary to cardiac channelopathies or Long QT syndrome (Dr Julian Gunn, University 
of Sheffield, Personal communication). The single-lead ECG tracings were retrospectively 
reviewed for all the dead animals. While the QT segments did not appear to be relatively 
prolonged, no reference range for a “normal” pig QT interval exists in the literature 
therefore this was difficult to quantify.  
Based on this, several alterations were made to the experimental protocol. Use of a rectal 
temperature probe with continuous monitoring and an attached heated mat to maintain a 
core temperature of 37oC was introduced. A decision was also made to administer 
prophylactic IV antiarrhythmic therapy at the beginning of the procedure. A regimen of 
amiodarone 75mg and lignocaine 50mg given as IV bolus at the start of the procedure was 
introduced. Although this can carry additional risk as both agents can also be 
proarrhythmic it was felt to be an appropriate strategy. From this point until the end of the 
experiments, no malignant hyperthermia or arrhythmic death occurred. The single animal 
that died in a later experiment suffered acute stent thrombosis.  
Using the Clearway RX to deliver two concentrations of Ad5 expressing LacZ (1x1010pfu 
and 5x1010pfu) to porcine coronary arteries previously treated with a BMS did not result in 
significant viral transduction of the arterial wall as assessed by β-galactosidase staining. 
The most likely explanation for this is that the Clearway RX was unable to provide a long 
enough duration of virus contact with the vessel wall. The virus was diluted to a final 
volume of 1ml. It was felt that to dilute the Ad5 vector in a larger volume than this (with 
resultant drop in viral concentration) would significantly impair effective transduction. 
Therefore the duration of viral delivery was short – with 1ml delivered at a pressure of 
2atm – at less than 60 seconds. To keep the balloon inflated in the hope that virus would be 
kept in contact with the vessel for longer, 0.9% saline solution was infused through a three-
way tap after all the virus had been injected, at a pressure of 1atm. This likely contributed 
to washing the virus into the circulation however. Once the perfusion balloon was deflated, 
coronary blood flow restored which completed the wash out of the virus. To have a 
Chapter 3 | Local Delivery of Viral Vectors 
 
130
constant viral infusion at an effective concentration would have resulted in a massive 
overall dose exposing the animal to a considerable risk of toxicity.  
The only other commercially available perfusion catheter that could be sourced was the 
GENIE drug delivery device. The design of this catheter, with its reservoir that could 
theoretically hold a concentrated virus solution in contact with the vessel wall for longer 
than the Clearway RX was felt to be a potentially viable alternative. Again no significant 
vessel transduction could be obtained using Ad5 LacZ. Using a high grade viral vector it 
was felt suitable to dilute to 5ml final volume giving a concentration of 2.5x1010 pfu/ml. In 
pre-clinical studies of paclitaxel to porcine coronary arteries a volume range of 2.9 +/- 
1.6ml was delivered over 120seconds (Dommke et al., 2007). Despite using a constant 
delivery pressure of 2atm and a fixed volume of 5ml, the viral delivery time achieved was 
variable at 2.75+/-0.89mins (Range 1-6 minutes). Again balloon inflation was maintained 
using an indeflator filled with 0.9% saline maintained at 2atm connected to the GENIE 
device via a three-way tap to avoid balloon deflation after delivery of the virus solution 
was complete. This provided a mean balloon inflation time of 7.08+/-1.88 minutes. Again, 
unavoidably, this may have resulted in a degree of virus wash-out. The variability in 
perfusion/inflation time despite constant pressure and volume is likely explained by slight 
variations in vessel diameter as this was determined by visual assessment.  
Although an improvement compared with the Clearway RX, a mean incubation time of 7 
minutes before restoration of coronary flow is still not enough to provide measurable in-
vivo VSMC transduction using unmodified Ad5 vectors. This was confirmed by the in-
vitro transduction of HCASMC. The incubation (inflation) time achieved was limited due 
to poor tolerance of the procedure by the animals as 50% (3 animals) suffered from 
complications occurring at the time of GENIE inflation. The pigs used in standard pre-
clinical models are juvenile, healthy animals that have minimal pre-existing coronary 
collateral flow (Maxwell et al., 1987, White et al., 1992). They therefore lack ischaemic 
preconditioning and are susceptible to complications with more prolonged balloon 
inflation.  
In conclusion, these findings suggest that there is little clinical utility in the use of 
unmodified Ad5 vectors for viral gene delivery to the vasculature, post-stent delivery in-
vivo, using currently available occlusive local delivery catheters with subsequent 
restoration of coronary flow.  
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The modern clinical setting favours the use of a stent platform to deliver therapeutic agents 
targeted at reducing ISR. Although results in pre-clinical models have been encouraging it 
has proven difficult to stably attach a given delivery vector to a metal platform and allow 
controlled and efficacious elution in-vivo. Methods used have become increasingly 
complex, ranging from the use of positively charged polymer coatings to “bind” more 
negatively charged viral particles (Johnson et al., 2005) to complex synthetic binding 
strategies (Fishbein et al., 2008). The final experiments in this chapter pursued a simpler 
approach.  
In previously reported pre-clinical studies, the biocompatible polyoxyethyl-polyoxypropyl 
block co-polymer poloxamer 407 has been shown to increase VSMC transduction in-vitro 
and in-vivo with adenoviral and lentiviral vectors (Dishart et al., 2003, Feldman et al., 
1997, Maillard et al., 2000, March et al., 1995, Van Belle et al., 1998). March et al 
identified a greater than 10-fold increase in VSMC transduction in-vitro when Ad 
expressing LacZ was combined with a 15% poloxamer 407 solution (March et al., 1995). 
They hypothesised that the poloxamer gel acted as a delivery reservoir for the virus and 
improved gene delivery by maintaining a high pericellular viral concentration. It has also 
been suggested that interactions between the poloxamer gel and cell membrane can 
facilitate cellular uptake of Ad (Cho et al., 2000). Subsequently, Feldman et al used a 15% 
poloxamer gel to improve the transduction efficiency of a similar Ad5 vector when 
delivered to balloon-injured rat carotid arteries in-vivo (Feldman et al., 1997). Furthermore, 
they showed that, importantly, using the poloxamer gel reduced the required incubation 
time without compromising the transduction efficiency. No specific tissue toxicity was 
observed, consistent with prior reports (Johnston and Miller, 1985). Using a channel 
balloon local delivery catheter, the same group identified a 3- to 15-fold increase in 
transduction efficiency when delivered to non-stented rabbit iliac arteries and a 7-fold 
increase when delivered prior to stent insertion (Van Belle et al., 1998). Their method 
allowed a reduction in transduction time from 30 to 5 minutes with minimal reduction in 
efficiency. The use of poloxamer gel did not significantly compromise vessel patency 
(thrombotic occlusion was rare) in these studies and prior work had shown that the gel 
disappears over 1-2hours in-vivo (Simons et al., 1992).  
Review of the literature did not suggest that this approach had been taken any further.  
Certainly the above results were encouraging in that a poloxamer gel/Ad5 combination 
could be an attractive way to achieve effective local biological effects with shorter 
transduction times.  It should be noted however, that in all of the above in-vivo studies 
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vessel blood flow was ceased during the incubation period, either by temporary vessel 
ligation or balloon occlusion. This is an important factor when considering the translation 
of results to a coronary artery model, where as previously described, prolonged flow 
occlusion can be problematic.  
A strategy was therefore devised using the thermoreversible properties of poloxamer 407 
and utility of the spray-coatable Yukon stent system (Mehilli et al., 2006) to create an Ad5 
LacZ-eluting stent platform with a transient biocompatible polymer predicted to last 1-2 
hours in the circulation (Simons et al., 1992). 
This approach again proved unsuccessful with no evidence of effective viral transduction 
of the arterial wall. In keeping with previous in-vivo studies, it became clear that the virus 
had sequestrated to non-target organs, namely the liver, spleen and lung. No evidence of 
viral transduction was seen within the myocardium. As discussed in chapter 1 this occurs 
due to Ad5 interaction with components of the circulating blood stream, principally 
coagulation factor X (Coughlan et al., 2010, Bradshaw and Baker, 2012). It had been 
hoped that the poloxamer 407 would overcome this effect, however it is highly water 
soluble and therefore likely dissolved in the circulation during positioning and deployment 
of the coated Yukon stents. With previous in-vivo models there had always been a short 
period of stasis when the poloxamer/virus mix was introduced to the target vasculature 
before restoration of circulating blood flow. This is clearly not possible in the coronary 
circulation with a percutaneously delivered device. Success of current DES technology 
utilises the liphophilic properties of the antiproliferative agents to influence drug 
absorption into the arterial wall as opposed to being dissolved and lost in the circulation 
(Garg et al., 2013). The lack of lipophilicity and marked aqueous solubility of poloxamer 
407 clearly inhibits its effectiveness in this setting.  
In summary, despite initial procedural issues a reproducible model of porcine stent 
implantation suitable for the evaluation of vascular gene therapy was developed. However, 
successful transduction of the stented arterial wall using unmodified Ad5 vectors could not 
be achieved using two commercially available delivery catheters or a stent platform coated 
with a biocompatible thermoreversible gel polymer. In view of the disappointing nature of 
these results and the costs involved in using this pre-clinical model, it was felt that further 
development of suitable viral vectors and alternative delivery methods was required. Both 
of these approaches are being investigated within our institution and will be further 
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discussed in chapter 6. However, both fell out-with the time frame available for completion 
of this PhD.  
The focus of this project therefore switched to the potential role of microRNAs in the 
development of ISR and the evaluation of their manipulation as a potential therapeutic 
option using the porcine model of intracoronary stent delivery. This will be discussed in 
the following chapter.  
  
4 Role of MicroRNAs in a Porcine model of In-
stent Restenosis 
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4.1 Introduction 
It was the aim of this chapter to investigate and validate expression levels of miRs thought 
to be important in the maintenance of vascular function and development of ISR and with 
potential for downstream therapeutic modulation. It was hypothesised that expression 
patterns of regulatory miRs in the vasculature would alter in response to stent-induced 
injury. 
Firstly, in-vitro experiments were performed using human coronary artery smooth muscle 
cells (HCASMC), the principle cell type involved in the formation of neointimal lesions. 
Expression levels of miRs implicated in the control of VSMC phenotype were assessed in 
HCASMC stimulated to a proliferative phenotype by classical mitogens and to a migratory 
phenotype using a wounding assay.  
Secondly, all previously reported studies in this area have used in-vitro or in-vivo rodent 
models of vascular injury. A more clinically relevant large animal (porcine) model of in-
stent restenosis was therefore utilised to assess the expression levels of miRs previously 
reported to play a role in VSMC regulation as well as novel targets. In-situ hybridization 
was used to co-localise dysregulated miRs within neointimal lesions to establish potential 
targets for future therapeutic modulation.  
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4.2 Results 
4.2.1 Changes in microRNA expression levels as HCASMCs 
proliferate  
Through the use of miRNA microarray and confirmation using qRT-PCR and Northern 
Blot analysis, Ji et al, identified 11 miRs that were significantly dysregulated in rat carotid 
arteries following balloon injury (Ji et al., 2007). MiRs-21, -146, -214 and -352 were all 
upregulated following vascular injury while miRs-125a, -125b, -133a, -143, -145, -347 and 
-365 were significantly downregulated. We wished to establish the importance of these 
miRs in a human in-vitro model.  Confluent HCASMC were incubated with serum-
free media for 48 hours to induce a differentiated contractile state. The cells were then 
stimulated to dedifferentiate to a proliferative phenotype by incubation with classical 
mitogens (Newby and George, 1993): 15% FCS, PDGF, IL-1α, PDGF and IL-1α in 
combination and bFGF. RNA was extracted from the cells at various time points namely 1, 
5, 18 and 24 hours. Expression levels of miRs at each time point were established using 
qRT-PCR and comparison made to differentiated cells held in serum free media for an 
identical length of incubation.  
The expression level of miR-21 was increased 2.5-3 fold at 1 hour when stimulated by 
FCS, PDGF or PDGF+IL-1α (Figure 4.4). Interestingly, levels had returned to baseline by 
5 hours. IL-1α in isolation and bFGF had no significant effect on miR-21 levels. Levels of 
mIR-146a were increased by stimulation with FCS and remained elevated out to 18 hours 
(Figure 4.5). In isolation PDGF had no effect, and IL-1α only increased levels at 18 hours, 
however, in combination miR-146a expression was increased 2.5 fold at 1 hour, 5.5 fold at 
5 hours and 4 fold at 18 hours (Figure 4.5). Only a marginal effect was seen using bFGF 
with a 2 fold increase at 18 hours only. Expression levels of miR-146b, however, were 
unaffected by mitogen stimulation at the measured time points (Figure 4.6).  MiR-365 
expression levels were increased between 3-6 fold by all mitogens at 1 hour, again 
returning to baseline by 5 hours (Figure 4.7). Levels of miR-221 (Figure 4.8), miR-
143/145 (Figure 4.9) and miR-133a (Figure 4.10) were unchaged compared with 
differentiated cells at all time points.  
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Figure 4-1 Change in expression level of miR-21 with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-21 expression determined using qRT-PCR with RNU48 as an endogenous control. 
All comparisons made to control (differentiated) cells held in serum-free (0.1%) media for an 
identical length of time. Results displayed as Relative Quantity (RQ) + RQmax calculated using the 
2-∆∆Ct
 
method. * = p<0.01, # = p<0.05, No symbol = no significant change, One-way ANOVA with 
Tukey post-correction. SF – serum free media. 15% = SMC media with 15% serum. PDGF – 
Platelet derived growth factor. IL1α – interleukin-1α. BFGF – basic fibroblast growth factor.   
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Figure 4-2 Change in expression level of miR-146a with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-146a expression determined using qRT-PCR with RNU48 as an endogenous 
control. All comparisons made to control (differentiated) cells held in serum-free (0.1%) media for 
an identical length of time. Results displayed as Relative Quantity (RQ) + RQmax calculated using 
the 2-∆∆Ct
 
method. * = p<0.01, # = p<0.05, No symbol = no significant change, One-way ANOVA 
with Tukey post-correction. SF – serum free media. 15% = SMC media with 15% serum. PDGF – 
Platelet derived growth factor. IL1α – interleukin-1α. BFGF – basic fibroblast growth factor.   
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Figure 4-3 Expression level of miR-146b with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-146b expression determined using qRT-PCR with RNU48 as an endogenous 
control. All comparisons made to control (differentiated) cells held in serum-free (0.1%) media for 
an identical length of time. Results displayed as Relative Quantity (RQ) + RQmax calculated using 
the 2-∆∆Ct
 
method. No significant change in expression level was identified at any time point 
compared to differentiated cells (One-way ANOVA with Tukey post-correction). SF – serum free 
media. 15% = SMC media with 15% serum. PDGF – Platelet derived growth factor. IL1α – 
interleukin-1α. BFGF – basic fibroblast growth factor.   
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Figure 4-4 Change in expression level of miR-365 with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-365 expression determined using qRT-PCR with RNU48 as an endogenous control. 
All comparisons made to control (differentiated) cells held in serum-free (0.1%) media for an 
identical length of time. Results displayed as Relative Quantity (RQ) + RQmax calculated using the 
2-∆∆Ct
 
method. * = p<0.01, # = p<0.05, No symbol = no significant change, One-way ANOVA with 
Tukey post-correction. SF – serum free media. 15% = SMC media with 15% serum. PDGF – 
Platelet derived growth factor. IL1α – interleukin-1α. BFGF – basic fibroblast growth factor.   
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Figure 4-5 Expression level of miR-221 with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-221 expression determined using qRT-PCR with RNU48 as an endogenous control. 
All comparisons made to control (differentiated) cells held in serum-free (0.1%) media for an 
identical length of time. Results displayed as Relative Quantity (RQ) + RQmax calculated using the 
2-∆∆Ct
 
method. No significant change in expression level was identified at any time point compared 
to differentiated cells (One-way ANOVA with Tukey post-correction). SF – serum free media. 15% 
= SMC media with 15% serum. PDGF – Platelet derived growth factor. IL1α – interleukin-1α. BFGF 
– basic fibroblast growth factor.   
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Figure 4-6 Expression level of miR-143 and miR-145 with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-143 (Panel A) and miR-145 (Panel B) expression determined using qRT-PCR with 
RNU48 as an endogenous control. All comparisons made to control (differentiated) cells held in 
serum-free (0.1%) media for an identical length of time. Results displayed as Relative Quantity 
(RQ) + RQmax calculated using the 2-∆∆Ct
 
method. No significant change in expression level was 
identified at any time point, for either miR, compared to differentiated cells (One-way ANOVA with 
Tukey post-correction). SF – serum free media. 15% = SMC media with 15% serum. PDGF – 
Platelet derived growth factor. IL1α – interleukin-1α. BFGF – basic fibroblast growth factor.   
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Figure 4-7 Expression level of miR-133a with HCASMC phenotypic switch 
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells then underwent mitogen-mediated 
stimulation to a dedifferentiated proliferative phenotype. RNA was extracted from cells at each time 
point and miR-133a expression determined using qRT-PCR with RNU48 as an endogenous 
control. All comparisons made to control (differentiated) cells held in serum-free (0.1%) media for 
an identical length of time. Results displayed as Relative Quantity (RQ) + RQmax calculated using 
the 2-∆∆Ct
 
method. No significant change in expression level was identified at any time point 
compared to differentiated cells (One-way ANOVA with Tukey post-correction). SF – serum free 
media. 15% = SMC media with 15% serum. PDGF – Platelet derived growth factor. IL1α – 
interleukin-1α. BFGF – basic fibroblast growth factor.   
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4.2.2 MicroRNA expression alters as HCASMC switch to a 
migratory phenotype 
To establish a potential role for these vascular miRs in the de-differentiation of human 
VSMC to a migratory phenotype, a scratch assay was performed. Representative images of 
scratched cell monolayers, then subsequent cell migration to close the wound are shown in 
Figure 4.11. Expression of miR-21 was elevated 4.8 fold (p<0.01 vs. 0hrs) at 6 hours, 
before decreasing to 1.8 fold at 16 hours (Figure 4.12). Levels of miR-221 were elevated 2-
fold at 6 hours, returning to baseline by 16 hours (Figure 4.12). Surprisingly, expression 
levels of miR-145 were also slightly elevated at 6 hours compared with cells at 0 hours 
(RQ 1.8, p<0.01 vs. control) but fell to 33% of initial levels at 16 hours (Figure 4.13). 
Expression levels of miR-143 were similarly elevated at 6 hours (RQ 1.77, p<0.01 vs. 
control) however returned to baseline at 16 hours with no evidence of any decrease in 
expression levels (Figure 4.13). Levels of miR-146a and -146b did not change across any 
time point (Figure 4.14).  
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Figure 4-8 In vitro scratch migration assay  
Representative images of a human coronary artery smooth muscle cell (HCASMC) monolayer 
during an in vitro scratch assay that mimics cell migration in vivo. Cells are quiesced to a 
differentiated phenotype before creation of an artificial wound or scratch. This promotes a migratory 
phenotype and cells will move together until new cell-cell contacts are made. Panel A shows cell 
layer at time of wounding with a 200µl pipette tip. Panel B shows same cells 18 hours later with 
evidence of cell migration closing the gap. Images at x4 magnification. Scale bar = 500µm. 
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Figure 4-9 Change in expression level of miR-21 and miR-221 with HCASMC switch to a 
migratory phenotype  
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells were then promoted to a migratory 
phenotype using a scratch assay technique. RNA was extracted from cells at each time point and 
miR-21 (Top panel) and miR-221 (Bottom panel) expression determined using qRT-PCR with 
RNU48 as an endogenous control. All comparisons made to control differentiated cells (at time 
point 0 - baseline). Results are displayed as Relative Quantity (RQ) + RQmax calculated using the 
2-∆∆Ct
 
method. * = p<0.01, NS = no significant change from baseline levels, One-way ANOVA with 
Tukey correction.  
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Figure 4-10 Change in expression level of miR-143 and miR-145 with HCASMC switch to 
a migratory phenotype  
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells were then promoted to a migratory 
phenotype using a scratch assay technique. RNA was extracted from cells at each time point and 
miR-143 (Top panel) and miR-145 (Bottom panel) expression determined using qRT-PCR with 
RNU48 as an endogenous control. All comparisons made to control differentiated cells (at time 
point 0 - baseline). Results are displayed as Relative Quantity (RQ) + RQmax calculated using the 
2-∆∆Ct
 
method. * = p<0.01, NS = no significant change from baseline levels, One-way ANOVA with 
Tukey correction.  
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Figure 4-11 Expression level of miR-146a and miR-146b with HCASMC switch to a 
migratory phenotype  
In vitro human coronary artery smooth muscle cells (HCASMC) were incubated with serum free 
media to induce a differentiated contractile state. Cells were then promoted to a migratory 
phenotype using a scratch assay technique. RNA was extracted from cells at each time point and 
miR-146a (Top panel) and miR-146b (Bottom panel) expression determined using qRT-PCR with 
RNU48 as an endogenous control. All comparisons made to control differentiated cells (at time 
point 0 - baseline). Results are displayed as Relative Quantity (RQ) + RQmax calculated using the 
2-∆∆Ct
 
method. No significant change from baseline levels was identified at any time point for either 
miR (One way ANOVA with Tukey post-correction).  
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4.2.3 In-vivo Porcine model of In-stent Restenosis 
In order to investigate the potential role of miRs in the development of ISR a porcine 
model was utilised as described in Chapter 2. To ensure vessel injury and stimulate 
neointimal development an established method of stent overexpansion was utilised (Gunn 
et al., 2002, Ialenti et al., 2011). For this experiment, and in keeping with the age of pigs 
used, 3.0x15mm Vision Multi-Link (Abbott Vascular, Santa Clara, CA, USA) bare-metal 
stents were implanted in most animals (3 groups, n=4/group). For the 4th DES (28 days) 
group (n=4), Endeavour (Medtronic, Minneapolis, MN, USA) drug-eluting stents were 
used. The stent to artery ratio used was 1.2:1 as assessed visually during angiography. 
Practically therefore this meant that a 3.0x15mm stent was implanted in a segment of 
artery measuring 2.5mm using nominal pressure (9 atmospheres). This is reported as being 
effective in inducing significant neointimal formation at 28 days in the porcine model  
(Ialenti et al., 2011, Watt et al., 2013). 
4.2.3.1   Histology 
As shown in Figure 4.15 Panels A-D, significant neointimal formation was achieved in 
animals receiving BMS. The mean neointimal thickness obtained was 0.08 + 0.01mm at 7 
days and 0.22 + 0.02mm at 28 days (p<0.001, 7 days vs. 28 days, Fig 4.28E).  
However, it ultimately proved impossible to electrolyse the Endeavour DES using the 
equipment available. This was despite use of maximal voltage available (10V) for 
prolonged duration (up to 1 hour) and with attempted disruption of the stent polymer using 
a scalpel. Due to excessive tissue trauma and disruption in these samples (Figure 4.16 
Panels F-G) no interpretable histology or in-situ hybridisation data was obtained from the 
animals who received DES.  
It was, however, possible to obtain some virtual histology data, ex-vivo in these animals 
using an optical coherence tomography (OCT) catheter. The mean neointimal thickness, as 
obtained by OCT, measured at 0.51 + 0.05mm in BMS at 28 days and 0.48 + 0.26mm in 
DES at 28 days (Figure 4.16 Panels A-B). There was no significant difference detected 
between the two groups (p=0.68). In keeping with the different methods of measurement 
inherent to each technique, OCT was seen to overestimate mean neointimal thickness as 
compared to histological analysis (0.51 ± 0.05mm vs. 0.22 ± 0.02mm, p<0.0001, Figure 
4.17). 
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Figure 4-12 Morphometric analysis of porcine arteries treated with bare-metal stents 
Measurement of mean neointimal thickness confirms development of significant neointimal 
hyperplasia at 28 days following the insertion of overexpanded (1.2:1) cobalt-chromium coronary 
stents (BMS). Panels A-D show representative photomicrographs, stained with haematoxylin and 
eosin, to allow morphometric analysis. Stents have been removed using electrolysis. Panel A – 
Control (Unstented vessel). Panel B – BMS (Day 0). Panel C – BMS (Day 7). Panel D – BMS (Day 
28). Scale bars = 300µm. Panel E - Mean neointimal thickness. * = p<0.0001(Student’s t test). 
Neointimal area = internal elastic laminal area minus the lumen area.  
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Figure 4-13 “Virtual” histology of BMS vs. DES at 28 days obtained using OCT 
Mean neointimal thickness as, measured by optical coherence tomography (OCT) ex vivo, in pigs 
receiving bare-metal (BMS) or drug-eluting (DES) stents (n=4/group, 2 stents/animal). All 
measurements taken from animals euthanized at 28 days post-stent implantation. Panels A and B 
show no difference in the extent of neointimal hyperplasia induced by 1.2:1 overexpansion of 
cobalt-chromium BMS or zotarolimus eluting DES. p = 0.68 (Student’s t test). Panels C-E show 
representative OCT images from unstented control artery, BMS at 28 days and DES at 28 days, 
respectively. Scale bar = 1mm.  Panel F shows intact stent struts dissected from an artery 
implanted with DES despite being subjected to prolonged electrolysis (dissecting microscope view). 
Panel G is a representative H&E stained section from an artery implanted with DES showing the 
typical tissue disruption encountered when stent dissolution was attempted. x4 magnification. Scale 
bar = 300µm. 
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Figure 4-14 Comparison of neointimal area as measured by OCT and H&E morphometry  
A comparison was made of neointimal thickness, as measured by morphometry in H&E stained 
sections, and optical coherence tomography in pigs implanted with BMS and euthanized at 28 days 
(n=4, 2 stents/animal). Following formalin-fixation arteries were assessed ex vivo with an OCT 
catheter before stent electrolysis, histological processing and H&E staining. For H&E sections, 
internal elastic laminal area is measured and then the lumen area is subtracted to give the mean 
neointimal thickness. For OCT, it was not possible to measure the IEL area due to loss of 
resolution following formalin-fixation. Therefore a tracing was made around the stent struts to give 
a stent area, from which the lumen area was subtracted. This results in a significant overestimation 
compared to classical histology (p<0.0001).  
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4.2.3.2   Choice of endogenous control 
When using qRT-PCR techniques for characterisation of miR expression patterns in tissue, 
corrections must be made for differences between samples arising due to variations in 
RNA quality and quantity (de Kok et al., 2005, Stahlberg et al., 2004). These variations 
occur due to sample collection, amount of starting material, the method of RNA extraction 
and cDNA synthesis. To control these variations a normalisation to a suitable endogenous 
control gene (or genes) is performed. To be used as an endogenous control, gene 
expression must be constant and highly abundant across tissue and cell types. Suitable 
endogenous control genes for use in porcine vascular tissue have not yet been established. 
In a previous report, Gu et al, studied 47 different porcine tissues and showed that the most 
stable EC genes for use in normalization were sus scrofa ssc-miR-17, -103 and -107 with 
ssc-miR-17, -23a and -103 being most reliable in muscle tissue (Gu et al., 2011). Vascular 
muscle tissue was not used in their analysis.  
To establish appropriate endogenous control genes for use in porcine models we analysed 
expression levels of apparently stable miRs in a TaqMan Low-Density microRNA 
microarray analysis of porcine vascular tissue (saphenous vein, carotid artery, SVG at 7 
and 28 days) used in a separate study within our institution (McDonald et al., 2013). These 
results are summarised in Figure 4.18 and Table 4.2. Both miR-17 and miR-199a-3p 
appeared suitable and stable for use as endogenous controls in porcine vascular tissue with 
abundant expression, narrow confidence intervals and standard deviations of <1. For all 
following experiments, miR-199-3p was used to maintain consistency within the in vivo 
models utilised in our institution (McDonald et al., 2013).  
Table 4-1 Mean cycle thresholds (Ct) of potential endogenous control microRNAs 
 U6 miR-17 miR-23a miR-23b 
miR-
103 miR-199a-3p 
Mean Ct 15.37 16.39 29.30 24.45 21.77 17.04 
Std. Deviation 0.6779 0.7327 2.993 2.845 1.172 0.9177 
Std. Error 0.1384 0.1496 0.6241 0.5807 0.2391 0.1873 
Lower 95% CI of 
mean 
15.08 16.08 28.00 23.24 21.28 16.65 
 
Upper 95% CI of 
mean 
15.66 16.70 30.59 25.65 22.27 17.43 
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Figure 4-15 Scatter plots of raw Ct values for potential porcine endogenous controls  
Ct values taken from TaqMan Low-Density microRNA microarray analysis of porcine vascular 
tissue (saphenous vein, carotid artery, and interposition saphenous vein grafts at 7 and 28 days) 
used in a separate study within our institution. U6 spliceosomal RNA, miR-17 and miR-199a-3p, 
show abundant expression, narrow confidence intervals and standard deviations of <1, suggesting 
suitability for use as endogenous controls in qRT-PCR analysis of porcine vascular tissue.  
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4.2.3.3   Expression of MiR-21/221 
MiR-21 levels were upregulated at 7 and 28 days in arteries stented with both BMS and 
DES (Figure 4.19). At 7 days post BMS insertion there is a greater than 5-fold increase in 
expression which was maintained out to 28 days (RQ 3.8, p<0.001). No differences were 
seen between BMS and DES at 28 days (p>0.05). MiR-221 levels were elevated at Day 7 
in the BMS group, returning to baseline at 28 days (Figure 4.19). No increase was 
observed at 28 days when a DES was used.  
4.2.3.4   Expression of MiR-143/145 
qRT-PCR analysis of miR-143 and miR-145 in stented vessels showed that expression 
levels of both were significantly down regulated at 7 and 28 days post stent implantation 
(Figure 4.20). Compared to unstented control vessels, miR-145 (but not miR-143) 
expression was down-regulated in vessels harvested immediately following stent insertion 
(Day 0) (Figure 4.20). Levels of miR-145 only were significantly lower in arteries 
receiving DES compared with BMS at 28 days (75% vs. 48% downregulation).  
 
4.2.3.5   Other Vascular MicroRNAs 
Analysis of other vascular associated miRs was performed in the stented vessels. Levels of 
miR-92a, miR-126, miR-155 and miR146a showed no change in expression compared 
with unstented control vessels (Figure 4.21 Panel A). Expression levels of miR-133a 
showed a statistically significant increase in vessels harvested immediately post stent 
insertion (RQ 5.6, p<0.05 vs. control) however had returned to baseline by Day 7 (Fig 4.21 
Panel B).  
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Figure 4-16 Expression levels of microRNAs upregulated in a porcine model of coronary 
in-stent restenosis 
Pigs received standardized BMS (cobalt alloy) or DES (Zotarolimus-eluting) (n=4/group, 2 
stents/animal) over-expanded at a ratio of 1.2:1 to induce neointimal hyperplasia. Animals were 
euthanized at 0, 7 or 28 days (BMS) and 28 days (DES). Total RNA was extracted from snap-
frozen stented tissue. miR expression levels were determined by quantitative real-time polymerase 
chain reaction and normalized to miR-199a-3p. For comparison, miR expression levels are given 
as fold-change versus control vessels (unstented arteries) calculated using the 2-∆∆Ct method. 
Significance was assessed by repeated measures ANOVA with a Tukey post-test. A value of 
p<0.05 was considered statistically significant. * = p<0.001 
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Figure 4-17 Expression levels of microRNAs downregulated in a porcine model of 
coronary in-stent restenosis 
Pigs received standardized BMS (cobalt alloy) or DES (Zotarolimus-eluting) (n=4/group, 2 
stents/animal) over-expanded at a ratio of 1.2:1 to induce neointimal hyperplasia. Animals were 
euthanized at 0, 7 or 28 days (BMS) and 28 days (DES). Total RNA was extracted from snap-
frozen stented tissue. miR expression levels were determined by quantitative real-time polymerase 
chain reaction and normalized to miR-199a-3p. For comparison, miR expression levels are given 
as fold-change versus control vessels (unstented arteries) calculated using the 2-∆∆Ct method. 
Significance was assessed by repeated measures ANOVA with a Tukey post-test. A value of 
p<0.05 was considered statistically significant. # = p<0.05, ** = p<0.01, * = p<0.001 (vs. unstented 
control unless otherwise indicated).  
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Figure 4-18 Expression profiles of vascular microRNAs not significantly altered in 
response to vessel injury and stent implantation in porcine model  
Panel A - miRs with no change in expression levels. Panel B – miR-133a expression levels. Pigs 
received standardized BMS (cobalt alloy) or DES (Zotarolimus-eluting) (n=4/group, 2 stents/animal) 
over-expanded at a ratio of 1.2:1 to induce neointimal hyperplasia. Animals were euthanized at 0, 7 
or 28 days (BMS) and 28 days (DES). Total RNA was extracted from snap-frozen stented tissue. 
miR expression levels were determined by qRT-PCR and normalized to miR-199a-3p with 
expression levels given as fold-change versus unstented control vessels calculated using the 2-∆∆Ct 
method. Significance was assessed by repeated measures ANOVA with a Tukey post-test. A value 
of p<0.05 was considered statistically significant. All above comparisons – p>0.05 vs. unstented 
control except miR-133a Day 0 vs. control as indicated.  
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4.2.3.6   Localisation of miR-21 
In-situ hybridisation (ISH) was used to localise the areas of increased miR-21 expression 
within the stented vessel wall. This proved challenging with initial significant tissue 
degradation occurring. By shortening the duration of tissue exposure to Proteinase K this 
was overcome, to a degree. Interpretation of the obtained images proved difficult due to 
persistent background staining in control samples exposed to a scrambled probe. However, 
despite these obstacles ISH revealed increased miR-21 expression in the neointima of 
vessels at Day 7 and Day 28 following BMS implantation, most notably around the stent 
struts (Fig 4.19). These findings were consistent with the qRT-PCR data. No interpretable 
data could be obtained from vessels receiving DES due to excessive tissue trauma caused 
by the electrolysis process in these samples.  
4.2.3.7   Localisation of miR-143/145 expression in neointima 
Again, ISH was used to further interrogate the expression of miR-143/145 in the vessel 
wall following stent deployment.  Consistent with the qRT-PCR data, this revealed an 
immediate rapid loss of miR-145 from the vessel wall (Fig 4.20A). However, at 7 and 28 
days post-BMS deployment both miRs were detectable in areas of neointima development 
(Fig 4.20A).  At day 28, both miRs were also detectable in the vessel media (Fig 4.20A).  
Positive staining for α-SMA (Fig 4.20B) was localised to a similar region as miR-143/145 
expression.  These patterns suggest that although the global level of miR-143/145 
expression detectable by qRT-PCR is down-regulated in response to vascular injury, 
expression of miR-143/145 emerges within the neointima and in the media at later time 
points.  
Staining for proliferating cell nuclear antigen (PCNA) showed concordance in the 
neointima with areas of miR-143 and miR-145 expression, particularly around the stent 
struts (Fig 4.21). Of note, no PCNA staining was present in the vessel immediately post 
stent deployment (Fig 4.21). These results suggest that miR-143 and miR-145 are 
expressed in dedifferentiated VSMCs within the neointima.  
Again, no interpretable data could be obtained from vessels treated with DES.  
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Figure 4-19 miR-21 localisation in stented porcine vessels 
Pigs received BMS or DES (n=4/group, 2 stents/animal).  Animals were euthanized 0, 7 or 28 days 
post procedure.  Representative in situ hybridization (violet) images using miR-21 and scrambled 
probes.  Panels A-B - Day 0 BMS (x4 magnification). Panels C-D - Day 7 BMS (x10 mag). Panels 
E-F - Day 28 BMS (x4mag). Panels G-H - Day 28 BMS (x10 mag). Panels I-J – Day 28 DES (x10 
mag). Panels K-L - unstented control (x4 mag). Scale bars = 300µm for x4 magnification and 
200µm for x10 magnification.  
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Figure 4-20 miR-143/miR-145 localisation in stented porcine vessels  
Pigs received bare-metal stents (n=4/group, 2 stents/animal).  Animals were sacrificed 0, 7 or 28 
days post procedure. Panel A - Representative in situ hybridization (violet) images using 
scrambled, miR-143 or miR-145 probes in control unstented, day 0, day 7 and day 28 stented 
vessels.  Panel B - Representative immunohistochemical staining of α-SMA in serial sections.  
Scale bar represents 100 µm. 
 
  
 
Figure 4-21 Immunolocalization of cells expressing miR-143 and miR-145 in stented porcine coronary arteries 
Upper two rows show representative in situ hybridization (violet) images using miR-143 or miR-145 probes in control unstented, day 0, day 7 and day 28 stented (BMS) 
vessels. Lower panels show immunohistochemistry staining for proliferating cell nuclear antigens (PCNA) in serial sections. Scale bars represent 100µm. 
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4.2.3.8   Novel MicroRNAs Dysregulated in Restenosis 
As discussed, the above investigated miRs have all been implicated in the development of 
restenosis in in-vitro or small animal in-vivo models. To identify potentially novel miRs 
that may be involved in the ISR pathway, we investigated a panel of miRs dysregulated, on 
microfluidic array analysis, in response to interpositional vein grafting in a porcine model 
utilised within our institution (McDonald et al., 2013). Verification was performed by 
qRT-PCR analysis in RNA samples from stented porcine coronary arteries (BMS and 
DES) as above.  
Both the miR-142-3p and miR-142-5p stem loops showed promise, with early approximate 
2-fold increases in expression immediately following BMS delivery and peaking at 5-6 
fold at day 7 post stent implantation (Figure 4.25). This increase in expression was 
maintained out to 28 days (Figure 4.25). These findings paralleled changes seen in porcine 
vein grafts at 7 and 28 days post-engraftment (McDonald et al., 2013). Interestingly, 
arteries stented with DES did not show any change in miR-142-3p or miR-142-5p 
expression.  
Expression levels of miR-23b showed a 46% reduction at day 7 following BMS 
implantation and had returned to baseline by day 28 (Figure 4.26 Panel A). No change was 
observed with DES at 28 days (Figure 4.26 Panel A). Levels of miR-30c were unchanged 
at day 7 post-BMS but then showed a marked (95%) reduction at day 28 (Figure 4.26 
Panel B). At 28 days following DES delivery however, there was no change in expression 
(Figure 4.26 Panel B). Lastly, miR-99b expression levels were reduced by 45% at day 7 
following BMS insertion, returning to baseline at day 28 while DES induced a more 
marked reduction of 60% at the 28 day time point (Figure 4.26 Panel C). These results 
were again consistent with the changes seen in response to vein engraftment at identical 
time points (Unpublished data).  
Of the other investigated miRs: let-7a, miR-24, miR-29a, miR-29b, miR-195 and miR-197 
none showed any change in expression levels following stent delivery in porcine coronary 
arteries (Figure 4.27).  
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Figure 4-22 Change in expression of miR-142-3p and miR-142-5p in response to coronary 
stent insertion  
Panel A – miR-142-3p. Panel B – miR-142-5p. Pigs received standardized BMS (cobalt alloy) or 
DES (Zotarolimus-eluting) (n=4/group, 2 stents/animal) over-expanded at a ratio of 1.2:1 to induce 
neointimal hyperplasia. Animals were euthanized at 0, 7 or 28 days (BMS) and 28 days (DES). 
Total RNA was extracted from snap-frozen stented tissue. miR expression levels were determined 
by quantitative real-time polymerase chain reaction and normalized to miR-199a-3p. For 
comparison, miR expression levels are given as fold-change (RQ) versus control vessels 
(unstented arteries) calculated using the 2-∆∆Ct method. Significance was assessed by repeated 
measures ANOVA with a Tukey post-test. A value of p<0.05 was considered statistically significant. 
* = p<0.05, ** = p<0.01, *** = p<0.001. 
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Figure 4-23 Other novel microRNAs dysregulated in porcine ISR model 
Panel A – miR-23b. Panel B – miR-30c. Panel C – miR-99b. Pigs received standardized BMS 
(cobalt alloy) or DES (Zotarolimus-eluting) (n=4/group, 2 stents/animal) over-expanded at a ratio of 
1.2:1 to induce neointimal hyperplasia. Animals were euthanized at 0, 7 or 28 days (BMS) and 28 
days (DES). Total RNA was extracted from snap-frozen stented tissue. miR expression levels were 
determined by quantitative real-time polymerase chain reaction and normalized to miR-199a-3p. 
For comparison, miR expression levels are given as fold-change (RQ) versus control vessels 
(unstented arteries) calculated using the 2-∆∆Ct method. Significance was assessed by repeated 
measures ANOVA with a Tukey post-test. A value of p<0.05 was considered statistically significant. 
* = p<0.05, ** = p<0.01, *** = p<0.001. 
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Figure 4-24 Investigated microRNAs with no change in expression in porcine ISR model 
A – let 7e. B – miR-24. C – miR-29a. D – miR-29b. E – miR-195. F – miR-197. Pigs received 
standardized BMS (cobalt alloy) or DES (Zotarolimus-eluting) (n=4/group, 2 stents/animal) over-
expanded at a ratio of 1.2:1 to induce neointimal hyperplasia. Animals were euthanized at 0, 7 or 
28 days (BMS) and 28 days (DES). Total RNA was extracted from snap-frozen stented tissue. miR 
expression levels were determined by quantitative real-time polymerase chain reaction and 
normalized to miR-199a-3p. For comparison, miR expression levels are given as fold-change (RQ) 
versus control vessels (unstented arteries) calculated using the 2-∆∆Ct method. Significance was 
assessed by repeated measures ANOVA with a Tukey post-test. p>0.05 for all comparisons.  
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4.3 Discussion 
As previously discussed, vascular injury is a critical mediator of neointimal formation 
during the development of ISR. The mechanical injury induced by stent deployment and 
atherosclerotic plaque disruption results in the release of cytokines and growth factors that 
trigger an inflammatory cascade, VSMC proliferation and migration and the deposition of 
ECM. From a therapeutic perspective therefore, neointima formation and the “healing” 
process of re-endothelialisation remain important targets for preservation of stent patency 
(Dangas et al., 2010).  
It is now well established that the de-differentiation of VSMC from a contractile to 
synthetic phenotype is integral to the progression of neointimal formation. De-
differentiation results in accelerated cell proliferation and migration in combination with 
increased cytokine production and resultant excessive ECM deposition (Ip et al., 1990). 
This phenotypic switch is mediated by multiple key transcription factors including SRF, 
myocardin and the KLF protein family (Kawai-Kowase and Owens, 2007, Miano et al., 
2007). Since the discovery of the key regulatory molecules, microRNAs, there has been a 
huge growth in studies investigating their importance in the regulation of VSMC gene 
expression and potential role in vascular physiology and pathologies. Due to the complex 
and multifactorial nature of ISR, miRs involved in both VSMC and EC function as well as 
the immune response may all be important in its progression.  
To-date there have been multiple reports describing key miRs that are highly expressed 
within the vascular wall and importantly dysregulated following vascular injury 
(McDonald et al., 2011b, Wei et al., 2013). These models suggest that this dynamic 
regulation of specific miRs during the development of neointima following vascular injury 
is critical to the dedifferentiation of VSMC and process of reendothelialisation through 
interactions with key transcription factors. The majority of these published models, 
however, involve rodents (cell lines or in-vivo injury) with minimal data from human 
tissue and none from the established large animal models of stent delivery routinely used in 
the assessment of stent technology (Schwartz et al., 2004, Schwartz et al., 2002).  
It was the purpose of this chapter therefore to further investigate the complex role of key 
vascular miRs in the development of restenosis following stent delivery using a novel 
porcine stent model and with a view to providing further insight into the potential for their 
therapeutic modulation in the setting of ISR.  
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As an initial approach it was felt to be important to attempt to investigate the role of these 
vascular miRs in human coronary artery smooth muscle cells using in-vitro models. When 
quiescent (differentiated) HCASMCs were stimulated to a de-differentiated proliferative 
phenotype using classical mitogen stimulation it was found that levels of miR-21, miR-
146a and miR-365 were increased when compared to unstimulated control cells. This 
observed dysregulation in miR-21 and miR-146a levels was consistent with previously 
published findings and provides further strength to the argument that both miR-21 and 
miR-146a play a role in VSMC dedifferentiation. However, it is unclear from these results 
whether this observed miR dysregulation represents “cause” or “effect”. Based on previous 
data it seems likely that these findings represent part of the mechanism controlling change 
in cell phenotype but could just be by-products and therefore be biomarkers for 
dedifferentiation. Under the above experimental conditions, miR-21 up-regulation 
appeared to be dependant on the presence of PDGF, whereas miR-146a was more 
consistently elevated when IL1α and PDGF were combined. It should be noted that under 
these experimental conditions serum contains a mix of mitogenic stimuli.  
MiR-365 has not previously been identified as being involved in the regulation of VSMC 
phenotype. It has been implicated as an oncomir in human cancers including those of the 
lung and skin (Qi et al., 2012). Under the above conditions it showed consistent 
upregulation at 1 hour across all mitogen groups, before quickly returning to baseline, 
suggesting that it may be important in the early dedifferentiation process. However, 
unfortunately due to time constraints I was not able to follow this up in the in-vivo model. 
These findings are however interesting and certainly merit future investigation.  
No evidence of dysregulation of miR-143, miR-145 or miR-221 levels was identified in 
this in-vitro model. There are multiple potential explanations for this finding. Principle is 
that in-vitro assays using isolated VSMC are simplistic and do not accurately reflect the 
complex nature of miR networks and particularly the cross-talk that occurs between cell 
types (e.g. EC, fibroblasts, immune cells) in-vivo. The choice of mitogens used will not 
accurately reflect the full range of stimuli that may result in VSMC dedifferentiation so it 
is entirely possible that the experimental protocol did not provide the right conditions to 
observe any dysregulation in these miRs. Also, with the defined time points used, it may be 
that earlier or later changes in miR expression were missed.  
It is possible that certain miRs may be more related to promoting or regulating a migratory 
rather than proliferative phenotype therefore in-vitro experiments were performed using a 
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wound assay. Again both miR-21 and miR-221 were found to be upregulated in a pattern 
consistent with previously published results. Both miR-143 and miR-145 showed an initial 
small upregulation in expression that was unexpected, however following this miR-145 
(but not miR-143) levels reduced significantly compared to control levels, consistent with 
previously published studies. No change in miR-146a levels were observed in this model 
of migration. Again, in interpreting these results the limitations described for the 
stimulation experiment apply.  
To summarise the results from these in-vitro experiments it is reasonable to hypothesise 
that miR-21, miR-146a, miR-221 and miR-365 overexpression may contribute to the 
promotion of a dedifferentiated VSMC phenotype in the development of human neointimal 
lesions. The results for miR-143 and miR-145 were less clear however, but it was felt that 
based on results from rodent studies that they still merited further investigation in-vivo.  
Although many in-vivo studies have been performed investigating the potential role of 
miRs in the development of neointima, they have predominately used balloon-injury to rat 
carotid arteries to induce NIH. There are many pathological similarities but also some 
differences between the lesions that develop following balloon injury and those that occur 
after stent implantation. Also, although evolutionarily conserved, species differences in the 
roles and importance of specific miRs likely exist. For these reasons the in-vivo 
experiments contained in this chapter were performed in the large animal porcine model of 
stent overexpansion. We believe that we are the first group to use this model to investigate 
the role of miRs in ISR.  
Implantation of both bare-metal and drug-eluting coronary stents into porcine coronary 
arteries results in upregulation of miR-21 as assessed by qRT-PCR. This increase was 
shown to persist out to at least 28 days post-implantation. Furthermore, In-situ 
hybridisation demonstrated the abundant expression of miR-21 throughout the vessel wall 
with the highest level in the developing neointima. A particularly strong signal was 
identified in neointima directly adjacent to stent struts. These findings are similar to those 
seen in rodent arteries following balloon injury and support the hypothesized role of miR-
21 in VSMC phenotypic modulation following vessel injury and the pathological 
development of ISR. Therapeutic modulation of miR-21 levels, e.g. by antisense-mediated 
knockdown, remains to be tested in a large animal model of stent delivery but has shown to 
be effective in reducing neointimal formation following balloon injury in rats (Ji et al., 
2007) and is therefore an approach worthy of consideration. In addition, inhibition of miR-
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21 has been suggested to attenuate fibrosis in a model of heart failure (Thum et al., 2008) 
and also improve the function of endothelial progenitor cells in patients with CAD 
(Fleissner et al., 2010). The inhibition of miR-21 could conceivably be a novel way to 
inhibit neointimal formation while also promoting re-endothelialisation in-vivo and thus 
reducing ISR and stent thrombosis in the clinical setting. However, it is a ubiquitous miR, 
expressed in multiple tissue types and performing complex roles. Therefore systemic 
delivery of a therapeutic agent could potentially create off-target safety issues (e.g. 
oncogenesis). Localised delivery via, for example, a stent-based platform could be one 
approach to overcome these issues.  
Similarly, miR-221 expression levels were shown to be elevated following stent delivery at 
7 days, although had returned to baseline by 28 days. Unfortunately, due to time and cost 
constraints I was not able to perform co-localisation experiments for this miR but these 
observations from the porcine model support the hypothesis that miR-221 contributes to 
VSMC phenotypic switch and merits further investigation.  
Current understanding regarding the role of the miR-143/miR-145 cluster in the control of 
VSMC phenotype has mainly been extrapolated from in-vitro and in-vivo small-animal 
models. Consistently, these studies have suggested that miR-145, and to a lesser extent 
miR-143, are key to maintaining VSMC in a differentiated state. This regulatory ability is 
lost following acute vascular injury when expression levels are seen to fall, presumably as 
part of a mechanism to allow vessel healing. In the setting of acute vascular injury, 
restoration of miR-145 was shown to limit neointimal formation in rodents. Following 
coronary stent insertion in pigs, miR-143/miR-145 levels are dynamic and consistent with 
the published data show a global decrease in expression as measured by qRT-PCR. In-situ 
analysis, however, suggested that although there is a significant decrease in expression 
within the injured vessel as a whole, a high level of expression develops in the media and 
emerging neointima. This increase was localised to areas with an increased expression of  
αSMA suggesting a correspondence to increasing VSMC re-popularisation. It has been 
proposed that rather than being essential for differentiation, the miR-143/miR-145 cluster 
acts to prevent de-differentiation and loss of the contractile VSMC phenotype associated 
with a decrease in αSMA expression and an increase in proliferation (Elia et al., 2009). 
The results from the porcine vessels are contrary to this with high levels of both miR-143 
and miR-145 present in the developing neointima and correlating strongly with SMC 
markers. These findings are consistent with other work performed in our laboratory 
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showing a similar picture in the neointima of vein grafts from both a porcine model and 
also pathological failed human grafts (MacDonald et al, Unpublished data).  
The exact reasons for these discrepancies require clarification as there are clear important 
implications for future therapeutics. In-situ hybridisation immediately following stent 
delivery (Day 0) confirms early loss of miR-145 expression consistent with qRT-PCR 
findings. It then “returns” when neointima has formed at the later time points, although 
overall vessel levels remain low. It is possible that this overexpression is not pathological 
and represents miR transfer from regenerating ECs that is designed to “terminate” 
neointimal formation by returning VSMCs to a contractile phenotype and thus prevent 
complete vessel occlusion. This would certainly be consistent with the observed difference 
in levels of miR-145 when BMS and DES were compared at 28 days. It is possible that the 
well recognised effect of DES on re-endothelialisation results in reduction of extracellular 
miR-145 transport. It should be noted, however, that no significant difference in neointimal 
area, as assessed by OCT, was seen between BMS and DES at 28 days. Further 
mechanistic studies are clearly required to investigate the relevance of these findings. 
Interestingly, in the porcine model, the location of miR-145 expression (and to a lesser 
extent miR-143) in the developing neointima appeared to be in the nucleus.  It may 
therefore represent an increase in the level of pri-miR within the cells, which is detectable 
using the in situ probes, but not using the qRT-PCR probes.  This suggests that 
transcription of the cluster is actively occurring within cells of the developing neointima 
and additional studies are required to assess the dynamics of miR-143/miR-145 expression 
and maturation under this form of pathological stress. This may also go some way to 
explaining the lack of significant miR-143/mir-145 dysregulation seen in my earlier 
described in vitro experiments.  
Based on prior studies, several groups have postulated that restoration of miR-143/miR-
145 levels following vascular injury could be a novel way of preventing neointimal 
formation and therefore ISR. However, my results suggest that the opposite may be true, 
and that pursuing local inhibition of these microRNAs may be more effective in view of 
their abundant expression within neointimal VSMC. Interestingly, Xin et al, have 
described a reduction in neointima formation after ligation of the carotid artery in miR-
145-null mice adding further weight to this argument (Xin et al., 2009).  
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I believe that both approaches merit further investigation and that future large animal 
studies should assess the effects of both promotion and inhibition of these microRNAs in 
the setting of ISR.  
Following stent delivery to porcine coronary arteries there was no evidence of 
dysregulation in miRs-92a, -126, -146a or -155 as compared to control unstented vessels 
and assessed by qRT-PCR. Levels of miR-133a were found to be significantly elevated 
immediately following vessel injury but unchanged from control at all other time points. 
These findings suggest that these micoRNAs do not play a significant role in the 
development of ISR in-vivo following stent delivery to porcine vessels. The change in 
miR-133a immediately following injury could be explained as an immediate response to 
VSMC injury as part of a reparative process however with no difference at any other time 
point is unlikely to play a significant role in ongoing neointimal development and therefore 
was not felt to represent a significant target for modulation in-vivo. Both miR-92a and 
miR-126 have been suggested to play important roles in the response of endothelial cells to 
injury (Harris et al., 2008, Nicoli et al., 2010, Zernecke et al., 2009) and in cell-to-cell 
communication between EC and VSMC (Zernecke et al., 2009, Hergenreider et al., 2012). 
While clearly not directly key to the VSMC response to injury and phenotypic switch they 
may still hold therapeutic potential through the stimulation of endothelial regeneration 
(Iaconetti et al., 2012). More rapid and complete endothelial recovery would be hoped to 
reduce the risk of stent thrombosis and artificial overexpression of miR-126 or inhibition 
of miR-92a may inhibit ISR development even though levels are not directly altered 
following injury. Further experiments are clearly required to justify this approach, for 
which the porcine model of stent delivery is ideal.  
Due to cost restrictions I was not able to perform microRNA profiling experiments (e.g. 
microarray) on the RNA extracted from porcine vessels treated with BMS or DES. This 
has previously been performed in a porcine model of interposition vein grafting and 
reported by our institution (McDonald et al., 2013). This model of vein-graft disease, 
vascular injury and intimal hyperplasia shares many pathological similarities to the stent 
model of neointimal ISR. I therefore investigated a series of novel miRs, not previously 
implicated in the response to vascular injury, but significantly dysregulated in engrafted 
porcine veins by performing qRT-PCR verification on RNA from the porcine stent model.  
The most interesting results related to miR-142-3p and miR-142-5p. Both were found to be 
significantly upregulated following delivery of BMS only. They are transcribed from 
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chromosome 17q22 and have not previously been reported as being involved in the 
vasculature. Previous reports have described miR-142 as being highly specific for 
haematopoietic cells and involved in immune regulation (Landgraf et al., 2007). They are 
also oncogenes with miR-142-3p being associated with leukaemia (Dahlhaus et al., 2013) 
and miR-142-5p with gastric mucosa-associated lymphoid tissue lymphoma (Saito et al., 
2012). Interestingly, miR-155 has been shown to negatively regulate miR-142-3p 
expression, suggesting a further role in inflammation (Sun et al., 2013). My findings 
suggest that miR-142 may be involved in vascular cell-cycle regulation and ISR formation 
and further mechanistic insight is required to test this hypothesis and establish any 
potential therapeutic effect.  
Other potential miRs of interest that arose from the qRT-PCR analysis were miR-23b, 
miR-30c and miR-99b. It has been reported that miR-23b acts as a tumour suppressor 
being found in high levels in tumours of the oesophagus, bladder, colon and prostate with 
possible involvement in human papilloma virus oncogenesis (Zheng and Wang, 2011). It 
acts as a cell-cycle regulator as a downstream target of the oncogene c-Myc (Dang, 2010). 
In the cardiovascular system it has been shown to block cell-cycle progression in EC in-
vitro (Boon et al., 2012) and is felt to play an atheroprotective role in vessels subjected to 
shear stress (Neth et al., 2013).  
As well as being dysregulated in lung, ovarian and breast carcinomas, miR-30c has an 
apparent effect on lipid metabolism in mice with hepatic overexpression reducing 
hyperlipidaemia and atherosclerosis and vice versa (Soh et al., 2013).  
Lastly, miR-99b is another oncomir that is implicated as a tumour suppressor in non-small 
cell lung cancer (Kang et al., 2012) and as a biomarker of papillary thyroid carcinoma 
(Dettmer et al., 2013).  
Further mechanistic and co-localisation experiments are clearly required to test the validity 
of these novel miRs as potential regulators of VSMC homeostasis and targets for 
therapeutic manipulation. These initial results are however, encouraging. All of these novel 
miRs play a role as either biomarkers or regulators of cell-cycle regulation in cancer and 
with the findings from the porcine stent model in conjunction with very similar parallel 
results from qRT-PCR analysis of porcine interposition grafts at 7 and 28 days it is highly 
likely that at least some are involved in the vascular response to injury, potentially as part 
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of a coexpressed microRNA regulatory network. Ongoing work within our institution will 
hope to clarify and expand on these initial findings in due course.  
The use of a combination of qRT-PCR to assess overall vessel expression levels and in-situ 
hybridisation to localise microRNA presence within the vessel wall and emerging 
neointima has allowed a comprehensive longitudinal analysis of the dynamic changes in 
miR-21, miR-145 and miR-143 following stent delivery and vessel injury. To-date there 
are no published studies using large animal models to investigate the role of microRNAs in 
the development of ISR, thus adding novelty to the above findings. Assessment of the role 
of miRs in multiple pre-clinical models is required as differences may be present across 
different species (e.g. rodent vs. pig), different vascular beds (e.g. carotid artery vs. 
coronary artery) or even with different mechanisms of vascular injury (e.g. balloon 
dilatation injury vs. stent delivery). Knockdown of miR-143 and miR-145 has been shown 
to affect different vessels to different extents (Boettger et al., 2009), possibly due to 
variation in normal levels of expression which may reflect differences in the importance 
and/or function of the cluster.  
Using a model of stent delivery is relevant to current clinical practice and would be hoped 
to provide more relevant findings that older models of balloon injury. It was also of interest 
to explore potential differences in miR levels in response to delivery of bare-metal versus 
drug-eluting stents. It is feasible that miRs may play an important role in mediating the 
effects of antiproliferative drugs on VSMC and EC proliferation or the sequelae of chronic 
inflammation and delayed arterial healing. In my experiments a second generation 
zotarolimus-eluting stent (EndeavorTM, Medtronic, Minneapolis, MN, USA) was used due 
to easy availability of a range of sizes suitable for comparison with my chosen bare metal 
platform. Zotarolimus is a more lipophilic analogue of the immunosuppressant rapamycin 
(sirolimus). It acts as an anti-proliferative agent, blocking cell-cycle progression from G1 to 
S phase through binding with the intracellular protein FKBP-12 and inhibiting VSMC and 
EC proliferation (Garcia-Touchard et al., 2006). When phosphorylcholine-coated 
Zotarolimus-eluting stents were tested in porcine coronary arteries in-vivo a 40% reduction 
of neointimal formation compared with a bare-metal platform at 28 days post-implantation 
was reported (Garcia-Touchard et al., 2006). In my experiments, a single 28 day time-point 
was used for the DES group to limit experimental costs and also due to limitations on 
available space for animal housing. The only vascular miR found to be significantly 
different between the two stent platforms used was miR-145. Of the novel miRs, both miR-
30c (reduced in BMS at 28 days) and miR-99b (reduced in DES at 28 days) showed 
Chapter 4 | MicroRNAs and in-stent restenosis 
 
175
potential differences. Also somewhat surprisingly, but in keeping with the qRT-PCR 
findings, mean neointimal thickness as assessed using OCT was similar in both the BMS 
and DES groups in my study. The reasons for these findings are not clear. The original 
Endeavor stent used has rapid drug-release kinetics with 95% of the zotarolimus eluted 
from the stent <15 days after implantation (Nakazawa et al., 2007). This has been 
suggested to potentially reduce local toxicity. In atherosclerotic plaques this highly 
lipophilic drug displays prolonged tissue retention (Nakazawa et al., 2007) however in my 
disease-free animals this is likely to be much less marked. Therefore my chosen 28 day 
time point, although normal for pathological studies, may have missed transient miR 
dysregulation in the presence of zotarolimus. It is also possible that the action of 
zotarolimus utilises a network of microRNAs distinct to those tested. This requires testing 
in in-vitro cell studies using miR microarray profiling. Lastly, the DES used in this chapter 
were all those that had passed their “use-by-date” and been removed from the shelf in a 
clinical catheter laboratory. Although unlikely, it is possible that the drug had degraded to 
become non-functional. This could explain the observed lack of difference in mean 
neointimal areas between BMS and DES at 28 days as observed by OCT. Clearly further 
and more rigorous experimental testing is required, utilising modern drug-eluting stent 
platforms to assess the role of microRNAs in both their antiproliferative action and delayed 
arterial healing. 
Most pre-clinical models utilising stent insertion have been limited in the histological 
analysis that can be performed due to the methods of tissue processing commonly used. 
Normal tissue fixation, paraffin embedding and cutting with a microtome cannot be 
effectively performed with an in-situ metal scaffold as the metal/tissue interface results in 
excessive damage to the tissue architecture. Initially, stented arteries were carefully 
sectioned and the metal stent fragments removed by hand prior to tissue processing. This 
was, however, time consuming and maintenance of tissue architecture was challenging. 
Methods were therefore developed of tissue fixation and resin embedding which allowed 
tissue sectioning through use of precision saws and grinding/polishing to obtain sections of 
the required thickness (Malik et al., 1998). This allows for excellent morphometric analysis 
due to preservation of the stent/tissue interface but the incompatibility of organic solvents 
with the embedding resins limits the histochemical staining techniques that can be used 
(Malik et al., 1998). Further limitations include the requirement for specialist equipment, 
the overall cost of the procedure, time consuming processing steps, significant tissue 
depletion during processing, and a minimum obtainable section thickness of 8-10µm that 
can affect quality of morphometric studies (Rippstein et al., 2006). Lastly, it would not 
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have been possible to perform in-situ hybridisation on my samples if resin embedded, 
again due to lack of compatibility with the resins and solvents.   
To circumvent these issues a novel method of stent dissolution using electrolysis was 
employed in the experiments in this chapter. By applying a differential voltage to an 
embedded stent and placing it in a mildly acidic salt solution, complete stent dissolution 
can be obtained (Samra et al., 2010, Bradshaw et al., 2009). This method is fast, cost-
effective and results in significantly less tissue loss than resin embedding. It therefore 
allows for a more complete examination of the whole tissue segment and most importantly 
normal histological processing facilitating a complete range of histochemical staining 
methods, immunohistochemistry and in-situ hybridisation.  
Complete dissolution of the cobalt chromium BMS platforms used in this chapter was 
achieved readily and consistently. Unfortunately, the DES platforms proved highly 
resistant to electrolysis and significant tissue destruction resulted, limiting the analysis that 
could be performed. It is noted that polymer-coated stents can impede process as the 
insulating coating prevents the continuity of the electrical circuit required for complete 
dissolution. This occurred despite using measures described in the original published 
methods (Bradshaw et al., 2009). As described in the above results section of this chapter, 
morphometric histology and in-situ hybridisation co-localisation of miRs was not obtained 
in the 28 day DES group.  
It was however possible to obtain a measurement of mean neointimal area in 4% PFA-
fixed stented arterial segments ex-vivo before dissolution and further processing using an 
optical coherence tomography catheter. This technique allows for accurate quantification 
of neointimal thickness and area and can also be used to assess strut coverage (Douglas et 
al., 2012). It is a useful adjunct to classical histological methods as neointimal 
measurements can be made along the whole vessel segment with a longitudinal 
reconstruction also being provided.  
In summary, the experiments described in this chapter support the hypothesis that 
microRNAs play an important role in regulating the pathogenesis of acute vascular injury 
and the development of coronary ISR. A large animal model of ISR has not previously 
been used in this setting adding both novelty and clinical relevance to the described 
findings. As does the use of combined qRT-PCR measurement with in-situ hybridisation 
for histological co-localisation. Both miR-21 and the miR-143/miR-145 cluster appear to 
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play a key role in the regulation of VSMC phenotypic switch and are shown to be both 
dynamic and significantly upregulated in developing neointima following stent 
implantation. This localised upregulation in the miR-143/miR-145 cluster, despite a 
consistent overall “whole-vessel” downregulation, is particularly novel and differs from 
previously published findings. This has important implications towards future therapeutic 
manipulation. Furthermore, this chapter provides the first validation of suitable 
endogenous controls for qRT-PCR analysis in porcine vascular tissue and also shows the 
suitability of the electrolysis method to achieve atraumatic stent dissolution thus allowing a 
comprehensive range of histological techniques to be performed. Finally, and consistent 
with suggestions that microRNAs operate in regulatory networks, a panel of novel miRs 
have been identified that may play an important role in the development of ISR and merit 
future investigation.  
Although the above findings do not fully explain the mechanisms behind this role they 
provide an important step towards our understanding. Although unsuccessful using the 
Endeavor zotarolimus-eluting platform the potential differences that may occur in 
microRNA expression following DES delivery remain intriguing. In our institution we 
therefore plan to repeat the porcine experiments using a widely used stainless-steel 
platform abluminally coated DES that we have recently shown to be amenable to 
dissolution and comparison with its BMS counterpart. This will allow both full microarray 
miR profiling and in-situ hybridisation in the DES arteries to fully investigate potential 
expression differences between the stent types. Lastly we plan to investigate the effect of 
systemically delivered antagomirs to miR-21 and miR-145, and miR-145 mimics on the 
development of ISR in the pig. If successful, it would be hoped to progress to local 
delivery via a suitable stent platform.  
  
5 Dynamic changes in circulating microRNA levels 
in patients undergoing Coronary Artery Bypass 
Surgery 
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5.1 INTRODUCTION 
Cardiovascular disease remains the principle contributing cause to mortality in Europe; 
responsible for approximately 4.3 million deaths per annum (48% of all deaths) (Allender 
et al., 2008). Coronary Artery Bypass Graft (CABG) surgery remains an important 
treatment modality in patients with severe coronary artery disease (CAD), and although 
numbers have stabilized due to the rise in use of percutaneous coronary intervention (PCI), 
more than 25,000 procedures are performed in the UK per annum (Scarborough et al., 
2011) and greater than 400,000 in the U.S.A (Roger et al., 2012). Although effective, 
CABG remains limited by conduit graft failure with only 50-60% of vein grafts being 
patent at 10 years post-surgery (Motwani and Topol, 1998, Parang and Arora, 2009). As 
previously discussed, vein graft disease occurs as a result of multiple pathological 
processes including thrombosis, intimal hyperplasia and accelerated atherosclerosis 
(Motwani and Topol, 1998) and results in recurrent symptoms and MI leading to repeat 
revascularisation carrying excess morbidity and mortality (Mehilli et al., 2011, Lopes et 
al., 2012). 
Risk factors for early graft occlusion are well characterized and include: female gender, 
obesity, unstable anginal symptoms, history of congestive heart failure, the artery to be 
bypassed (RCA>LAD), quality of the distal bed, diameter of the grafted vessel, lack of 
antiplatelet therapy and use of a nonsequential technique (Paz et al., 1993). However due 
to the heterogeneity of these patients it remains difficult to predict. The use of an 
extracorporeal circulation for cardiopulmonary bypass (CPB) is shown to be a major 
contributing factor to post-operative morbidity including neuropsychological impairment 
(Khan et al., 2004), systemic inflammatory response syndrome (Day and Taylor, 2005) and 
tissue injury due to ischaemia and reperfusion (Chandrasena et al., 2009, Nair et al., 2012). 
Early elevations in serum levels of cardiac enzymes (principally creatine kinase and 
troponin) post-CABG have been shown to correlate with increased intermediate- and long-
term mortality (Domanski et al., 2011). Although markers of cardiac cell necrosis, these 
enzyme rises do not help to differentiate between the multiple potential causes of cell death 
such as graft failure, insufficient myocardial protection, air embolism, regional or global 
ischaemia or inflammation. There is therefore an unmet clinical need for reliable, sensitive 
and specific biomarkers that may predict particular complications or more accurately those 
at increased risk of a poor outcome post-surgery.  
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As previously discussed, microRNAs are short, non-coding ribonucleic acids (RNAs) that 
act to control gene expression at a posttranscriptional level and have been shown to play a 
key role in cellular function in both normal physiology and disease states. There has been a 
proliferation of studies in the literature describing miRs as being key regulators within the 
cardiovascular system. Through the display of distinct tissue expression profiles they 
appear to mediate cardiac development, vasculature homeostasis, response to vascular 
injury, neoangiogenesis and tissue repair (Latronico et al., 2007, Small et al., 2010).  
More recently it has been shown that miRs can be detected in the circulation (Mitchell et 
al., 2008), either as a result of cellular damage or active secretion (Laterza et al., 2009), as 
regulators of an underlying pathological process (Gilad et al., 2008) or even as part of an 
inter-cellular signalling network (Zampetaki et al., 2012a). These circulating miRs are 
stable (Tsui et al., 2002b, Weber et al., 2010a), being packaged in microvesicles 
(exosomes, microparticles and apoptotic bodies) or bound to RNA-binding proteins or 
lipoprotein complexes, conferring resistance to degradation from circulating RNAse 
activity (Zampetaki et al., 2012a, Creemers et al., 2012). This, in combination with the 
poor risk prediction provided by traditional risk factors and existing soluble biomarkers, 
has lead to great interest in their potential as diagnostic and prognostic biomarkers.  
There is an emerging body of literature associating specific circulating “miR signatures” 
with cancer, acute coronary syndromes/myocardial infarction, coronary artery disease, 
hypertension, heart failure, diabetes mellitus as well as many other non-cardiovascular 
conditions (Mitchell et al., 2008, Fichtlscherer et al., 2011, Creemers et al., 2012, 
Engelhardt, 2012). These studies suggest that the presence of miRs within the circulation 
may reflect the activation state of cells important to the disease process, such as smooth 
muscle cells, endothelial cells, platelets, monocytes and macrophages. They therefore 
provide an integrated read-out of both cell activation and tissue injury in response to 
cardiovascular risk factors and resulting tissue injury (Zampetaki et al., 2012a). 
The aim of this chapter therefore, was to analyze, for the first time, the temporal expression 
profile of a selected group of miRs in the serum of patients undergoing CABG to 
investigate their future potential as biomarkers in this group of patients. Although not 
directly related to ISR, it was felt to be appropriate to include this Chapter within the 
thesis. To fully understand the complex regulatory role that miRs play within the 
developing neointima and damaged endothelium following vascular injury, it is important 
to recognise their presence  and purpose within the circulation. 
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5.2 RESULTS 
5.2.1 Demographics 
Baseline characteristics from the cohort of 21 patients are shown in Table 5.1. Intra-
operative characteristics are summarised in Table 5.2 and post-operative course described 
in Table 5.3. This cohort reflects a group of predominately male (76%), symptomatic (55% 
unstable symptoms) patients with extensive coronary disease (95% 3-vessel disease) and 
good LV systolic function (Mean Ejection Fraction: 57+11%), undergoing uncomplicated 
CABG at a single centre. Operations were performed by 4 surgeons with one senior 
operator being involved in 67% of procedures.  
5.2.2 Panel of MicroRNAs Studied 
A panel of miRs associated with both acute and stable chronic coronary artery disease were 
chosen (Fichtlscherer et al., 2011, Creemers et al., 2012). Muscle-enriched miRs-133a and 
-499 are elevated in pre-clinical models of, and patients with, MI/ACS (Wang et al., 2010a, 
D'Alessandra et al., 2010, Kuwabara et al., 2011, De Rosa et al., 2011) or stable CAD 
(Fichtlscherer et al., 2010). The cardiomyocyte-specific miR-208a and miR-208b cluster 
are undetectable in normal controls but elevated in patients with MI/ACS (Corsten et al., 
2010, Widera et al., 2011, Wang et al., 2010a, De Rosa et al., 2011) and stable CAD 
(Fichtlscherer et al., 2010). Endothelial cell enriched miR-126 and miR-92a, 
leucocyte/inflammatory miR-155 and liver-specific miR-122 have also been identified as 
having potential as biomarkers in both acute and chronic coronary disease (Fichtlscherer et 
al., 2010, De Rosa et al., 2011). Furthermore, it was felt important to investigate miRs 
shown to be important in vascular injury (previously discussed in Chapter 4); namely miR-
21, miR-143 and miR-145. 
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Table 5-1 Patient’s Baseline Characteristics2 
 
 
CABG Group 
(n=21) 
Sex (M/F) 16/5 
Age (yrs) 66.3±9.5 
Body weight (kg)  67.8±12.9 
BSA (m2) 1.71±0.18 
Risk Factors 
Cigarette Smoking 
T2DM 
HBP 
Hyperlipidaemia 
 
10 (50%) 
9 (43%) 
18 (86%) 
9 (43%) 
Clinical Features 
Angina  
(≥CCS III) 
Unstable 
Previous MI 
Family Hx IHD 
CHF 
Ejection Fraction (%) 
 
 
15 (71%) 
12 (55%) 
8 (38%) 
0 (0%) 
1 (5%) 
57±11 
Angiographic Findings 
TVD 
LMS Involvement 
Calcification reported 
 
20 (95%) 
14 (67%) 
2 (9%) 
Medications 
Aspirin 
Clopidogrel 
Statin 
β-blocker 
ACEi/ARB 
OHA 
Insulin 
Heparin 
Warfarin 
ά-blocker 
Allopurinol 
 
21 (100%) 
20 (95%) 
19 (86%) 
20 (95%) 
16 (76%) 
9 (43%) 
1 (5%) 
3 (14%) 
1 (5%) 
4 (19%) 
1 (5%)  
                                         
2 All numbers given as absolute values + standard deviation as appropriate. Percentage of full 
cohort given in brackets. ACEi – Angiotensin Converting Enzyme inhibitors. ARB – Angiotensin 
Receptor Blockers. BSA – Body Surface Area. CABG – coronary artery bypass grafting. CCS – 
Canadian Cardiovascular Society. CHF – Congestive Heart Failure. HBP – hypertension. IHD – 
ischaemic heart disease. LMS – left main stem. MI – myocardial infarction. OHA – oral 
hypoglycaemic agents. T2DM – Type 2 diabetes mellitus. TVD – triple vessel disease. 
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Table 5-2 Intra-Operative Characteristics3 
 
 CABG Group (n=21) 
Procedural Urgency 
Emergency 
Urgent 
Elective 
 
1 (5%) 
2 (9%) 
18 (86%) 
Vein Harvest Technique 
Open 
EVH 
 
16 (76%) 
5 (24%) 
Number of Grafts 
3 
2 
 
17 (81%) 
4 (19%) 
LIMA used 17 (81%) 
CPB Duration 
Bypass time (mins) 
Ischemic time (mins) 
 
103±32 
58±21 
Blood Product use 
RBC required 
1U 
2U 
3U 
4U 
Platelets required  
1U 
2U 
3U 
4U 
5U 
6U 
Fresh Frozen Plasma 
1U 
2U 
3U 
4U 
Cryoprecipitate (1U) 
 
16 (76%) 
4 (25%) 
5 (31%) 
3 (19%) 
4 (25%) 
13 (62%) 
1 (8%) 
1 (8%) 
2 (15%) 
8 (61%) 
0 (0%) 
1 (8%) 
6 (29%) 
1 (17%) 
2 (33%) 
2 (33%) 
1 (17%) 
1 (5%) 
  
                                         
3 All numbers given as absolute values + standard deviation as appropriate. Percentages given in 
brackets. CABG – coronary artery bypass grafting. CPB – cardiopulmonary bypass. EVH – 
endoscopic vein harvest. LIMA – left internal mammary artery. RBC – red blood cells. U – units. 
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Table 5-3 Post-Operative Course4 
 
 CABG Group (n=21) 
Time to Extubation (hrs) 8±4 
Duration of ICU Stay (hrs) 20±2 
Blood Products required (RBC) 2 (9%) 
Post-op Medication Use 
Clopidogrel 
Aspirin 
Tramadol 
 
18 (86%) 
21 (100%) 
17 (81%) 
Complications 
Dysrhythmia 
Atrial Fibrillation 
Atrial Flutter 
Unspecified Tachycardia 
 
5 (24%) 
2  
1 
2 
  
 
                                         
4 All numbers given as absolute values + standard deviation as appropriate. Percentages given in 
brackets. AF – atrial fibrillation. CABG – coronary artery bypass grafting. ICU – intensive care 
unit. RBC – red blood cells. VR – ventricular rate. 
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5.2.3 Temporal Changes in Circulating MicroRNA Levels 
All temporal comparisons were made to pre-op (PO) expression levels. Circulating levels 
of miR-133a showed a 6-fold elevation (RQ 5.89; p<0.001) on the first post-operative day 
(POD1) returning to baseline at day 5 post-op (POD5) (Figure 5.1). Levels of miR-122, 
previously shown to be down-regulated in patients with myocardial infarction 
(D'Alessandra et al., 2010), were significantly reduced on POD1 (77% reduction, RQ 0.23, 
p<0.001) but returned to baseline at POD5 with no significant difference when compared 
to PO levels (RQ 0.89, p>0.05) (Figure 5.2). These statistically significant associations 
persist when Ct values are normalized to the mean of all measured miRs (Figure 5.3-5.4). 
Levels of miR-92a (43% reduction, RQ 0.57, p<0.05, POD5) and miR-126 (33% 
reduction, RQ 0.67 p<0.01, POD1; 29% reduction, RQ 0.71, p<0.05, POD5) were reduced 
post-CABG (Figure 5.2) when normalized to “spiked-in” cel-miR-39. These significant 
associations at POD5 were lost when Ct values were normalized to the mean of all 
measured miRs, however this method is known to weaken observed associations 
(Zampetaki et al., 2012a) (Figure 5.5-5.6). No significant temporal changes in levels of 
miR-145, miR-143 or miR-21 were observed (Figure 5.1) with either normalization 
method. MiR-155 levels were also unchanged post-CABG (Figure 5.2). MiR-208a, miR-
208b, and miR-499 were undetectable (Ct = Undetermined) in all patients at all time 
points, using the previously described experimental protocol.  
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Figure 5-1 Circulating microRNA levels in serum from patients undergoing CABG – 
miRs showing increase or no change 
RNA extraction from serum and levels determined by qRT-PCR. Ct values normalised to “spiked-
in” cel-miR-39. RQ values calculated using 2-∆∆Ct method and reported as RQ + RQmax. p values 
are versus PO levels and calculated from ANOVA with Tukey adjustment for multiple comparisons. 
PO – Pre-op. POD1 – Post-op Day 1. POD5 – Post-op Day 5. RQ – Relative Quantity. 
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Figure 5-2 Circulating levels of microRNAs showing a post-op reduction 
RNA extraction from serum and levels determined by qRT-PCR. Ct values normalised to “spiked-
in” cel-miR-39. RQ values calculated using 2-∆∆Ct method and reported as RQ + RQmax. p values 
are versus PO levels and calculated from ANOVA with Tukey adjustment for multiple comparisons. 
PO – Pre-op. POD1 – Post-op Day 1. POD5 – Post-op Day 5. RQ – Relative Quantity. 
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Figure 5-3 Comparison of normalisation methods for miR-133a 
Quantitative real time PCR data for miR-133a normalised to both cel-mir-39 (above) and the mean 
of all measured microRNAs (below). RQ (Relative Quantity) + RQmax. All comparisons made vs. 
control group (PO) using repeated measures ANOVA with Tukey’s post test.  *p<0.05, **p<0.01, 
***p<0.001, NS p>0.05 (non-significant). 
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Figure 5-4 Comparison of normalisation methods for miR-122 
Quantitative real time PCR data for miR-122 normalised to both cel-mir-39 (above) and the mean 
of all measured microRNAs (below). RQ (Relative Quantity) + RQmax. All comparisons made vs. 
control group (PO) using repeated measures ANOVA with Tukey’s post test.  *p<0.05, **p<0.01, 
***p<0.001, NS p>0.05 (non-significant). 
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Figure 5-5 Comparison of normalisation methods for miR-92a 
Quantitative real time PCR data for miR-92a normalised to both cel-mir-39 (above) and the mean 
of all measured microRNAs (below). RQ (Relative Quantity) + RQmax. All comparisons made vs. 
control group (PO) using repeated measures ANOVA with Tukey’s post test.  *p<0.05, **p<0.01, 
***p<0.001, NS p>0.05 (non-significant). 
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Figure 5-6 Comparison of normalisation methods for miR-126 
Quantitative real time PCR data for miR-126 normalised to both cel-mir-39 (above) and the mean 
of all measured microRNAs (below). RQ (Relative Quantity) + RQmax. All comparisons made vs. 
control group (PO) using repeated measures ANOVA with Tukey’s post test.  *p<0.05, **p<0.01, 
***p<0.001, NS p>0.05 (non-significant). 
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5.2.4 Correlation with Existing Biomarkers 
To investigate the potential of these dynamic circulating miRs for use as biomarkers we 
performed correlations with existing classical biomarkers. Serum cTnT levels (Table 5.4) 
increased from undetectable levels in all but one patient PO to median 0.16µg/L (Range 
0.07-13.00µg/L) at POD1 (p<0.001) and 0.11µg/L (Range <0.03-9.60µg/L) at POD5 
(p<0.01). The increase in miR-133a at POD1 correlated with the rise in cTnT (p<0.0466) 
(Figure 5.7). MiR-122, 92a and 126 levels showed no significant correlation with cTnT 
(p>0.05) at any time point (Figure 5.8). Serum CRP levels increased from 4.3+8.0mg/L PO 
to 159.7+11.7mg/L at POD1 and decreased to 106.4+54.4mg/L at POD5 (Table 5.4). 
There was no association between any of the studied miRs and serum CRP levels (p>0.05, 
all comparisons). 
Table 5-4 Serum levels of C-reactive protein and cardiac isoform of Troponin T5 
 
Patient No Pre-op POD1 POD5 Pre-op POD1 POD5
1 11.3 111.0 29.3 <0.03 0.18 0.13
2 <0.6 117.6 40.6 <0.03 0.13 0.11
3 <0.6 236.9 100.9 <0.03 0.10 0.07
4 1.7 130.0 112.1 <0.03 0.22 0.18
5 <0.6 124.0 25.9 <0.03 0.14 0.05
6 <0.6 100.9 67.0 <0.03 0.12 0.06
7 <0.6 157.0 164.9 <0.03 0.85 0.70
8 1.7 122.6 125.4 <0.03 0.10 <0.03
9 0.7 88.2 48.1 <0.03 0.07 <0.03
10 1.2 141.6 189.6 <0.03 0.15 1.10
11 35.9 158.6 115.4 <0.03 0.16 0.15
12 8.3 125.1 132.7 <0.03 0.32 0.33
13 7.4 <0.03
14 2.9 147.0 60.3 <0.03 0.08 0.05
15 2.9 234.7 125.7 <0.03 0.42 0.37
16 8.3 157.3 240.5 0.15 0.58 0.33
17 8.3 257.3 136.4 <0.03 13.00 9.60
18 1 173.1 134.0 <0.03 0.13 0.04
19 <0.6 212.0 122.4 <0.03 0.37 0.09
20 <0.6 95.9 64.3 <0.03 0.11 <0.03
21 3.3 204.8 70.5 <0.03 0.48 0.09
22 <0.6 258.8 128.5 <0.03 0.79 0.58
CRP(mg/L) cTnT (ug/L)
 
 
 
                                         
5 Patient 13 excluded from all analysis due to complicated post-operative course. POD1 = Post-
operative day 1. POD 5 = Post-operative day 5 
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Figure 5-7 Correlation between change in circulating miR-133a levels and rise in serum 
Troponin T at day 1 post-op 
∆∆Ct calculated by subtracting PO levels from POD1 levels. ∆logTnT calculated by log 
transforming cTnT levels then subtracting PO from POD1. Increasing negative ∆∆Ct values 
represent increasing serum levels of miR-133a at POD1 compared with corresponding PO. Ct – 
threshold cycle. PO – Pre-op POD1 – Post-op Day 1 POD5 – Post-op Day 5. 
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Figure 5-8 Absence of correlation between circulating microRNAs and rise in serum Troponin T  
Scatter plots showing the lack of correlation (non-linear association) between rise in cardiac Troponin T (log∆TnT) from baseline and change in circulating microRNA 
(ddCt) levels at Day 1 (POD1) or Day 5 (POD5) post-op for miR-122, miR-92a or miR-126. Only graphs relating to significant changes in circulating microRNA levels 
are shown. p>0.05 for all comparisons (Pearson correlation).  
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5.2.5 Relationship to Intra-operative Factors 
Despite protective measures (e.g. blood cardioplegia), cardiopulmonary bypass results in 
myocardial ischemia/reperfusion injury (Moens et al., 2005). It is therefore important to 
exclude any potential association between the change in circulating miR levels and 
important intra-operative variables, namely the duration of cardiopulmonary bypass (CPB) 
time and ischaemic time (length of time that the aorta is cross-clamped). No correlation 
was found between change in circulating levels of any of the studied miRs and ischemic or 
CPB time at either POD1 or POD5 (Figure 5.9-5.11). 
5.2.6 Relationship to Renal and Liver Function 
Animal studies have shown that although circulating miRs are protected from degradation 
by circulating ribonucleases, they are excreted by the renal (predominately), hepatic and 
gastrointestinal systems (Neal et al., 2011, Liu et al., 2007, Sepp-Lorenzino and Ruddy, 
2008). It is therefore important to exclude relative changes in levels of circulating miRs 
due to alterations in renal and hepatic function secondary to operative factors that could 
result in impaired excretion. Small statistically significant increases in median urea and 
creatinine (Figure 5.12) and albumin, total bilirubin and ALP levels (Figure 5.13) were 
noted. No positive correlations were seen between these changes and levels of circulating 
miRs (Figure 5.14). These do not represent significant clinical alterations in renal or 
hepatic function and therefore would not explain the magnitude of change in miR levels 
that were identified.  
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Figure 5-9 Absence of correlation between circulating miR-133a or miR-122 and intra-operative factors 
Scatter plots showing the lack of correlation (non-linear association) between cardiopulmonary bypass time or ischaemic time and change in circulating microRNA 
(ddCt) levels at Day 1 (POD1) post-op for miR-133a and miR-122. Only graphs relating to significant changes in circulating microRNA levels are shown. p>0.05 for all 
comparisons (Pearson correlation). 
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Figure 5-10 Absence of correlation between circulating miR-92a or miR-126 and intra-operative factors (POD1) 
Scatter plots showing the lack of correlation (non-linear association) between cardiopulmonary bypass time or ischaemic time and change in circulating microRNA 
(ddCt) levels at Day 1 (POD1) post-op for miR-92a and miR-126. Only graphs relating to significant changes in circulating microRNA levels are shown. p>0.05 for all 
comparisons (Pearson correlation). 
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Figure 5-11 Absence of correlation between circulating miR-92a or miR-126 and intra-operative factors (POD5) 
Scatter plots showing the lack of correlation (non-linear association) between cardiopulmonary bypass time or ischaemic time and change in circulating microRNA 
(ddCt) levels at Day 5 (POD5) post-op, compared with pre-op, for miR-92a and miR-126. Only graphs relating to significant changes in circulating microRNA levels are 
shown. p>0.05 for all comparisons (Pearson correlation). 
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Figure 5-12 Renal function in the peri-operative period 
N = 20 as one-patient excluded due to pre-op end-stage renal failure and established renal replacement therapy. Statistical analysis made using a Friedman’s test with 
Dunn’s Multiple Comparisons. Comparisons made to pre-op levels. p<0.05 was considered statistically significant. Although statistically significant increases in serum 
Urea and Creatinine levels at POD1 were observed, these do not represent a significant clinical alteration in renal function. 
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Figure 5-13 Hepatic function in the peri-operative period 
Statistical analysis made using a Friedman’s test with Dunn’s Multiple Comparisons. Comparisons made to pre-op levels. p<0.05 was considered statistically 
significant. All statistically significant differences between pre- and post-op levels do not equate to clinically significant changes in hepatic function. ALP – Alkaline 
Phosphatase. ALT/GPT - Alanine transaminase/Glutamic pyruvic transaminase.   
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Figure 5-14 Absence of correlation between circulating microRNAs and change in serum creatinine 
Representative scatter plots showing a lack of correlation (non-linear association) between change in circulating miR-133a or miR-122 levels (ddCt – y axis) and rise in 
serum creatinine from baseline (log∆Cr) at Day 1 (1-p) or Day 5 (5-p) post-op. p>0.05 for all comparisons (Pearson correlation). 
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5.3 DISCUSSION 
The experiments described in this chapter show altered levels of circulating miR-133a, 
miR-122, miR-92a and miR-126 in the serum of patients who have undergone CABG 
surgery.  
Overexpression of miR-133a has been shown to inhibit cardiac hypertrophy and also may 
play a role in regulating cardiac electrical properties (Care et al., 2007). Expression of this 
miR-133a is reduced in areas of muscle infarction post-MI leading to the suggestion that it 
may play a protective role, being involved in the heart’s repair mechanism following 
ischaemic damage (Care et al., 2007). Although shown to be increased in serum following 
ACS, it is not cardiac-specific, being expressed at high levels in both cardiac and skeletal 
muscle (De Rosa et al., 2011, Creemers et al., 2012, D'Alessandra et al., 2010). Although 
part of the marked increase in serum levels of miR-133a at POD1 in patients undergoing 
CABG may be explained by non-cardiac tissue damage, its correlation with the increase in 
cTnT suggests at least some degree of cardiac origin.  
The observed reduction in circulating endothelial cell-enriched miR-92a and miR-126 
expression levels parallel those seen in patients with stable CAD (Fichtlscherer et al., 
2010) and ACS (De Rosa et al., 2011). MiR-126 is known to facilitate VEGF signalling 
and thus regulate endothelial homeostasis and vascular integrity (Wang et al., 2008). A 
recently published prospective study revealed that not only are serum miR-126 levels 
positively associated with future MI but also elevated in an ischaemia/reperfusion model, 
with platelets being a major contributor (Zampetaki et al., 2012b). The same group have 
previously shown a reduced circulating level in patients with Type 2 diabetes mellitus 
suggesting a predictive role for manifest disease (Zampetaki et al., 2010). There is an 
increasing body of evidence suggesting that circulating miR-126 levels may represent 
endothelial or platelet dysfunction and therefore be a useful predictor of future vascular 
events. In our patients, exposed to ischemia/reperfusion in the setting of CABG, the 
observed reduction in detectable serum miR-126 may reflect EC or platelet damage or be a 
component (or even trigger) of a reparative process. This merits further study and 
elucidation.  
MiR-92a, although also highly endothelial cell enriched, is present in both cardiac 
fibroblasts and cardiomyocytes (Bonauer and Dimmeler, 2009). It is a negative regulator of 
angiogenesis and when inhibited was shown reduce infarct size, decrease apoptosis (thus 
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promoting cardiomyocyte survival) and promote neorevascularization in a murine coronary 
occlusion model (Bonauer et al., 2009).  More recently, local catheter delivery of a locked 
nucleic acid-based inhibitor of miR-92a to a porcine model of ischemia/reperfusion has 
been shown to reduce miR-92a expression within the infarct zone, reduce infarction size 
and improve markers of cardiac function (Hinkel et al., 2013). The authors hypothesised 
that these effects were mediated through conferred endothelial protection, vascular 
(capillary) preservation or growth, suppression of post-ischaemic inflammation and direct 
cardiomyocyte protection (Hinkel et al., 2013). The observed reduction in circulating 
levels of miR-92a post-CABG supports the presence of a protective/reparative process for 
the endothelium and/or cardiac muscle occurring in response to tissue ischaemia, 
hyopoxia, hypothermia and inflammation.  
MiR-122 levels were reduced on POD1 but had returned to baseline by POD5. This differs 
from patients with STEMI whose levels remained reduced out to 30 days (D'Alessandra et 
al., 2010). It has been generally accepted that miR-122 is liver specific, accounting for 
70% of the livers total miR content and playing a key role in homeostasis and disease (Tsai 
et al., 2012, Ding et al., 2012). However, more recently miR-122 has been shown to be 
elevated in the plasma of patients post cardiac arrest, where it was found to correlate with 
neurological outcome (Stammet et al., 2012), and in a porcine model of cardiogenic shock 
where it was attenuated by therapeutic hypothermia (Andersson et al., 2012). In-vitro 
experiments have revealed that it can be released by neuronal cells (Stammet et al., 2012). 
The transient reduction observed in patients following CABG could possibly be explained 
by reduced liver perfusion, however clinically significant alterations in measures of hepatic 
function were not observed. Another more plausible explanation may be as part of a 
neuroprotective process activated in the setting of ischaemia/reperfusion.  
MiR-208a, -208b and miR-499 have been shown to sensitively and specifically correlate 
with troponin in ACS studies and to be more cardiac specific than miR-133a (De Rosa et 
al., 2011, Corsten et al., 2010, Widera et al., 2011, Gidlof et al., 2012). However, in the 
post-CABG patient cohort these miRs were undetectable in serum pre- and post-op. The 
observed median cTnT rise in this study was relatively low, with only one patient suffering 
a marked rise consistent with periprocedural myocardial infarction (Table 5.4). It is 
therefore likely that miR-208a, miR-208b and miR-499 only become useful detectable 
biomarkers in the presence of significant myocardial necrosis. It is also possible that the 
experimental protocol, as designed, missed any potential rise in these miRs with the first 
sample not being taken until day 1 post-op. MiR-208a has been shown to be an early 
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marker of myocardial necrosis (within 4 hours) so transient changes in the circulation may 
have been missed (Wang et al., 2010a).  
This chapter is the first to investigate a temporal serum profile of dynamic microRNAs in 
the setting of uncomplicated CABG and show early potential for use as biomarkers in this 
setting. It is currently unclear if these miRs represent only cell necrosis/damage or are 
acting as mediators of disease or protectors from the pathological process, or indeed in 
communication between cells, tissues and organs. It is becoming increasingly evident that 
microRNAs operate in co-expression networks and that any analysis of change in miR 
levels should ideally be examined within these set signatures (Zampetaki et al., 2012a). 
Comparison with reported findings from other models of CVD, suggests that these 
dynamic changes in miR expression may reflect part of a wider ischaemia/reperfusion 
network that merits further investigation.  
The experiments in this chapter are limited by relatively small patient numbers. The 
findings can therefore only be considered as observational at this point. As temporal 
comparisons have been made within individual patients and not compared to healthy 
controls, this provides a reduction in bias (for example due to differing risk factor profiles 
or medications) and a more robust analysis. Unfortunately patient numbers are currently 
too small to allow for important sub-group analyses e.g. age, sex, diabetes mellitus, patient 
stability.  
As previously mentioned, several miRs (e.g. miR-133a) are present in both cardiac and 
skeletal muscle. Although the correlation to troponin strongly suggests a cardiac origin, 
supportive data is required. Comparison to patients undergoing other surgical procedures 
would help in this regard. Samples from patients undergoing Aortic Valve Replacement on 
cardiopulmonary bypass but not requiring CABG (therefore not having significant CAD) 
are in the process of being collected from the same surgical centre. Repeat analysis of these 
miRs on these samples will be performed in the future and should provide clarification.  
To fully assess the potential for these miRs as biomarkers in the setting of CABG will 
require several further studies. The results in this chapter are from a single surgical centre 
and therefore require replication in an independent, larger, study population. Corroboration 
with animal models is important to allow investigation of potential underlying mechanisms 
and assess cause versus effect. Lastly, and most importantly, a prospective analysis relating 
dynamic serum miR levels to patient outcome and occurrence of specific operative 
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complications is required. If it could be shown that changes in circulating miR profiles 
were predictive of poor operative outcome or of complications such as early vein-graft 
failure or impaired ventricular function then this would confer a clear advantage over 
existing protein biomarkers. Potential advantages in using miRs for this purpose are that 
current PCR technology allows both amplification and detection with high sensitivity and 
specificity. Many miRs can be detected simultaneously in a single experiment allowing 
assessment of coexpression networks to improve diagnostic and predictive accuracy. And 
lastly they are stable and protected from degradation within the circulation. However, 
qPCR-based analysis is also time consuming and expensive in comparison to laboratory-
based protein assays which are cheaper and can provide results in minutes. Also accurate 
and reproducible normalisation remains a challenge. It has recently been shown that the 
presence of pre-analytical variation (e.g. haemolysis) can affect miR quantification, and 
that the spiking in of synthetic exogenous miRs does not correct for this or for variations in 
extraction efficiency (McDonald et al., 2011a, Duttagupta et al., 2011).  There remain 
several hurdles to overcome for microRNAs to fulfil their potential in meeting the 
undoubted clinical need for accurate and reproducible disease biomarkers.  
In summary, this data adds to the growing evidence for the presence of a circulating 
microRNA network for cardiovascular disease that may hold significant future potential as 
both biomarkers and potential therapeutic targets in specific pathological settings.  
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This thesis has focused on the use of vascular gene therapy and potential role of 
microRNAs in the pathophysiological response to vascular injury, underpinning the 
development and treatment of coronary in-stent restenosis. Consideration has also been 
paid to vein graft failure following CABG surgery as this shares many pathological 
similarities. Lastly, following on from experience gained in the investigation of miRs, both 
in-vitro and in-vivo, attention was directed to their emerging use as cardiovascular disease 
biomarkers, in this case in the setting of CABG surgery.  
Atherosclerotic coronary artery disease remains one of the major causes of morbidity and 
mortality worldwide (Libby et al., 2011). This progressive disease process leads to 
consequent flow-limiting vascular narrowing or acute vessel occlusion and resultant 
clinical sequelae, principally angina pectoris, cardiac dysrhythmia and myocardial 
infarction (Libby, 2013). Revascularization, either by percutaneous coronary intervention 
or coronary artery bypass surgery, are routinely performed to relieve symptoms and treat 
acute MI (Serruys et al., 2009). Also with respect to patient outcome (ie, decreasing the 
chance of premature death or myocardial infarction), revascularization of ischemia-
associated lesions has proven effective (Tonino et al., 2009). Despite their widespread use 
and clinical effectiveness, both are limited by conduit failure - in-stent restenosis or 
thrombosis in PCI and vein graft failure in CABG.  
Although ISR and VGD represent two distinct pathologies, many similarities exist, 
principally endothelial dysfunction and the development of intimal hyperplasia. The 
development of IH/NIH, occurring as a direct consequence of vascular injury, represents 
an important target for therapeutic interventions aimed at improving clinical outcomes 
following revascularisation. (Park et al., 2012). As previously discussed in detail, this 
dynamic process involves the complex interplay of multiple cell types and molecular 
mechanisms resulting in vascular remodelling and extracellular matrix deposition. Gene 
therapy remains an intuitive and attractive approach to both the prevention of ISR and 
VGD (Wan et al., 2012, Bradshaw and Baker, 2012). 
In pre-clinical studies, the inhibition of cell proliferation and migration by arresting 
VSMCs in GO/G1 phase of the cell cycle has been a common approach. This has been 
achieved using either cell cycle regulatory proteins, or manipulation of mitogens, 
transcription factors, cytokines, growth factors, promoters of apoptosis or antioxidants. 
Treatment effects have been impressive, ranging from a 30% reduction in NIH at 28 days 
post-vein grafting in pigs with adenoviral gene transfer (Wan et al., 2004, Kibbe et al., 
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2001) to a >90% reduction in intimal thickness in a rabbit model (Banno et al., 2006). 
Disappointingly, these impressive results have, as yet, failed to translate into measureable 
improved outcomes in clinical trials.  
In pre-clinical studies of “gene-eluting” stent technology to-date, overall vessel 
transduction efficiency has been low and concerns have persisted regarding the role that a 
durable polymer coating may play in the development of arterial wall inflammation, 
delayed vascular healing and resultant late stent thrombosis. This has contributed to the 
lack of translation to the clinical setting. Furthermore, advancement in DES technology has 
been rapid. New second and third-generation DES with thinner stent struts, more 
biocompatible, less thrombogenic or biodegradable polymers, new antiproliferative agents 
and even completely biodegradable platforms have all appeared with excellent efficacy and 
safety data (particularly in regard to late and very-late stent thrombosis), at least in the 
short-to-medium term (Palmerini et al., 2013). In addition, improvements in individual 
stent performances have made the detection of statistically robust and clinically relevant 
differences between contemporary devices hugely difficult (Garg et al., 2013). As event 
rates continue to fall, the size of clinical trial required to show superiority continues to rise 
with the risk of becoming prohibitively expensive. Therefore, gene-eluting technology 
faces stiff competition. Despite this, a clinical need for novel and cost-effective approaches 
persists as stent thrombosis and delayed restenosis have been far from eliminated (Garg, 
2013) and rates of vein graft failure remain high at 10 years post-surgery (Goldman et al., 
2004). Targeted gene therapy remains perfectly placed to improve vascular healing, whilst 
still inhibiting the physiological repair processes leading to device/graft complications.  
Ongoing research seeks to identify the optimal vector for vascular gene therapy. Viral 
vectors so far hold the most potential with retargeting and detargeting strategies in Ad and 
AAV vectors seeking to maximise transduction efficiency in the target tissue of choice and 
minimise toxicity, inflammation and interaction with circulating blood components. 
Helper-dependant adenoviruses hope to overcome problems with humoral immunity and 
lentiviruses show encouraging preclinical results in vascular tissues although some safety 
concerns need to be explored, namely the potential for insertional mutagenesis. It is 
unlikely that one single vector will emerge as an out-right choice for all situations but a 
selection of tailored options to suit the clinical scenario is entirely feasible. For example, 
adenoviruses may prove to be most effective in the setting of VGD where ex-vivo 
incubation removes problems with in-vivo interactions and allows a longer exposure time 
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(20-30mins), whereas an efficient lower dose lentivirus stably attached to a stent might be 
better placed to provide effective local inhibition of ISR.  
With respect to failure of translation to the clinical setting, the variability of described 
effects across pre-clinical models, and also some conflicting results (e.g. use of VEGFs) 
have shown that there are many important considerations. Choice, design and dose of 
vector and therapeutic transgene are all clearly important. When pre-clinical animal models 
are used, species specific differences exist in arterial healing, atherogensis, response of the 
fibrinolytic system, inflammatory response, degree and rate of re-endothelialisation and 
host-virus interactions (Schachner et al., 2006, Havenga et al., 2001). This may reduce the 
effectiveness of a particular gene of interest, or viral vector, when translated to abnormal, 
inflamed, atherosclerotic human vessels. In stent studies, overall levels of cell transduction 
have been low, and this may contribute to a lack of clinically measurable effect so far. Also 
for ISR, the dose administered needs to correlate with the size of the target tissue to be 
transduced and the larger circulating blood volume in humans. It is likely that 
“combination gene therapy” targeting multiple regulators of the cell cycle, different points 
in the neointimal cascade or promoting re-endothelialisation while inhibiting NIH might 
result in improved efficacy in the clinical setting.  
Lastly, finding the optimal method of delivery to target tissue is important. Vein grafts can 
be accessed ex-vivo allowing incubation with a chosen vector but with PCI this remains 
more difficult. Intuitively a “gene-eluting” stent platform seems most likely to be effective 
but achieving stable, controllable and reproducible vector binding and elution, as well as 
sufficient longevity of therapeutic gene expression is required to allow progression to 
clinical trials and compare favorably with current DES technology.  
Taking into account these considerations, translation of gene therapy to clinical use will 
ultimately require the support of the large device companies. Pre-clinical studies to-date 
strongly suggest that targeted therapeutic viral vectors, tailored to augment positive vessel 
healing, could quite conceivably out-perform existing anti-proliferative agents with regards 
to the suppression of NIH. If a given vector can be proven to be effective in pre-clinical 
models and safe in phase I/II clinical trials then combining it with existing third-generation 
stent architecture, biocompatible/biodegradable polymers or even bioabsorbable platforms 
is commercially attractive and entirely feasible. This provides impetus and motivation to 
ongoing vascular gene therapy research.  
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With ongoing rapid improvement in gene delivery vectors, encouraging and robust pre-
clinical mechanistic studies and evidence of safety and feasibility from clinical trials I do 
believe that gene therapy may still play an important future role in the prevention of the 
important clinical issues of in-stent restenosis and vein graft disease, despite the significant 
barriers that remain to be overcome Gene therapy has recovered from some of the early 
hurdles that reduced enthusiasm in the scientific and clinical communities and further 
developments are awaited with interest (Giacca and Baker, 2011, Verma, 2013).  
Since their discovery 20 years ago (Lee et al., 1993), growth in the understanding of the 
key regulatory role played by small, non-coding, regulatory microRNA molecules in 
physiological development, homeostatsis and development of pathology has been 
exponential. Increasingly, pre-clinical research has shown their importance in the 
regulation of VSMC proliferation and migration in vascular pathologies (McDonald et al., 
2011b).  As discussed in chapter 4, dysregulation of specific miRs during the development 
of NIH and re-endothelialisation after vascular injury indicates that their dynamic 
regulation is a key determinant of VSMC phenotype. Consequently, this raises the 
possibility that the manipulation of these miRs could prevent neointimal formation, reduce 
thrombogenicity and promote re-endothelialisation after coronary stent or vein graft 
implantation. The rapidly evolving development of antisense oligonucleotide-mediated 
(antimiR/antagomir) knockdown and miR-mimic-mediated overexpression technologies 
provides opportunities for the therapeutic modulation of miRs in the clinical setting (Small 
et al., 2010).  
As with vascular gene therapy, clinical translation is dependent on both choice of 
therapeutic strategy and method of delivery. Pre-clinical models have suggested that while 
systemic delivery (e.g. IV) of a miR-manipulating agent could achieve measurable changes 
in miR levels, it is unlikely to be clinically optimal, as in keeping with the complex role of 
miRs across many cell- and tissue-types, off-target effects could be apparent. In the setting 
of vascular disease the need for localized delivery of the therapeutic entitiy, requirement 
for short- or long-term manipulation to achieve a given effect, and whether reduction or 
augmentation of miR levels is required would all influence the choice of a given 
therapeutic strategy. The fields of vascular gene therapy and miR biology are clearly not 
exclusive and the development of viral or non-viral vector mediated mimic or antagonism 
approaches targeting miR(s) of interest hold promise as innovative therapies.  
Further detailed mechanistic studies are required to define the importance and contribution 
of not only individual miRs, but miR clusters, their mRNA and pathway targets, 
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environmental factors (e.g. presence of atherosclerosis, ischaemia or inflammation) and co-
expression networks in the settings of ISR and VGD. Concomitantly, evaluation and 
refinement of delivery techniques (ex-vivo incubation in vein grafts, local catheter or stent-
based delivery in-vivo) including suppressing the risk of off-target effects is required. It is 
not inconceivable that in the setting of acute MI, a biocompatible polymer stent coupled 
with a synthetic miR-vehicle-complex, delivered to a culprit lesion could be tailored to 
provide a 3-fold benefit – plaque stabilization, prevention of ISR and promotion of positive 
vessel healing (re-endothelialisation) simultaneously addressing the 3 most significant 
current issues relating to PCI.  
Several difficulties remain to be overcome before miRs can move forward as viable 
therapeutic targets. Across pre-clinical models, as shown with my findings in Chapter 4, 
levels of dysregulation in a given disease state and results obtained from the knockdown or 
overexpression of a given miR have been variable. An individual miR can have hundreds 
or even thousands of predicted mRNA targets but at a particular physiological expression 
level only affect a small percentage of them. Forced overexpression or inhibition may 
change this balance resulting in targeting of mRNAs not normally affected in the 
physiological state and therefore unwanted “off-target” effects. Given that miRs regulate 
the genome to a much greater degree than originally though, and that many have shown 
dysregulation in cancer studies, tumorigenesis is a specific concern that warrants attention 
(O'Sullivan et al., 2011). Recent data has suggested that miRs can act as endocrine 
molecules, mediating cell-cell and tissue-tissue signaling, a further important consideration 
when monitoring the effects of therapeutic modulation in-vivo (Polimeni et al., 2013). 
Additionally, recent work has shown that a single miR can exert its regulatory effect by 
targeting multiple points of a single pathway concurrently, and that any therapeutic effect 
could be diluted or ablated if all these conditions are not met, adding a further level of 
complexity (Ganesan et al., 2013). Lastly, it is now evident that miRs may not be the only 
important regulatory RNA involved in cardiovascular development and disease. Long non-
coding RNAs (lncRNAs) are an emerging class of transcripts that regulate cellular 
processes by controlling gene expression and may hold potential for therapeutic 
modulation (Scheuermann and Boyer, 2013). Their biological and mechanistic functions 
are complex with initial evidence pointing towards an important role in regulatory 
networks (Schonrock et al., 2012). This area of cardiovascular research remains fast-paced 
and promises both an increased understanding of vascular biology and pathophysiology 
and potentially novel therapeutic opportunities. Encouragingly, significant recent progress 
was made in an early Phase II clinical trial where a course of systemic antimiR-122 was 
Chapter 6 | Final Discussion 
 
213 
not only well-tolerated but provided evidence of efficacy with suppression of viraemia in 
patients with Hepatitis C infection (van Rooij and Olson, 2012).  
Additional interest in miRs has developed from the finding that they are present in stable 
and detectable levels within the circulation. Increasingly it has been suggested that these 
miRs are released into the circulation from injured tissue or are highly expressed in 
patients with specific cardiovascular diseases. The implication being, that these miRs could 
act as potential biomarkers for clinical diagnosis or prognosis in patients with 
cardiovascular diseases. However many question remain to be answered, including the 
basis for their altered expression (cause or effect), their relationship to disease progression 
and their power for predicting disease progression and clinical outcome (Fichtlscherer et 
al., 2011).  
With respect to taking the results reported in this thesis forward, there were several 
avenues that could have been explored if time and financial constraints had allowed. The 
development of modified Ad vectors with improved vascular transduction efficiency is 
ongoing within our institution. Considerable success has been achieved thus far with the 
creation of a vector that combines hexon amino acid mutations to abrogate FX binding, 
fiber pseudotyping to improve vascular cell transduction lower immunogenicity (White et 
al., 2013).  Unfortunately, this vector is not yet ready for in-vivo testing in the pig model as 
it utilises the CD46 receptor for cell-binding and a low level of homology exists between 
porcine and human CD46 (Havenga et al., 2001). Additionally, efficient and effective 
vascular gene transfer can be achieved using integrase-deficient lentiviral vectors (IDLV) 
in-vitro (Chick et al., 2012). It would have been interesting to administer novel modified 
Ad or IDLV to the porcine model using both the Clearway RX and GENIE systems to fully 
investigate the clinical potential of local delivery in this setting. Potentially even more 
useful would have been the direct spray coating of Yukon stents with IDLV expressing 
NogoB. The sand-blasted abluminal surface of the Yukon provides a series of crypts that 
could conceivably have stored enough lentivirus to allow efficacious local gene delivery. 
Unfortunately the cost required to perform this experiment is currently prohibitive.  
Concurrently, work is ongoing between our institution and the Department of Chemistry to 
investigate chemical methods of binding Ad vectors to the surface of a metal stent allowing 
stable and controlled vector elution. Our plan is to test this in the in-vivo pig model in due 
course, although considerable attention will need to be paid to the biocompatibility of this 
technology and its effect on vessel inflammation. Should a given vector display proven 
effectiveness and compatibility in in-vitro models then we hope that collaboration with a 
Chapter 6 | Final Discussion 
 
214 
commercial stent company would allow us to move towards our aim of a gene-eluting stent 
platform suitable for clinical testing.  
As previously mentioned, we are repeating the analysis of previously discussed levels of 
vascular-miRs in porcine neointima using a modern stainless steel DES platform with 
biodegradable polymer and limus agent (Biomatrix FlexTM, Biosensors International, 
Singapore) and its sister BMS counterpart (GazelleTM, Biosensors International, Singapore) 
both of which are amenable to the electrolysis process. It would be expected to see 
differences in neointimal area between the two stents at 28 days and to establish potential 
differences in miR dysregulation using a microarray approach, qRT-PCR conformation 
and co-localisation using in-situ hybridisation. This would be hoped to provide further 
insights into the effect of DES on the vasculature. Ultimately, the porcine model will allow 
us to test both miR-mimic and antimiR approaches to the treatment of ISR prior to 
assessment in clinical trials.  
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